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I. Zusammenfassung 
Im Alter nimmt die Häufigkeit an neurodegenerativen Erkrankungen zu, die mit einem 
generellen oder zelltypspezifischen Abbau von Nervenzellen einhergehen. Mikroglia, die 
Gehirnmakrophagen, stehen im ständigen Kontakt mit Nervenzellen, um kleinste 
Veränderungen wahrnehmen zu können. Dies geschieht über die zelluläre Glykokalyx, ein 
Geflecht aus verschiedenen Zuckern mit Sialinsäuren als terminaler Zucker. 
In der vorliegenden Studie wurde der Einfluss einer veränderten Glykokalyx im Gehirn in vivo 
untersucht. In vitro-Experimente zeigten bereits, dass die Entfernung der Sialinsäuren von der 
neuronalen Glykokalyx zur Komplementrezeptor 3-vermittelten Phagozytose der Nervenzellen 
durch Mikroglia/Makrophagen führt. Dieser Mechanismus wurde nun erfolgreich in ein 
Mausmodell übertragen. Als Modell wurde eine Maus verwendet, die heterozygot für das 
bifunktionelle Enzym UDP-N-Acetylglucosamin-2-Epimerase/N-Acetylmannosaminkinase 
(GNE+/--Maus) ist und dadurch eine niedrigere Sialylierung aufweist. Diese Mäuse zeigten 
einen Verlust von Nervenzellen in verschiedenen Gehirnregionen, der sich mit dem Alter weiter 
verstärkte. Parallel dazu wurde gezeigt, dass vor allem die langkettigen Polysialinsäuren 
reduziert waren. Trotz kontinuierlichem Nervenzellabbau konnten keine 
Entzündungsreaktionen im Gehirn festgestellt werden. Sowohl eine Transkriptom-Analyse, als 
auch eine Astrozyten- und Mikrogliaanalyse im Gehirn zeigten keine großen Auffälligkeiten. 
Lediglich die stärkere Exprimierung eines Mikroglia-/Makrophagenmarkers deutete auf eine 
erhöhte Mikroglia-Aktivität hin und lässt auf eine homöostatische Phagozytose schließen. 
Wichtige Erkenntnisse brachte die Kreuzung der GNE+/--Maus mit einer Komplementfaktor 
C3-defizienten Maus. Durch die vollständige Inhibierung des Komplementsystems konnte der 
Nervenzellabbau selbst bei alten GNE+/--Mäusen verhindert und dadurch die Involvierung des 
Komplementsystems auch in vivo nachgewiesen werden. 
Somit zeigt die vorliegende Arbeit, dass Sialinsäuren auch im komplexen Organismus eine 
zentrale Funktion in der Mikroglia-Nervenzell-Kommunikation einnehmen. Eine reduzierte 
Sialylierung führt zu einer Komplement-vermittelten Phagozytose der Nervenzellen durch 
Mikroglia. Das untersuchte Mausmodell, sowie die daraus gewonnenen Erkenntnisse bilden 
eine sehr gute Grundlage um den altersabhängigen Nervenzellverlust weiter zu untersuchen und 
geeignete Therapieansätze zur Vermeidung von neurodegenerativen Erkrankungen zu 
entwickeln.   
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II. Abstract 
Every neuronal cell is covered with a dense structure of glycoconjugates, the glycocalyx. Sialic 
acids form the terminal ends of the glycocalyx and thus, are more accessible for the cellular 
environment. Microglia, the brain macrophages constantly survey the brain parenchyma and 
can sense small alterations in the glycocalyx. Recently, it was demonstrated in murine and 
human neuron-microglia/macrophage co-cultures that healthy neurons with reduced surface-
bound sialic acids were removed by microglia/macrophages in a complement-dependent 
manner. Although microglial phagocytosis is considered as beneficial, the role of microglia in 
recognizing sialic acids in neurodegenerative and neuroinflammatory processes is still not fully 
understood. 
In this study, the situation of a desialylated glycocalyx in vivo was mimicked by using a mouse 
heterozygous for the bifunctional enzyme glucosamine-2-epimerase/N-acetylmannosamine 
kinase (GNE; GNE+/- mice). It was shown that gne transcription was reduced in the brain of 
young and old GNE+/- mice and a reduced sialylation status was confirmed. In accordance with 
the in vitro data, an increased age-dependent neuronal loss was found in different brain regions 
of GNE+/- mice compared to their wildtype littermates. Histological staining indicated 
morphological changes in microglia but not in astrocytes. Furthermore, only very minor 
inflammatory changes were observed in the transcriptome data of the brain pointing towards a 
homeostatic removal of neurons in GNE+/- mice by microglia. Based on the in vitro studies, the 
GNE+/- mice were crossbred with mice deficient for the complement component 3 (C3), the 
central player of the complement cascade, to confirm the involvement of the complement 
system. The C3-deficiency was able to rescue the neuronal loss in the GNE+/- mice. Thus, this 
study successfully showed that the complement system is involved in microglial removal of 
neurons in vivo. 
The in vivo data demonstrate the importance of microglial sensing of small alterations in the 
glycocalyx. Sialic acids seem to play an essential role in maintaining brain homeostasis and 
might also be in involved in synaptic plasticity. However, oxidative stress or aging can lead to 
a decrease of sialic acids that then might lead to unwanted reactivation of developmental 
synaptic pruning and consequently to the loss of neurons in the brain. Thus, targeting the 
neuronal glycocalyx could be a beneficial therapy in age-dependent neuronal loss and 
neurodegenerative diseases.  
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1 Introduction 
The brain is a highly complex organ with millions of neurons that control and regulate the body. 
The communication between each neuron as well as the crosstalk with glial cells, such as 
astrocytes and microglia, is essential for the proper function of the brain. The rich glycan-coated 
surface of every neuron, the neuronal glycocalyx, plays a central role in this network. However, 
in several diseases and during aging these cell-cell interactions undergo various changes and 
can become dysregulated. Thus, understanding the crosstalk between neurons and glial cells 
and its mediators at the level of the glycocalyx is an essential research goal. 
1.1 The neuronal glycocalyx 
1.1.1 The structure and function of the neuronal glycocalyx 
The neuronal cell surface is the interface between the cell and its environment. It is covered 
with a dense array of different glycans that form a matrix, the glycocalyx. The complex 
composition of the glycocalyx varies among tissues and cell types and encodes a huge variety 
of information that is essential for health and in diseases. 
Glycans like proteoglycans, glycoproteins, and glycolipids are glycosylated biopolymers with 
one or more carbohydrate chain(s). Glycosylation is a complex process of the secretory pathway 
and describes the modification of proteins, lipids or other organic molecules by adding sugars. 
These enzymatic processes are important for the structure, folding, stability, and function of the 
acceptor molecules (as reviewed in Schnaar et al., 2014a). Glycosylation starts in the 
endoplasmic reticulum with co- and posttranslational modifications of carbohydrate chains. The 
core structure of the glycoconjugates consists of the seven essential sugars: mannose, glucose, 
galactose, fucose, N-acetylgalactosamine, N-acetylglucosamine, and N-acetylneuraminic acid 
(sialic acid) as arranged in Figure 1 (Linnartz and Neumann, 2013). In contrast to nucleic acids 
or proteins, which are encoded by a DNA template, glycan structures are determined by its 
specific glycosyltransferases and can be tissue-dependent. Various sugar-specific 
glycosyltransferases mediate the transfer of sugar residues to an acceptor hydroxyl group on a 
serine or threonine (O-linked) or to nitrogen of an asparagine residue (N-linked) and determine 
their linkages. Further modifications like acetylation occur in the Golgi apparatus and can lead 
to a highly diverse structure of the glycocalyx (Ohtsubo and Marth, 2006; Varki and Schauer, 
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2009). This explains why a few building blocks are sufficient for the great diversity of the 
glycocalyx.  
 
Figure 1: Glycosylation pattern of the neuronal glycocalyx. All secreted or cell-surface proteins in mammals 
are glycosylated. Oligosaccharide chains on the cell surface are formed in a specific order of sugars. Intact cells 
usually present sialic acids at the terminal ends of their glycoproteins or glycolipids. Thus, sialic acids are exposed 
at the cell surface. Asn, asparagine; Ser, serine; Thr, threonine. (Image was taken and modified from Linnartz and 
Neumann, 2013.) 
The importance of glycosylation is shown by several human diseases with glycosylated defects 
that can be summarized by the term ‘congenital disorders of glycosylation’ (CDG). CDG 
studies show that correct N-glycosylation of proteins is essential for normal development, 
including the brain (Sato and Endo, 2010) and can result in severe developmental defects 
(Freeze, 2013). Alterations in glycosylation can not only lead to loss of function or altered 
cellular transport of proteins but might also result in misfolding and subsequent degradation by 
the proteasome. 
The architecture of the glycocalyx is very dynamic and assumed to reflect the cellular well-
being (Rachmilewitz, 2010; Varki, 2011a). The mostly hydrophilic and negatively charged 
surface likes to spread out in space and facilitates cell-cell interactions (Rudd et al., 2002). 
Glycans like heparin and chondroitin sulfate are one of the major cell surface structures and 
thus, dominate the physical and structural properties of the glycocalyx (Raman et al., 2005). In 
general, the glycosylation pattern of the glycocalyx regulates various functions within the local 
environment, like protein folding and stability within the cellular membrane, protein 
trafficking, or protein signaling. The specific function of each glycan is usually determined by 
the outermost sugars. In the mammalian glycocalyx it is sialic acid that is incorporated at the 
outermost ends of the glycostructures (black symbol , Figure 1). Due to this exposed position, 
sialic acids are considered to play a crucial role in cell-cell recognition and to mediate the initial 
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cellular interactions in physiological and pathological processes (Schauer, 2009; Cohen and 
Varki, 2010; Linnartz-Gerlach et al., 2014). Thus, sialic acids have a major impact on the 
neuronal glycocalyx. Furthermore, with their highly negative charges sialic acids contribute to 
protein hydration and thus, shield glycoproteins from enzymes and other receptors. This makes 
them an interesting therapeutic target on the neuronal cell surface. 
1.1.2 The biosynthesis of sialic acids 
Sialic acids are nine-carbon backbone sugars that form a diverse family of over 40 neuraminic 
acid derivates (Schauer, 2000). Sialic acids are abundant in the deuterostome lineage (Angata 
and Varki, 2002) but rather an exception in other lineages. Thus, it happens that the expression 
of sialic acid is, for instance, exploited by a group of gram-negative bacteria that is associated 
with human or animal hosts and cause severe illness (Varki, 2008). The most abundant forms 
in mammals are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). 
They differ in their chemical structure only at carbon position C5 (Acetyl- or Glycolyl-group) 
as displayed in Figure 2. Humans are the only mammals that lost the ability to synthesize 
Neu5Gc. Two to three million years ago, a 92 base pair deletion in the cytidine monophospho-
N-acetylneuraminic acid hydroxylase (CMAH) gene, the gene of the Neu5Gc converting 
enzyme, caused a frameshift and an inactivation in humans (Chou et al., 1998). This 
evolutionary event not only changed the ‘sialome’ in humans but was also followed by an 
evolutionary rise of sialic acid binding receptors (Varki, 2009). 
 
Figure 2: The two major forms of sialic acids. The chemical structures of N-acetylneuraminic acid (Neu5Ac) 
and N-glycolylneuraminic acid (Neu5Gc) are shown. Neu5Ac and Neu5Gc share the same chemical structures 
except of the chemical group at position C5 (red box). (Image was taken and modified from Bhide and Colley, 
2017.) 
However in the brain of mammals mainly exclusively Neu5Ac is expressed (Linnartz-Gerlach 
et al., 2014). It is synthesized in the cytosol from the precursor UDP-N-acetylglucosamine 
(UDP-GlcNAc) by four reactions (Figure 3). The two initial, essential reactions of the sialic 
acid biosynthesis are catalyzed by the bifunctional enzyme glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine kinase (GNE) in the cytosol. GNE is ubiquitously expressed 
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in all organs from early development onward (Horstkorte et al., 1999) and plays an important 
role in the sialic acid biosynthesis. It is the rate-limiting enzyme (Keppler, 1999). The complete 
inactivation of the GNE gene causes early embryonic lethality in mice (Schwarzkopf et al., 
2002) emphasizing its fundamental role in development. The activity of GNE can be controlled 
on transcription level and is regulated on protein level via a feedback inhibition loop by CMP-
sialic acid as shown in Figure 3, the end product of the sialic acid biosynthesis (Kornfeld et al., 
1964). N-acetylmannosamine (ManNAc)-6-P, the product of GNE is further catalyzed by N-
acetylneuraminic acid synthase (NANS) and N-acetylneuraminic acid phosphatase (NANP) to 
Neu5Ac in the cytosol (Figure 3). 
 
Figure 3: Overview of the sialic acid biosynthesis. N-acetylneuraminic acid (Neu5Ac) is synthesized from 
uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) in four different reactions in the cytosol. The two rate-
limiting steps are catalyzed by the glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE, 
yellow shaded box). The following steps are taken over by N-acetylneuraminic acid synthase (NANS) and N-
acetylneuraminic acid phosphatase (NANP). The activation of Neu5Ac takes place in the nucleus by the cytidine 
monophosphate (CMP)-sialic acid synthethase (CMAS). Sialoglycoconjugates are formed in the Golgi apparatus 
by the transfer of the activated sialic acid molecule onto a glycoconjugate. CMP-Neu5Ac enters the Golgi complex 
via the specific CMP-Sia transporter. ADP - adenosine diphosphate; ATP - adenosine triphosphate; CTP - cytidine 
triphosphate; ER - endoplasmic reticulum; ManNAc - N-acetylmannosamine; PEP - phosphoenolpyruvic acid; Pi 
(or PPi) - activated phosphate(s). (Image was adapted from a figure by Bhide and Colley, 2017.) 
Neu5Ac is then transported into the nucleus. In the nucleus, the cytidine monophosphate 
(CMP)-sialic acid synthetase (CMAS) activates Neu5Ac by adding a nucleotide sugar donor 
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(‘CMP-‘; Figure 3). In the next step, the activated sialic acid molecules (CMP-Neu5Ac) are 
exported from the nucleus through the nuclear pores and are imported into the Golgi apparatus 
by the CMP-Sia transporters. In the trans cisternae of the Golgi apparatus sialyltransferases 
transfer the sialic acid from the activated nucleotide sugar donor (CMP-) to the terminus of an 
oligosaccharide chain of a glycolipid or -protein to form sialoglycoconjugates (Figure 3). 
1.1.3 Sialoglycoconjugates and their regulation 
Twenty different sialyltransferases are known in mammals, which differ in their linkage and 
saccharide acceptor specificity. They are all type II membrane proteins with a short N-terminal 
cytoplasmic part and a large proteolytic and catalytic luminal domain (Paulson and Colley, 
1989) and share conserved sialylmotifs for binding. They can add mono-sialic acid (Neu5Ac1), 
di-sialic acids (Neu5Ac2), oligo-sialic acid (Neu5Ac3-7) or long sialic acid polymers (Neu5Ac8-
90+). Polysialyltransferases (PolySTs) are specifically responsible for long polysialylation 
(homopolymers of n≥90 Neu5Acn molecules) of glycans. Polysialoconjugates have exceptional 
biochemical and physical properties. Interestingly, only a few polysialylation acceptors were 
discovered until now. Those include the neural cell adhesion molecule (NCAM; Hoffman et 
al., 1982; Rothbard et al., 1982; Finne et al., 1983), the synaptic cell adhesion molecule-1 
(SynCAM-1; Galuska et al., 2010), neuropilin-2 (NRP-2; Curreli et al., 2007), the C–C 
chemokine receptor type 7 (CCR7; Kiermaier et al., 2016), E-selectin ligand-1 (Werneburg et 
al., 2016), the α subunit of the voltage-dependent sodium channel (James and Agnew, 1987; 
Zuber et al., 1992), and the CD36 scavenger receptor in human milk (Yabe et al., 2003). 
Polysialylation is a widely occurring event in the developing brain but diminishes in the adult 
brain except for a few areas. It is essential for brain development and plays an important role in 
plasticity and regeneration in the adult brain. Polysialylation was also found on polySTs 
themselves, which has been referred to as autopolysialylation (Mühlenhoff et al., 1996; Close 
et al., 2000), but the function of this remains unknown so far.  
However, the major sialoglycoconjugates in the brain are gangliosides (= sialoglycolipids) 
(Varki, 2008; Schnaar, 2016). Gangliosides share the same core structure but vary in their 
number of attached sialic acid molecules. Although gangliosides represent only 0.6 % of all 
brain lipids, they carry 75 % of the total brain sialic acids (Norton and Poduslo, 1973; Yu et al., 
1988; Schnaar et al., 2014). The four major brain gangliosides are GM1, GD1a, GD1b, and 
GT1b (Figure 4) and comprise 97 % of all gangliosides (Tettamanti et al., 1973). Gangliosides 
are important for the development of the central nervous system (CNS; Yamashita et al., 2005) 
and for maintaining healthy cellular interactions during lifetime. While in cis interaction they 
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are involved in proper formation of lipid rafts, in trans they interact with possible binding 
partners, like the sialic acid-binding immunoglobulin-type lectins (Siglecs). For instance, they 
play a role in neuronal excitability, synaptic transmission, or axon-myelin interaction (detailed 
reviewed in Schnaar et al., 2014b; Palmano et al., 2015; Schnaar, 2016b). While in the 
developing brain rather simple gangliosides are expressed (e.g. GM3, GD3), the levels of more 
complex gangliosides, like GD1a and GT1b, rise after birth until mainly the four major complex 
gangliosides are present in the adult brain (Tettamanti et al., 1973; Schnaar, 2004). In the adult, 
gangliosides are differently distributed all over the brain (Kracun et al., 1991; Vajn et al., 2013; 
Saville et al., 2017). The enzymes being involved in synthesizing the different types of 
gangliosides are shown in Figure 4. Mutations in any of these enzymes results in severe 
cognitive decline as shown in diverse mouse models and human patients (Simpson et al., 2004; 
Yamashita et al., 2005; Boukhris et al., 2013). 
 
Figure 4: Biosynthesis of the major brain gangliosides. A set of different glycosyltransferases (white boxes) 
are responsible for the stepwise build-up of complex gangliosides. The building blocks of the brain gangliosides 
are glucose, galactose, N-acetylgalactosamine (GalNAc) and sialic acid (Neu5Ac). The major brain gangliosides 
comprise up to 97% of all brain gangliosides in the human CNS (shaded grey box). The structures are color-coded 
according to the widely accepted nomenclature of Svennerholm (Svennerholm, 1994; Varki et al., 2015). Cer, 
ceramide. (Design was adapted from Schnaar et al., 2014c). 
The expression of sialic acids on the neuronal cell surface is regulated by its biosynthesis and 
its degradation. A good example for a well-regulated sialoglycoconjugate of neuronal cells is 
NCAM, the major protein-bound sialoglycan in the brain. NCAM shows a highly polysialylated 
form during embryogenesis, which peaks in the perinatal phase and is down regulated rapidly 
in the adult for mainly maintaining “neural plasticity” (Seki and Arai, 1993; Varki and Schauer, 
2009). The removal of sialic acids from glycans is mediated via specific subcellular sialidases 
(also known as neuraminidases; Neu). In mammals, four sialidases are known (Neu1-Neu4) as 
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it was recently reviewed in details (Schnaar et al., 2014; Bhide and Colley, 2017). They differ 
mainly in their cellular localization and their substrate specificity. Sialidases are also necessary 
to degrade glycoconjugates. Patients and mice with mutations in sialidases develop severe 
lysosomal storage diseases (Bonten et al., 1996; Gowda et al., 2017; Pan et al., 2017). 
Additional knowledge about sialidases is based on research findings in the field of cancer. 
Cancer cells are often highly sialylated, which protects them from the removal by immune cells. 
Especially investigations on Neu1 and Neu3 show the direct involvement in cancer progression 
(Miyagi and Yamaguchi, 2012; Miyagi et al., 2012; Pearce and Läubli, 2016). 
1.1.4 The functions of sialic acids 
Sialic acids fulfill a wide range of different functions (Schauer, 2000; Varki, 2011b; Linnartz-
Gerlach et al., 2014). Their function is mainly dependent on the linkage to the underlying sugars 
and glycan classes (glycolipid or glycoprotein). First, sialic acids are involved in the binding 
and transport of micro- and macromolecules and can influence the stability of the cellular 
membrane and its functions. Sialoglycan-rich microdomains were observed on the membrane, 
which are for instance important for the crosslink with extracellular lectins (Brewer et al., 2002; 
Boscher et al., 2011) as well as for the formation of membrane rafts (Simons and Sampaio, 
2011). Secondly, sialic acids can prevent receptor binding by either masking underlying sugars 
or masking the receptor itself on the cellular surface. For example the coverage of mannose 
residues by sialic acids prevents the activation of the lectin pathway of the complement system 
(Murphy et al., 2008). The highly negatively charged and hydrophilic structure of sialic acids 
not only masks underlying structures but is even strong enough to cause repulsion from 
neighboring cells. Especially, polysialylation contributes strongly to the overall negative charge 
of glycans and is important in neural cell interactions, synaptic plasticity in the hippocampus 
and regulates neurotransmitter activity (Sato and Kitajima, 2013). Furthermore, the hydrophilic 
structures of polysialylation can serve as scavengers of soluble factors and thus, support ligand-
receptor signaling. On the other hand, dysregulation of polysialylated NCAM was associated 
with psychiatric disorders (Vawter, 2000; Brennaman and Maness, 2010). 
Most importantly, sialic acids can act as biological recognition sites and are described as “self” 
ligands or as a barometer of the cellular well-being. According to the model of Rachmilewitz 
(Rachmilewitz, 2010), a healthy cell displays a normal pattern of sialylation on the glycocalyx. 
This can be recognized and monitored by receptors like the inhibitory Siglecs on microglia and 
acts immunosuppressive. However, in the absence of sialic acids or after slight alterations of 
the glycocalyx (= removal of “self” ligands) the inhibition of immune cells is disrupted and 
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phagocytes become activated as it was observed in several studies (Meesmann et al., 2010; 
Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016). Especially in the brain, microglial sensing 
of the glycocalyx is important to maintain homeostasis or to respond fast to altered cells under 
pathological conditions. 
Furthermore, sialic acids as terminal caps of the neuronal glycocalyx are exposed to free 
radicals during oxidative stress. Oxidative stress plays an important role during aging and in a 
number of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease 
(Andersen, 2004). Several findings like site-specific degradation of sialoglycoconjugates after 
oxidative stress (Eguchi et al., 2002) or elevated serum level of sialic acids during inflammatory 
processes (Painbeni et al., 1997; Goswami et al., 2003) indicate that sialic acid caps are removed 
under pathological conditions. In addition, sialic acid supplementation was able to ameliorate 
oxidative stress in a rat model of puromycin aminonucleoside nephrosis (Pawluczyk et al., 
2014) or in a rat model with high fat diet-induced oxidative stress (Yida et al., 2015). 
All in all, the sialic acid pattern in the neuronal glycocalyx serves as a fine-tuned barometer of 
the cellular health’s status and an interesting recognition site for microglia. 
1.2 The innate immune system as sensor of the glycocalyx 
1.2.1 Microglia – the brain macrophages 
Microglia are the innate immune cells of the brain. They represent approximately 10 % of all 
brain cells (Lawson et al., 1992; Soulet and Rivest, 2008). Microglia express the common 
myeloid- and macrophage-specific markers: ionized calcium binding adapter molecule 1 (Iba1), 
F4/80, and fractalkine receptor and share the main features of phagocytes, such as phagocytosis, 
antigen presentation, or production and release of immunomodulatory factors (reviewed by 
Prinz and Priller, 2014). However, in contrast to peripheral macrophages, microglia arise from 
primitive myeloid progenitors in the yolk sac that appear around embryonic day (E) 7.5 and 
migrate to the brain at E9.5 (Ginhoux et al., 2010). Thus, microglia are distinct from 
macrophages with unique kinetic features, like being long-lived cells, not normally replaced by 
circulating peripheral myeloid cells, and able to self-renew in a context-dependent manner 
(Ajami et al., 2007). Microglia are much more than only immune cells. They play a key role in 
the brain development and in the maintenance of the adult brain. Thus, it is not surprising that 
microglial sensing of the neuronal glycocalyx is involved in many neurodegenerative diseases. 
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1.2.1.1 Microglial sensing in brain development 
Microglia are essential in the development of the brain as reviewed in details by Frost and 
Schafer (2016). As professional phagocytes, they can remove entire cells, cellular debris, as 
well as cellular substructures like synapses (Figure 5). Microglia also recognize cells that 
already undergo apoptosis (e.g. via purinergic receptors). During brain development about 50 % 
of all synthesized neurons and glial cells are eliminated by microglia (Bilimoria and Stevens, 
2015). Microglia mediate the migration and differentiation of neuronal precursor cells and 
control neurogenesis. To do so, they either actively initiate cell death as it was observed in vitro 
(Frade and Barde, 1998; Marín-Teva et al., 2004) as well as in vivo (Cunningham et al., 2013; 
Mazaheri et al., 2014) or promote neuronal survival and proliferation by secreting neural 
survival factors (Nagata et al., 1993; Chamak et al., 1994). 
 
Figure 5: Different microglial phenotypes during development and adulthood of the brain. This schematic 
overview shows the different microglial states from early embryonic development until the fully developed brain. 
During this time microglia change their morphology from amoeboid forms to widely ramified cells. Upon 
activation and in the diseased brain microglia again adopt an amoeboid form. Functional modifications occur in 
parallel to morphological changes. (Scheme is based on a figure from Soulet and Rivest, 2008.) 
The term ‘synaptic pruning’ describes the elimination of excess synaptic connections. Studies 
in the visual cortex could show how presynaptic inputs from retinal ganglion cells were tightly 
monitored by microglia in the dorsal lateral geniculate nucleus (Tremblay et al., 2010). In 
addition, mouse studies have implemented that the complement system is also involved in this 
process by possibly tagging unwanted synaptic structures that can then be recognized by the 
complement receptors expressed on microglia (Stevens et al., 2007; Schafer et al., 2012; Bialas 
and Stevens, 2013; Hong et al., 2016b). Later during postnatal development microglia still play 
a major role in synapse maturation and pruning. Furthermore, a study in the mouse 
hippocampus could show microglial engulfment of synapses via fractalkine (Paolicelli et al., 
2011). Fractalkine (CX3CL1) is another essential mediator during development that is secreted 
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by neurons and can be recognized by the fractalkine receptor (CX3CR1) expressed on microglia 
(Ransohoff and El Khoury, 2015). 
1.2.1.2 Microglial sensing in the adult and in the aging brain 
During homeostasis (‘resting’ state), microglia permanently surveil the brain parenchyma for 
alterations with their highly motile processes (Nimmerjahn et al., 2005; Figure 5). Occasionally, 
microglial processes rest for a certain time and contact neuronal synapses. In the visual cortex, 
it was shown that these contacts were dependent on neuronal activity. Less active synapses 
were removed to support strong firing neuronal networks (Tremblay et al., 2010). 
In a dangerous situation or upon ligand binding the so called ‘quiescent’ state (surveillance 
state) of microglia gets modulated into an ‘activated’ state (remodeling state; Figure 5), which 
must not be mixed up with the term ‘polarization’, the functional reprogramming of 
macrophages upon stimulation. This macrophage concept is not appropriate for microglia. 
Microglia ‘activation’ is normally accompanied by retraction of processes, increased 
proliferation, and expression and release of certain cytokines (Brown and Vilalta, 2015). 
Depending on the external trigger, microglia can develop numerous phenotypes. Microglia 
‘activation’ was typically considered to induce inflammation by secreting signaling proteins 
that activate and recruit other immune cells. Recent in situ studies, in contrast, point out that 
the highly dynamic microglial states can be neurotoxic and neuroprotective at the same time 
and vary in a context- and tissue-dependent manner (Park et al., 2008; Shigemoto-Mogami et 
al., 2014). Microglia specificity is further achieved by a regional microglial heterogeneity that 
was first described in 1990 by Lawson and colleagues (Lawson et al., 1990) and by the observed 
differences in microglial density in different brain regions, being highest in the hippocampus, 
basal ganglia, substantia nigra and the olfactory bulbs (Yang et al., 2013). 
A phenotype called ‘microglial priming’ defines the enhanced and prolonged response to 
homeostatic disturbances by microglia compared to naïve ones (Norden and Godbout, 2013; 
Perry and Holmes, 2014). Primed microglia show a more amoeboid morphology with enlarged 
soma and shorter processes. In parallel, cytokine release of pro- and anti-inflammatory factors 
like tumor necrosis factor alpha (TNFa), interleukin 1 beta (IL1b), IL6, IL10, transforming 
growth factor beta (TGFb), CD11c, major histocompatibility complex-II and AXL receptor 
tyrosine kinase are increased. Microglial priming occurs during normal aging but can also be 
induced by persistent neuroinflammation, chronic exposure to misfolded proteins and neuronal 
debris (e.g. in Alzheimer’s disease, see Heneka et al., 2015). In human brain tissue, dystrophic 
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microglia are characterized by deramification, loss of fine cytoplasmic processes, cytoplasmic 
beading, and cytoplasmic fragmentation (reviewed in Streit and Xue, 2014). Presumably, the 
reduction of microglia-neuron interactions and the accompanied downregulation of neuronal 
ligands that normally activate microglial inhibitors (e.g. CX3CL1, CD42, or CD202) are the 
major underlying mechanisms that lead to this increased responsiveness to intrinsic and 
extrinsic stimuli in aging microglia. Consequences of brain aging are (1) increased neuronal 
loss, (2) neuroinflammation, and (3) increased oxidative stress due to mitochondrial damage 
and enhanced reactive oxygen species (ROS) production by microglia (von Bernhardi et al., 
2015). 
1.2.1.3 The role of microglia in diseases 
In neuroinflammatory diseases, such as multiple sclerosis (MS) or stroke, microglial activation 
is one of the major occurring events (Benakis et al., 2014; Bogie et al., 2014). In MS studies 
(mainly on mouse models), microglia become activated and proliferate already before onset of 
disease. They migrate to degenerating axons to remove myelin debris, which was shown to be 
beneficial in MS (Giunti et al., 2014). However, microglia also function as antigen-presenting 
cells and recruit T cells to the brain that increases the inflammation and leads to further 
neurotoxic events. 
Hallmarks of neurodegenerative diseases (e.g. Alzheimer’s disease, Parkinson’s disease or 
amyotrophic lateral sclerosis) are aggregated and misfolded proteins and age-related deposition 
of debris (Heneka et al., 2014; Ransohoff and El Khoury, 2015). In Alzheimer’s disease (AD) 
pathology, increasing numbers of proinflammatory microglia surround amyloid beta plaques. 
Single-nucleotide polymorphism in genes related to phagocytosis and cytokine signaling (e.g. 
TREM2 [= triggering receptor expressed on myeloid cells 2], CD33, CR1 [= complement 
receptor 1], APOE [= apolipoprotein E]) are associated with increased AD risks. Consensus 
agrees that insufficient protein degradation and decreasing microglia clearance capability 
correlates with amyloid beta plaques formation and that it is difficult to distinguish between 
age-related and purely AD-related microglial changes. Another major neurodegenerative 
disease is amyotrophic lateral sclerosis (ALS). While in early stages of ALS microglia are 
protecting the brain by increased release of brain-derived neurotrophic factor (BDNF), in later 
stages chronic activation of microglia becomes neurotoxic and finally results in a complete 
microglia impairment and accelerated disease progression (Brites and Vaz, 2014; Radford et 
al., 2015). Microglia activation also plays a central role in Parkinson’s disease (PD). The 
occurrence of Lewy bodies and alpha-synuclein aggregates in the brain of PD patients goes 
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along with microglial phagocytosis and activation as it was observed in positron emission 
tomography imaging studies (Cicchetti et al., 2002; Bartels et al., 2010; Surendranathan et al., 
2015). Beside the beneficial removal of the protein aggregates increasing cytokine release leads 
to enhanced stress and neuronal death in the substantia nigra of PD patients (Machado et al., 
2016). 
Microglia also play a central role in psychiatric disorders. In contrast to neuroinflammatory and 
neurodegenerative diseases the diagnoses of psychiatric disorders are more diffuse. In general, 
a dysbalance of the peripheral immune system drives neuroinflammation and microglia 
activation in the brain (Stertz et al., 2013; Leza et al., 2015; Inta et al., 2017). In schizophrenia, 
this is thought to interfere with the expression of local brain mediators, like serotonin, glutamate 
and dopamine. In autism spectrum disorders (ASD) microglia activation and/ or proliferation, 
and defective BDNF signaling was reported (Estes and McAllister, 2015; Koyama and Ikegaya, 
2015; Petrelli et al., 2016). Similar to ASD, studies from postmortem brain of schizophrenia 
and bipolar disorders patients indicate abnormalities in regional microglia density and 
morphology that are changing during disease progression. Recently, genome-wide association 
studies linked microglial sensing receptors, like the major histocompatibility complex 
(Mokhtari and Lachman, 2016) and alleles of the complement component 4 (Sekar et al., 2016) 
with schizophrenia. Taken together, these data show that environmental risk factors combined 
with a genetic disposition might result in aberrant microglial activation or dysregulated synaptic 
pruning. The disruption of the fine interplay between microglia and the neuronal network might 
then develop into a psychiatric disorder. 
1.2.1.4 Microglial sensing of the neuronal glycocalyx 
Microglia have a diverse set of surface receptors to recognize the neuronal glycocalyx and to 
survey the brain parenchyma for foreign structures (reviewed in ElAli and Rivest, 2016). Some 
of these receptors belong to the group of pattern recognition receptors (PRRs), such as toll-like 
receptors, which recognize pathogen- as well as damage-associated molecular patterns (PAMPs 
and DAMPs). While PAMPs are normally found on microbes, DAMPs are generally released 
by damaged or dysfunctional cells as a result of aging or environmental risk factors (e.g. 
proteins like amyloid beta, alpha-synuclein, and hungtintin) and the activation of PRRs 
normally induces neuroinflammation. Scavenger receptors, like CD68 (also known as 
Macrosialin) are important for an innate immune response (Peiser et al., 2002). Under normal 
conditions, CD68 is expressed on the intracellular membrane of late endosomes and is actively 
involved in microglial phagocytosis. Its expression is increased upon activation by oxidized 
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low density lipoproteins (Ramprasad et al., 1996) and therefore, also seen as a typical microglia 
activation marker. Cytokine receptors play a crucial role in modulating microglial cell function. 
Microglia can be activated by cytokines from other cell types but also by their own released 
cytokines in a positive autocrine manner (Nadeau and Rivest, 2000; Kuno et al., 2005). 
Microglia are the main source of the proinflammatory cytokine TNFa in the brain (Dopp et al., 
1997). IL1b signaling leads to nuclear factor-kappa B (NF-κB) pathway activation (Spörri et 
al., 2001), whereas IL4 and IL10 are potent anti-inflammatory modulators of microglial 
function (Ledeboer et al., 2000). 
 
Figure 6: A schematic overview of several microglial receptors. Microglia express a diverse set of receptors on 
their cell surface. The location can be close to the soma as well as in the distant processes. The different surface 
receptors help microglia to communicate with other cells and to sense alterations in the brain. Internal receptors 
like CD68 are mainly involved in phagocytosis and degradation pathways. CR – complement receptor; CX3CR1 
– fractalkine receptor; NADPH - nicotinamide adenine dinucleotide phosphate; NTM-R – neurotransmitter 
receptor; ROS – reactive oxygen species; Siglec - sialic acid-binding immunoglobulin-type lectins; TLR – toll-
like receptors. 
Chemokine signaling is another way of cell-cell communication in the brain. Chemokines are 
produced by different cell populations in the brain and are soluble mediators that function as 
chemoattractant and direct cell motility. One specific case is CX3CL1, which is produced by 
neurons. It can act either as soluble mediator or bound to the neuronal membrane (Fernandez 
and Lolis, 2002). CX3CL1-CX3CR1-signaling in neuron-microglia communication regulates 
microglial dynamics and migration during neuronal maintenance (Paolicelli et al., 2014). 
Microglia even express receptors for different neurotransmitters, like ATP, glutamate, gamma-
aminobutyric acid (GABA), dopamine or acetylcholine to ensure an optimal neuron-microglia 
crosstalk (reviewed in Kettenmann et al., 2011). 
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To specifically recognize sialic acids on the neuronal glycocalyx microglia express Siglecs 
(reviewed in Linnartz and Neumann, 2013). Siglecs are type 1 transmembrane receptors and 
are only expressed on cells of the myeloid lineage (Crocker et al., 2007). These regulatory 
receptors tightly control the microglial immune function and can signal via the immunoreceptor 
tyrosine-based activation motif (ITAM) in their cytoplasmic tail or act as an inhibitory receptor 
via the immunoreceptor tyrosine-based inhibition motif (ITIM). Downstream of ITAM the Src 
and Syk tyrosine kinases are recruited (Daëron, 1997) that generate a mitogen-activated protein 
kinase (MAPK)-NF-κB response, while ITIM activation results in the recruitment and 
activation of Src homology region 2 domain-containing phosphatase-1 (SHP1) and Src 
homology region 2 domain-containing inositol phosphatase-1 (SHIP1) and thus, an inhibitory 
response (Billadeau and Leibson, 2002). Siglec signaling is mainly inhibitory and contributes 
to microglial cell adhesion, endocytosis, cytokine release and phagocytosis. The inhibitory 
mouse Siglec-E (or CD33) was proven to recognize sialic acids on the neuronal glycocalyx, 
which prevented phagocytic removal. Furthermore, this neuroprotective effect disappeared 
after enzymatic removal of sialic acids (Claude et al., 2013). 
1.2.2 The complement system 
The complement system is one of the major mechanisms of effective host defense against initial 
infections as described in detail by Murphy and colleagues (Murphy et al., 2008). In short, the 
activation of the complement system by foreign structures leads to a rapidly amplifying cascade 
starting with the coating of the foreign structures (opsonization). Recognition of opsonized 
structures by complement-specific receptors on macrophages leads either to the uptake via 
phagocytosis or alternatively, to detrimental inflammatory downstream processes that result in 
the lysis of the opsonized cells (Figure 7). In contrast, recent publications also described the 
complement cascades as key system in brain homeostasis and is reviewed by Ricklin et al. 
(2010). 
1.2.2.1 Complement components and its signaling pathways 
In general, the complement system consists of different plasma proteins, which can be activated 
either directly by pathogens or indirectly by antibodies bound to pathogens. These activated 
plasma proteins on the pathogen surface initiate a cascade of protease cleavage reactions with 
the active form of complement component 3b (C3b) as central event and three final defense 
strategies as described below. 
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Depending on the initial trigger three different pathways are discriminated: the classical 
pathway, the lectin pathway, and the alternative pathway (see Figure 7). In the classical 
pathway, the cascade is triggered directly by the pathogen itself or by pathogen-bound 
antibodies (lower pathway, Figure 7). The recognition protein C1q binds to the charged targets 
on the pathogen and activates the proteases C1r and C1s within the C1 complex 
(C1q:C1r2:C1s2). Activated C1s then cleaves C4 and C2, thereby generating a C3 convertase 
complex (C4b2a), which can cleave the complement component 3 (C3) into the active form 
C3b and the soluble mediator C3a (“Opsonization”, Figure 7). The lectin pathway is activated 
upon mannose-binding lectins (MBL) on the pathogen surface or upon the binding of 
carbohydrates through ficolins (middle pathway, Figure 7). Like the C1 complex, MBL or 
ficolin form a complex with MBL-associated serine proteases (MASPs). Upon binding, 
activated MASPs cleave and activate C4 and C2 resulting in the formation of a C3 convertase 
(C4b2a) as well. In the alternative pathway, the cleavage cascade is triggered by spontaneous 
hydrolysis of C3 into the active form C3b in the absence of a specific antibody (upper pathway, 
Figure 7). This alternative event is accompanied by binding of plasma protein factor B and a 
protease called factor D to form another active C3 convertase (C3bBb). Only if the active form 
C3b immediately tags the foreign cell, the pathway is amplified. Otherwise it will be directly 
deactivated. Thus, the alternative pathway provides a basic pattern recognition mechanism and 
an amplification loop for the other two pathways. After the initial activation, all three pathways 
converge on the convertase C3 that cleaves C3 into the active form C3b and a smaller soluble 
fragment C3a (see red square in Figure 7). The active form C3b binds directly to the pathogen 
(opsonization) and is the central event in the complement activation. 
Abundant C3b opsonization of the pathogen is recognized by immune cells via complement 
receptors and is followed by phagocytic removal as one of three defense strategies. In addition, 
C3b can also form a C5 convertase (C4b2a3b or C3bBb3b) that cleaves C5 and produces the 
very potent inflammatory peptide C5a and the large fragment C5b. The active C5b recruits the 
terminal complement components. In the final phase (“Lysis”, Figure 7) the complement 
components C5b, C6, C7, C8, and C9 assemble the membrane-attack complex (MAC) to form 
a pore in the membrane of the pathogen surface, which leads to the lysis and the death of the 
pathogen (second defense strategy). The third defense strategy is accomplished by the small 
soluble cleavage fragments C4a, C3a, C5a (see Figure 7, encircled in orange). These fragments 
are powerful peptide mediators of inflammation contributing to the prompt initiation of the 
adaptive immune cells but also function as chemoattractant to recruit phagocytes to the site of 
infection. 
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Figure 7: Overview of the three complement signaling pathways. The complement signaling pathways are 
cascades of protease cleavage reactions. Dependent on the initial trigger three different pathways can be 
distinguished: the classical pathway, the lectin pathway, and the alternative pathway. All three pathways can be 
divided into a recognition phase, an opsonization phase and a lysis phase. In the opsonization phase all three 
pathways converge on the central cleavage event of C3 into C3b and C3a (red box). This leads further downstream 
to either the assembly of the membrane-attack complex (MAC) with subsequent lysis, to the chemotactic 
recruitment of immune cells, and to phagocytosis (orange arrows). MBL - mannose-binding lectins (Images taken 
and modified from Murphy et al., 2008 and Mayilyan, 2012.)  
The complement system is an amplifying cascade that can be initiated by only a small number 
of complement proteins but then turns rapidly into a large effective immune response. To 
prevent unintentional, spontaneous activation of the complement cascade and unnecessary 
tissue damage, several regulatory proteins have coevolved. Complement regulatory proteins 
can be found as soluble plasma proteins (e.g. factor H and Properdin) or bound to the host-cell 
membrane (e.g. decay-accelerating factor, DAF and CR1). These molecules ensure that correct 
complement activation only takes place close to the cell surface. 
However, inappropriate activation of the complement system or defects in complement 
regulator proteins can lead to impaired host defense against certain pathogens and increased 
susceptibility to autoimmune diseases (Mayilyan, 2012). For instance, deficiency in early 
components of the cascade like C1, C2, C4 or MBL is often associated with systemic lupus 
erythematosus (Agnello et al., 1972; Day et al., 1973; Bowness et al., 1994; Pickering et al., 
2000; Yang et al., 2004; Glesse et al., 2011), whereas recurrent invasive infections are more 
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associated with deficiencies in the terminal components C5, C6, C7, C8, and C9 (Mayilyan, 
2012). Impaired neutrophil or monocyte recruitment can be due to mutations in complement 
receptor 3 (CR3; Springer et al., 1984, 1986) and a deficiency in the regulatory factor H 
contributes to age-related macular degeneration (AMD; Skerka et al., 2007). 
1.2.2.2 The role of complement system in homeostasis 
In the recent years, our view of the complement system has fundamentally changed as reviewed 
by Ricklin and colleagues (Ricklin et al., 2010). Beside immune surveillance the complement 
system seems to play a not negligible role in cell homeostasis and tissue development and 
repair. The involvement of the complement system in processes, like synapse maturation 
(Stevens et al., 2007; Kraft et al., 2016), clearance of immune complexes and endogenous 
debris, angiogenesis (Nozaki et al., 2006), mobilization of hematopoietic stem-progenitor cells 
(Shinjyo et al., 2009), neurogenesis, and tissue regeneration (Nozaki et al., 2006; Markiewski 
et al., 2009) are currently under investigations. Most homeostatic pathways are carried out by 
the classical complement pathway. In contrast to a normal immune response, the activation of 
the inflammatory C5a-C5aR-axis or the MAC formation (Gershov et al., 2000) are inhibited 
and tightly regulated during homeostasis. Pathways that normally lead to oxidative burst in 
macrophages are strictly downregulated. Additionally, a connection between the complement 
system and metabolism was recently pointed out (Hotamisligil, 2006; Kolev and Kemper, 
2017). Data demonstrated that adipocytes communicate with macrophages (Wellen and 
Hotamisligil, 2005) and for instance, C3 was reported as a strong marker of insulin resistance 
in elderly patients (Muscari et al., 2007). 
Likewise, failure in effective housecleaning (e.g. removal of apoptotic debris or immune 
complexes) not only impairs host homeostasis but can have detrimental consequences for the 
whole system. The complement system was linked to a number of neurological diseases, like 
AD (Fonseca et al., 2009), PD (Loeffler et al., 2006), glaucoma (Stevens et al., 2007), MS 
(Ingram et al., 2009; Michailidou et al., 2016), and schizophrenia (Mayilyan et al., 2008; Sekar 
et al., 2016). Furthermore, in a mouse model of repeated systemic challenge with 
lipopolysaccharides (LPS), inflammation induces neuronal loss in the substantia nigra by the 
activation of the microglial complement-phagosome pathway (Bodea et al., 2014). 
These findings once more highlight the close interaction between the complement system and 
microglia in the brain and support the emerging view that the functions of the complement 
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system go beyond pure immune surveillance and might contribute substantially to the 
homeostasis in the brain. 
1.3 Modelling alterations in the glycocalyx 
Previous publications from Linnartz-Gerlach and colleagues (Linnartz et al., 2012b; Linnartz-
Gerlach et al., 2016) showed that the removal of sialic acids from the glycocalyx, the “Don’t 
eat me”-signal, leads to neuronal removal in vitro. This complement-mediated phagocytosis by 
microglia was investigated in both, murine and human neuron-microglia/macrophage co-
cultures. Blocking of the CR3 (but not of the additionally existing CR1 in the human system) 
was able to prevent the phagocytic removal of neurons by microglia in vitro. However, to 
understand how microglia deal with alterations of the glycocalyx in the complex in vivo 
situation a suitable model for mimicking an altered glycocalyx was needed. Enzymatic removal 
of sialic acid residues by sialidases as it was performed in these cell culture experiments was 
not an option for in vivo studies. In 2002, Schwarzkopf and colleagues engineered a mouse 
heterozygous for GNE (GNE+/- mice), the essential enzyme of the sialic acid biosynthesis 
(Schwarzkopf et al., 2002). The inactivation of GNE was realized by targeted mutagenesis of 
exon 2 of the UDP-GlcNAc 2-epimerase gene. As mentioned before, GNE catalyzes the two 
initial steps in the sialic acid biosynthesis (see also Figure 3). However, the complete knockout 
of the GNE gene (GNE-/-) in mice leads to prenatal lethality between E8.5 and E9.5 and could 
only be fully investigated in embryonic stem cells (Schwarzkopf et al., 2002). Nevertheless, 
first studies showed that the mice heterozygous for GNE (GNE+/-) expressed decreased levels 
of sialic acids in different organs (Gagiannis et al., 2007). Gagiannis and colleagues described 
an overall reduction of membrane-bound sialic acids by 25 % in the otherwise healthy 
appearing GNE+/- mice making them a suitable model for investigating the role of an altered 
glycocalyx. 
1.4 Aims of this project 
Neuronal loss is a central event in neurodegenerative diseases and during aging. Although 
thorough research investigations are taking place to understanding the principles of the neuronal 
loss, suitable therapies are still missing. As described before, sialic acids can be easily removed 
during oxidative stress and are shown to be decreased in the aged brain as well. Therefore, I 
addressed in this study the question whether such reduced levels of sialic acids can lead to 
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neuronal loss in the brain as proposed in the model based on in vitro data (Figure 8) and whether 
aging plays a role. 
The first intention of this study was to set up an in vivo model to mimic an altered glycocalyx 
as shown previously in vitro (Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016). Secondly, I 
wanted to understand if the neuronal loss in vivo is also mediated via microglia and the 
complement system as the in vitro data has shown and if this mechanism is causing 
neuroinflammation in the brain. Furthermore, I wanted to clarify if the neuronal loss can be 
prevented via inhibition of the complement system in such a complex system and what effect 
aging might play. 
To solve these questions, I characterized the sialylation status in the brain of the transgenic 
GNE+/- mice during aging in more depths and evaluated the GNE+/- mice as model for an altered 
glycocalyx. The neuronal density was investigated in different brain regions of GNE+/- mice at 
several time points and possible microglia alterations on transcription and protein levels were 
examined. Furthermore, the transcription analysis of inflammatory cytokines and investigations 
for astrogliosis helped to elucidate if neuroinflammation is occurring in the brain of these mice. 
I reconsidered the complement system as underlying pathway and checked for typical markers 
on transcription level. In addition, a transcriptome analysis was performed on adult mouse 
brains to understand the full impact of altered sialylation. Once the in vitro data were confirmed 
and I could show that in vivo reduced sialic acid levels lead to neuronal loss by microglia in a 
complement-dependent manner, GNE+/- mice were crossed with mice deficient for the central 
complement factor C3 (C3-/- mice) to rescue the neuronal loss in vivo. 
In summary, with this project the previously discovered in vitro mechanisms were transferred 
into the living system to confirm and understand the impact of glycocalyx alterations. This 
study highlights the importance of sialic acids on the glycocalyx in prevention of neuronal loss 
especially during aging. 
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Figure 8: Proposed model of glycocalyx alteration. Sialic acids on the neuronal glycocalyx serve as “Don’t eat 
me”-signal and inhibit microglia via the inhibitory Siglecs. Environmental factors, like oxidative stress and aging 
can reduce the level of sialic acids. Consequently, an altered neuronal glycocalyx with reduced sialic acids misses 
the inhibitory signal and simultaneously is recognized by the complement system that activates microglial 
phagocytosis. This pathway leads to removal of desialylated neurons by microglia. The proposed model highlights 
the important function of sialic acids on the neuronal glycocalyx. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Name Company 
1,4-diazabicyclo[2.2.2]octane (DABCO) Sigma, Germany 
4',6-diamidino-2-phenylindole (DAPI) Sigma, Germany 
Agarose (PeqGOLD Universal) PeqLab, Germany 
AquaPoly/Mount Polysciences Europe, Germany 
Boric acid (H3BO3) Roth, Germany 
Bovine serum albumin (BSA) Sigma, Germany 
Double-distilled water (ddH2O) autoclaved and filtered in the institute 
Dulbecco’s Phosphate Buffer Solution (PBS) Gibco, Germany 
Ethanol (C2H6O) Roth, Germany 
Ethidium Bromide (10g/l) Roth, Germany 
Ethylendiamintetraacetate (EDTA) Roth, Germany 
Glycerol Sigma, Germany 
Hexanucleotide Mix (10x) Roche, Germany 
Isopropanol Roth, Germany 
KETANEST® S (Ketamin) Pfizer Pharma, Germany 
Mowiol 4-88 Kremer Pigmente, Germany 
Normal goat serum (NGS) Sigma, Germany 
O.C.T.TM Compound, Tissue Tek® Sakura, USA 
Paraformaldehyde (PFA) Sigma, Germany  
QIAzol Lysis Reagent Qiagen, Germany 
Rompun® 2% (Xylazin) Bayer, Germany 
Sodium azide Sigma, Germany 
Sodium chloride (NaCl) Roth, Germany 
Sodium hydroxide (NaOH) Roth, Germany 
Sodiumhydrogenphosphate (NaH2PO4*7H2O) Roth, Germany 
Sodiumhydrogenphosphate (NaH2PO4*H2O) Roth, Germany 
Sucrose Roth, Germany 
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SuperScript® III Reverse Transcriptase Invitrogen, Germany 
SYBR® Green ERTM qPCR Super Mix Invitrogen by Life Technologies, USA 
Tert-amyl alcohol Sigma, Germany 
Trichloromethane/chloroform Roth, Germany 
Tris base Roth, Germany 
Tris buffer, 0.2 M Roth, Germany 
Triton X-100 Sigma, Germany 
2.1.2 Consumables 
Name Company 
1 ml syringe Braun, Germany  
10 μl, 100 μl, 1000 μl pipette tips StarLab, Germany  
15 ml plastic tubes Greiner, Germany  
5 ml, 10 ml, 25 ml plastic pipettes Costar, Germany  
50 ml plastic tubes Sarstedt, Germany  
Cell strainer 40 µm Nylon  BD Falcon, Germany  
Cell strainer 70 µm Nylon BD Falcon, Germany 
Disposable vinyl specimen molds (Cryomold®, 
25 x 20 x 5 mm) 
Tissue-Tek® Sakura, USA 
Erlenmeyer flask, 250 ml Schott-Duran, Germany 
Examination gloves (Micro-Touch)   Ansell Healthcare, Belgium 
Glass cover slips (24 x 60 mm) Thermo Scientific, USA 
Injection needles Braun, Germany  
Polymerase chain reaction (PCR) tubes, 500 µl Biozym Scientific GmbH, Germany  
QPCR Seal optical clear film PeqLab, Germany 
QPCR Semi-skirted 96 Well PCR Plate PeqLab, Germany 
Stainless steel beads (7 mm) Qiagen, Germany 
SuperFrost® Plus microscope slides Thermo Scientific, USA 
2.1.3 Technical equipment 
Name Company 
Agilent 2100 Bioanalyzer Agilent, Luxembourg 
AxioImager.Z1/ApoTome microscope Zeiss, Germany 
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BD fluorescence-activated cell sorter (FACS) 
Calibur 
BD Biosciences 
Biofuge Fresco/ pico  (centrifuges) Heraeus, Germany  
Electrophoresis Power Supply EPS-301 Amersham Bioscience, Germany 
Fluoview1000 Confocal microscope Olympus, Germany 
Freezer -20 °C ProfiLine Liebherr, Germany 
Freezer -80 °C Herafreeze Heraeus, Germany 
GelDoc BioRad, Germany 
HI 9321 Microprocessor pH meter Hanna Instruments, Germany  
Mastercycler epgradient S Eppendorf, Germany  
Megafuge, 1.0 R. (centrifuge) Heraeus, Germany  
Microm Cryo Star HM 560 Thermo Scientific, USA 
NanoDrop 2000c spectrophotometer Thermo Scientific, USA 
NextSeq 500 Illumina, USA 
Perfect BlueTM Horizontal Midi/Mini Gel 
Systems 
PeqLab, Germany 
Pumpdrive 5001 (perfusion pump) Heidolph, Germany 
Thermocycler T3 (PCR maschine) Biometra, Germany 
Thermomixer compact (heating block) Eppendorf, Germany  
Tissue Lyser LT Qiagen, Germany 
Vortex Genie2 Scientific Industries Inc., USA  
2.1.4 Buffers and solutions 
Name Ingredients 
1 % Agarose gel 0.6 g agarose 
3 µl ethidium bromide 
60 ml Tris/Borate/EDTA buffer (1x) 
10x (0.125 M) phosphate buffered saline (PBS), 
pH 7.3 
0.007 M NaH2PO4*H2O 
0.034 M NaH2PO4*7H2O 
0.6 M NaCl 
up to 1 liter ddH2O 
10x BSA  10 g BSA in 100 ml 1x PBS 
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10x Tris/Borate/EDTA (TBE) buffer 1.78 M Tris base 
1.78 M boric acid 
0.04 M EDTA (pH 8.0) 
up to 2 litre ddH2O 
30 % sucrose solution 30 g sucrose in 100 ml 1x PBS 
0.1 % sodium azide 
4 % paraformaldehyde (PFA), pH 7.3 20 g PFA + 30 ml NaOH + 50 ml PBS (1x) 
up to 1 litre ddH2O 
Anaesthesia solution (Ketamin/Xylazin) 2 ml Ketanest 
0.5 ml Rompun 
2.5 ml ddH2O 
Mowiol 4.8 g Mowiol 4-88 
12 g Glycerol 
24 ml 0.2 mM Tris buffer, pH 8.5 
1.32 g DABCO 
12 ml ddH2O 
Tris buffer pH 8.5 50 mM Tris 
150 mM NaCl 
Adjust pH with HCl to pH 8.5 
2.1.5 Mice 
Mouse line Mouse strain Origin/Provider 
C57BL/6J C57BL/6J Charles River, Sulzfeld, Germany 
C3-/- B6;129S4-C3tm1Crr/J Charles River, Sulzfeld, Germany 
GNE+/- 129/OLA and Balb/C mixed 
background mouse with 
heterozygous deletion of GNE 
gene (Schwarzkopf et al. 2002) 
Animals were kindly provided by Prof. 
Horstkorte (University of Halle-
Wittenberg, Halle [Saale], Germany). 
GNE/C3 GNE+/- mice crossed with C3-/- 
mice 
 
2.1.6 Primers 
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Target Orientation Sequence 
37 forward 5’ –CACCAGGCTCCACACGATTG– 3’ 
42 reverse 5’ –GATTGAAATATGCCCAATACTTTG– 3’ 
Aif1 forward 5’ –GAAGCGAATGCTGGAGAAAC– 3’ 
reverse 5’ –AAGATGGCAGATCTCTTGCC– 3’ 
A541 forward 5’ –CGAAGGAGCAAAGCTGCTATTGGCC– 3’ 
C1qa forward 5’ –AGAGGGGAGCCAGGAGC– 3’ 
reverse 5’ –CTTTCACGCCCTTCAGTCCT– 3’ 
C1qb forward 5’ –GACTTCCGCTTTCTGAGGACA– 3’ 
reverse 5’ –CAGGGGCTTCCTGTGTATGGA– 3’ 
C1qc forward 5’ –GCCTGAAGTCCCTTACACCC– 3’ 
reverse 5’ –GGGATTCCTGGCTCTCCCTT– 3’ 
C3 forward 5’ –TAGTGCTACTGCTGCTGTTGGC– 3’ 
reverse 5’ –GCTGGAATCTTGATGGAGACGCTT– 3’ 
C3geno forward 5’ –ATCTTGAGTGCACCAAGCC– 3’ 
C3mt reverse 5’ –GCCAGAGGCCACTTGTGTAG– 3’ 
C3wt reverse 5’ –GGTTGCAGCAGTCTATGAA– 3’ 
C4b forward 5’ –TGGAGGACAAGGACGGCTA– 3’ 
reverse 5’ –GGCCCTAACCCTGAGCTGA– 3’ 
Cd68 forward 5’ –CAGGGAGGTTGTGACGGTAC– 3’ 
reverse 5’ –GAAACATGGCCCGAAGTATC– 3’ 
GAPDH (ms) forward 5’ –ACAACTTTGGCATTGTGGAA– 3’ 
reverse 5’ –GATGCAGGGATGATGTTCTG– 3’  
Gne forward 5’ –AAACTGGCCCCGATCATGTT– 3’ 
reverse 5’ –TCTACCATGGCCGCTTCATC– 3’ 
Il1b forward 5’ –CTTCCTTGTGCAAGTGTCTG– 3’ 
reverse 5’ –CAGGTCATTCTCATCACTGTC– 3’ 
Itgam forward 5’ –AATTGGGGTGGGAAATGCCT– 3’ 
reverse 5’ –TGGTACTTCCTGTCTGCGTG– 3’ 
Tmem119 forward 5’ –GTGTCTAACAGGCCCCAGAA– 3’ 
reverse 5’ –AGCCACGTGGTATCAAGGAG– 3’ 
Tnfa forward 5’ –GGTGCCTATGTCTCAGCCTC– 3’ 
reverse 5’ –TGAGGGTCTGGGCCATAGAA– 3’ 
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2.1.7 Antibodies 
2.1.7.1 Primary antibodies 
Antigen host company dilution 
A2B5 mouse BD Pharmingen, #563775 1:200 
CD56 rat BD Pharmingen, #556325 1:200 
CD68 rat AbD Serotec, MCA1957 1:500 
Glial fibrillary acidic protein (Gfap) rabbit DAKO, #Z0334 1:500 
IgM kappa mouse BD Pharmingen, #557275 1:200 
IgM kappa rat BD Pharmingen, #553940 1:200 
Ionized calcium binding adaptor 
molecule 1 (Iba1) 
rabbit Wako, #019-19741 1:1000 
Neuronal nuclei (NeuN) mouse Millipore, MAB377 1:500 
Polysialylated neural cell adhesion 
molecule (PSA-NCAM) 
mouse Millipore, MAB5324 1:200 
Tyrosine hydroxylase (TH) rabbit Sigma, # T8700 1:1000 
2.1.7.2 Secondary antibodies 
Fluorophore reactivity host company dilution 
Alexa Fluor® 488 rabbit goat Invitrogen, #A11008 1:500 
Alexa Fluor® 488 rat goat Invitrogen, #A11006 1:500 
Cyanine 3 (Cy3)-conjugated 
F(ab’)2 fragment 
mouse goat Dianova, #115-166-072 1:200 
Cy3-conjugated F(ab’)2 
fragment 
rat goat Dianova, #112-166-072 1:200 
R-Phycoerythrin (PE)-
conjugated F(ab’)2 fragment 
rat goat 
Jackson Immuno 
Research, #112-116-143 
1:200 
PE-conjugated F(ab’)2 fragment mouse goat 
Jackson Immuno 
Research, #115-116-146 
1:200 
2.1.8 Kits and markers 
Name Company 
100 base pair DNA ladder Invitrogen, Germany 
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KAPA mouse genotyping Hot Start Kit PeqLab, Germany 
Qubit dsDNA HS assay Kit Thermo Scientific, USA 
RNase-Free DNase Set Qiagen, Germany 
RNeasy® Mini Kit Qiagen, Germany 
SuperScript First-Strand Synthesis System Invitrogen, Germany 
TruSeq Stranded mRNA Library Prep kit Illumina, USA 
2.1.9 Software 
Name Company 
AxioVisio V4.8.2.0 Zeiss, Germany 
Corel Draw® X5 + X8 Corel GmbH, Germany 
Ensembl8 (GRCm38.p3, release 79) EMBL-EBI, UK 
FastQC v0.11.3 Babraham Bioinformatics, UK 
FlowJo 8.6 Tree Star, USA 
GraphPad QuickCalcs GraphPad Software Inc., USA 
IBM SPSS Statistics (v.22) IBM Corporation, Germany 
ImageJ 1.46h + NeuronJ plugin National Institute of Health, USA 
Ingenuity Pathway Analysis® Qiagen, USA 
Master cycler ep realplex Eppendorf, Germany 
Mendeley Desktop (v1.17.9) Mendeley Ltd., USA 
Microsoft Office 2010 Microsoft, USA 
NanoDrop 2000/2000c  Thermo Fisher Scientific, USA 
Olympus FluoView V3.1 Olympus, Germany 
Prism 7 (v7.01) GraphPad Software Inc., USA 
QuantityOne Bio-Rad, Germany 
R (v3.4.0; free software) R Core Team, https://www.R-project.org/ 
RStudio (v1.1; free software) RStudio, http://www.rstudio.com/ 
Spliced Transcripts Alignment to a 
Reference9 (STAR) v2.5.2b 
Illumina, USA 
STATA®/IC (v13.1 for Windows) Stata Corp. LP, USA 
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2.2 Methods 
2.2.1 Mice 
For the characterization of an altered glycocalyx in vivo, mice heterozygous for the bifunctional 
enzyme GNE (referred as GNE+/- mice in the text) were kindly provided by Prof. Horstkorte 
(University of Halle-Wittenberg, Halle [Saale], Germany). The GNE+/- mice have a targeted 
deletion in exon 2 of the mouse Gne coding region by insertion of a neomycin cassette and were 
engineered by Schwarzkopf and colleagues (Schwarzkopf et al., 2002). The mice were 
subsequently backcrossed with C57BL/6J mice for at least ten generations in the institute’s 
animal facility. For rescue experiments, GNE+/- mice were crossbred with B6;129S4-C3tm1Crr/J 
(referred as C3-/- mice in the text) to obtain GNE+/-C3-/- mice. The C3-/- mice have a targeted 
deletion of the nucleotides 1850-2214 within the mouse C3 coding region (AA 620-741, pro-
C3 numbering) and were originally purchased from Charles River (Sulzfeld, Germany). For 
further offspring and to keep the GNE/C3 mouse line, breeding of GNE+/-C3-/- mice was 
performed. Animals were housed in the institute’s animal facility in specific pathogen free 
environment with water and food ad libitum at 12 hours dark/night cycle. Housing and breeding 
of the animals were performed in accordance with the German guidelines of the animal care 
and use committee. All efforts were made to minimize the number of animals used and their 
suffering.  
2.2.1.1 Genotyping of mice 
Tissue of either ear or tail was taken for the isolation of genomic DNA using the KAPA mouse 
genotyping Hot Start Kit according to the manufacturer’s protocol. Genomic DNA was eluted 
in ddH2O. Then, PCR with the genotype-specific primers (see Table 1) was performed using 
the KAPA2G Fast Hot Start Genotyping Mix from the same kit as described in Table 2.  
Table 1: Genotyping primer mix 
Mouse line Primer mix Expected product length 
GNE+/- 37      10 µM 
A541 10 µM 
42      20 µM 
(modified from Weidemann 
et al., 2010) 
wildtype allele (37/42) - 500 bp 
knockout allele (A541/42) - 750 bp 
heterozygous: both bands 
 
C3-/- C3wt    7.8 µM 
C3mt  4.46 µM 
C3geno 7.8 µM 
wildtype allele – 350 bp 
knockout allele – 500 bp  
heterozygous: both bands 
GNE/C3 see primer mix for GNE+/- 
and for C3-/- 
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Table 2: Genotyping PCR reaction mix 
Master Mix for GNE 1x  Master Mix for C3 1x 
KAPA Genotyping Mix 10 µl  KAPA Genotyping Mix 10 µl 
ddH2O 5 µl  ddH2O 6 µl 
primer mix 4 µl  primer mix 3 µl 
DNA 1 µl  DNA 1 µl 
     
The two different settings for the thermocycler are described in Table 3. 
Table 3: Genotyping programs for thermocycler 
GNE PCR 
Initial denature 94 °C 4:00 minutes 
Denature 94 °C 0:30 minutes 
Annealing 58 °C 0:45 minutes       32x 
Elongation 72 °C 0:60 minutes 
Final elongation 72 °C 7:00 minutes 
 4 °C ∞ 
C3 PCR 
Initial denature 94 °C 3:00 minutes 
Denature 94 °C 0:20 minutes 
Annealing 64 °C 0:30 minutes       12x 
Elongation 72 °C 0:35 minutes 
Denature 94 °C 0:20 minutes 
Annealing 58 °C 0:30 minutes       25x 
Elongation 72 °C 0:35 minutes 
Final elongation 72 °C 7:00 minutes 
 4 °C ∞ 
   
PCR products were loaded onto 1 % agarose gel containing ethidium bromide. A 100 base pair 
ladder was used as reference marker. The samples were run at 100-120 V and 110 mA for 45 
minutes. The gels were visualized using GelDoc with QuantityOne software. 
For mouse genotyping the presence of the knockout gne allele on the gel was important as 
shown in Figure 9. For wildtype mice the presence of only the wildtype allele with a band at 
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500 bp was detected. Heterozygous mice were determined by the presence of one wildtype and 
one knockout allele with two bands, at 500 bp and at 750 bp. The additional band for the 
knockout allele at around 2500 bp was not detectable within the normal number of PCR cycles 
and was therefore not taken into account. 
 
Figure 9: GNE genotyping example. (A) Illustration of the wildtype (GNE+/+) and the knockout (GNE+/-) allele 
showing the binding sites of GNE-specific primers (A541/42 – 750 bp; 37/42 – 500 bp or 2500 bp). In GNE+/- 
mice a neomycin (neo) cassette was introduced in exon 2 of one allele. (Scheme was adapted and modified from 
Weidemann et al. 2010). (B) A 1 % agarose gel with the representative PCR products of both genotypes is shown. 
The genotypes were determined by the bands as following: GNE+/+ 500 bp; GNE+/- 500 bp and 750 bp. 
2.2.1.2 Tissue preparation 
If not stated otherwise male animals were weighed routinely, followed by an anesthesia with 
200 µl per 10 g body weight anesthesia solution (Ketamin/Xylazin; for more details see 2.1.4) 
and then perfused with 1x PBS. The brain was directly removed and cut into both hemispheres. 
One hemisphere was directly used for RNA isolation, the other half was stored in 4 % PFA for 
24 hours at 4 °C, followed by incubation in 30 % sucrose solution at 4 °C until the brain was 
fully soaked and sank to the bottom of the tube. The fixed brains were embedded in Tissue 
Tek® and stored at -80 °C for immunohistochemistry. 
2.2.2 Analysis of gene transcription 
2.2.2.1 RNA isolation of brain samples 
RNA from freshly taken hemispheres of male transgenic mice or wildtype littermates (see 
section 2.2.1.2) was extracted using the RNeasy® Mini kit from Qiagen. Shortly, tissue was 
directly homogenized twice with 1 ml Qiazol Lysis Reagent and a stainless steel bead (mean 
diameter: 7 mm) in a Tissue Lyser LT for 3 minutes at 50 Hz. After 5 minutes incubation at 
room temperature, 200 µl chloroform were added. The mixed suspension was again incubated 
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for 3 minutes at room temperature before centrifuging at 12000 x g for 15 minutes at 4 °C. The 
upper, aqueous phase was transferred into a new tube and 500 µl 70 % ethanol were added and 
mixed. Then, 600 µl of the solution were transferred into an RNeasy column and centrifuged at 
8000 x g for 20 seconds at room temperature. The flow-through was discarded and the 
remaining solution was transferred in the same way until the complete lysate was loaded onto 
the column. The RNA isolation procedure was then continued according to the manufacturer´s 
protocol. 50 µl eluted RNA was either stored at -80 °C or directly used for reverse transcription. 
2.2.2.2 cDNA synthesis by reverse transcription of RNA 
Reverse transcription of RNA was performed with SuperScript III reverse transcriptase and 
random hexanucleotide mix according to the Invitrogen protocol for SuperScript First-Strand 
Synthesis. The concentration of transcribed cDNA was measured using NanoDrop and was 
diluted to a working concentration of 100 ng/µl. 
2.2.2.3 Semi-quantitative real-time polymerase chain reaction (sqRT-PCR) 
Semi-qRT-PCR with specific oligonucleotides was performed using the SYBR® Green ERTm 
qPCR Super Mix. Gene transcripts of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were applied as internal RNA loading control. For quantitative real-
time PCR the following mix was prepared in a 96-well-plate: 
12.5 µl SYBR Green Mix 
1 µl mix of forward and reverse primers 
(each 10 pmol/µl) 
2 µl  cDNA 
9.5 µl ddH2O 
For the non-template control cDNA was replaced with ddH2O. The plate was covered with a 
plastic lid and analyzed in a Mastercycler epgradient S with the following program: 
Cover T° = 105 °C    
Initial denature 95 °C 10:00 minutes 
Denature 95 °C 00:15 minutes 
Annealing 60 °C 00:30 minutes 
Elongation 72 °C 00:30 minutes 
Amplification for 40 cycles 
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To ensure that a specific product was obtained, a dissociation curve analysis was performed 
using the following program:  
95 °C 01:00 minutes 
55 °C 00:15 minutes 
95 °C 00:15 minutes 
ramp rate: 20:00 minutes 
  
Amplification specificity was confirmed by analysis of the melting curves. Results were 
analyzed with the Master cycler ep realplex software after establishing the reaction efficiency 
for each primer pair. Values were normalized with their respective GAPDH values. Delta cycle 
threshold (CT) values were normalized to 3 months wildtype (=100 %) and quantification using 
the delta delta CT method was applied. 
2.2.3 RNA sequencing 
2.2.3.1 RNA isolation of brain samples for RNA sequencing 
Freshly taken hemispheres of female transgenic mice or wildtype littermates (see section 
2.2.1.2) were directly homogenized twice with 1 ml Qiazol Lysis Reagent and a stainless-steel 
bead (mean diameter: 7 mm) in a Tissue Lyser LT for 3 minutes at 50 Hz. Homogenates were 
centrifuged for 10 minutes at 12000 x g and 4 °C. Supernatant was transferred into a new tube 
and incubated for 5 minutes at room temperature. Then, 200 µl chloroform were added to each 
sample, shaken well and again incubated for 3 minutes at room temperature before centrifuging 
for 15 minutes at 12000 x g and 4 °C. The upper, aqueous phase was transferred into a new tube 
and isopropanol was added in a 1:1 volume ratio. The samples were mixed well and incubated 
at -20 °C overnight to let also smaller RNA particles precipitate. On the following day, the 
samples were centrifuged for 20 minutes at 12000 x g and 4 °C. The supernatant was discarded. 
Then, 1 ml 75 % ethanol was added to the sample and gently mixed. After centrifugation for 
5 minutes at 7500 x g and 4 °C the supernatant was discarded again, ethanol was added and the 
procedure was repeated. The remaining pellet was left for about 10 minutes at room temperature 
to dry. Subsequently, the pellet was resuspended in 50 µl RNAse-free water and stored at -
80 °C until usage. An RNA aliquot was kept separately for quality and quantity measurements 
at the NanoDrop and for reverse transcription into cDNA for further PCR controls (see 
paragraphs 2.2.2.2 and 2.2.2.3). 
2.2.3.2 RNA sequencing and analysis 
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The sequencing and the analysis of the RNA samples was performed in collaboration with Dr. 
Sinkkonen and his Epigenetics Team at the University of Luxembourg (Belvaux, Luxembourg). 
Libraries for the brain total RNA samples were built using the TruSeq Stranded mRNA Library 
Prep kit (Illumina) with 1 µg of RNA as starting material according to the manufacturer’s 
protocol. The library quality was assessed using an Agilent 2100 Bioanalyzer and quantified 
using Qubit dsDNA HS assay Kit. Following this quantification, libraries were adjusted to 4 nM 
and sequenced on a NextSeq 500 (Illumina) following the manufacturer’s instructions. 
Library preparation and sequencing were performed at the Luxembourg Center for Systems 
Biomedicine Sequencing Facility. The quality of raw reads was checked by FastQC version 
0.11.3 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Cutadapt6 version 1.8.1 
was used to trim low quality reads (-q 30 parameter), remove Illumina adapters (-a parameter) 
and to remove reads shorter than 20 bases (-m 20 parameter) with an error tolerance of 10 % (-
e 0.1 parameter). Additionally, reads mapping to ribosomal RNA species were removed using 
SortMeRNA7 with the parameters “--other; --log; -a; -v; --fastx enabled”.  
Lastly, the reads were processed by FastQC version 0.11.3 to control whether bias could have 
been. As no obvious bias were observed, the reads were mapped to the mouse genome mm10 
by using the gene annotation downloaded from Ensembl8 (GRCm38.p3, release 79) and by 
using the Spliced Transcripts Alignment to a Reference9 (STAR) version 2.5.2b and the 
optimized parameters (Baruzzo et al., 2017). Briefly, the tweaked command arguments were: 
--twopassMode Basic --outSAMunmapped Within --limitOutSJcollapsed 1000000 \ 
--limitSjdbInsertNsj 1000000 --outFilterMultimapNmax 100 --outFilterMismatchNmax 33 \ 
--outFilterMismatchNoverLmax 0.3 --seedSearchStartLmax 12 --alignSJoverhangMin 15 \ 
--alignEndsType Local --outFilterMatchNminOverLread 0 --outFilterScoreMinOverLread 0.3 
--winAnchorMultimapNmax 50 --alignSJDBoverhangMin 3 
The reads were further counted using the function featureCounts from the R package Rsubreads 
(v1.26; Liao et al., 2013) and the statistical analysis was performed using the R package 
DESeq2 (v1.15; Love et al., 2014). Most computation and plotting were done using R (v3.4.0; 
R Core Team, 2017) and RStudio (v1.1; RStudio Team, 2016). Principle component analysis 
was computed using the function plotPCA() from the DESeq2 package and plotted by the R 
package factoextra (v1.0.4; Kassambara and Mundt, 2017). Other plots were done using the R 
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package ggplot2 (v2.1; Wickham, 2009) and the collection of packages tidyverse (v1.1; 
Wickham, 2017). For Ingenuity Pathway Analysis® (IPA), the list of differentially expressed 
genes in GNE+/-C3+/+ mice (false discovery rate, FDR<0.1) was uploaded in the IPA tool 
(Ingenuity Systems, www.ingenuity.com). The significance of the association of the genes with 
a function or canonical pathway was measured by Fisher’s exact test. For upstream regulator 
analysis only regulatory proteins were considered. 
The sequencing data will be deposited in the European Nucleotide Archive (accession number 
not yet known). 
2.2.4 Flow cytometry analysis of GNE+/- mice 
Female GNE+/- mice and wildtype littermates were weighed routinely, consequently set under 
anesthesia with an anesthesia solution (Ketamin/Xylazin; for more details see 2.1.4) and then 
perfused with 1x PBS. The brain was directly removed, crushed through a 70 µm cell strainer 
into a falcon tube with 1x PBS and centrifuged for 3 minutes at 1500 rpm. The cell suspension 
was fixed with 4 % PFA for 10 minutes on ice. The cells were washed twice with 1x PBS and 
subsequently incubated in blocking solution (10 % BSA + 0.1 % Triton X-100 + 5 % NGS in 
PBS) for one hour on ice. Brain cells were taken up in 1x PBS and were separated into equal 
samples for the incubation with the primary antibodies (2.5 µg/ml) against PSA-NCAM, A2B5, 
and CD56, and their respective isotype controls for one hour on ice. After two washing steps, 
the cells were stained with PE-coated secondary antibodies for 30 minutes on ice in the dark. 
Cells were washed twice with 1x PBS and were resuspended in 500 µl 1x PBS. For each mouse 
one sample was kept on ice without any staining and was measured as blank sample. Analysis 
was done with a FACS Calibur flow cytometer and FlowJo Software. The main cell population 
in the blank sample was gated for each mouse data set, and then 1 %-positive cells in the isotype 
sample were gated and applied for the respective antibodies. For quantification the mean 
fluorescence intensity of the isotype controls were subtracted from the mean fluorescence 
intensity of PSA-NCAM, A2B5, and CD56. All samples were normalized to 3 months wildtype 
mice (=100 %). 
2.2.5 Immunohistochemistry of murine brains 
O.C.T.TM Compound-embedded hemispheres of male transgenic mice or wildtype littermates 
(see section 2.2.1.2) were cut into 20 µm thick sagittal sections at a microtome and stored at -
20 °C until usage. 
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2.2.5.1 Cell density quantification 
For quantifying the cell density in the substantia nigra and the hippocampus, sections of lateral 
levels between 1.10 mm and 1.20 mm were immunohistochemically stained. Sections were 
washed once with 1x PBS and incubated in blocking solution (10 % BSA + 0.2 % Triton X-
100 + 5 % NGS in PBS) in a wet chamber for one hour at room temperature, followed by 
incubation in primary antibodies directed against TH (1:500) and NeuN (1:500) in blocking 
solution for two hours at room temperature. After washing, sections were subsequently stained 
with the corresponding Alexa Fluor® 488- (1:500) or Cy3-conjugated antibodies (1:200) for 
two hours at room temperature. After two washing steps with 1x PBS, sections were stained for 
nuclei (DAPI, 1:10000) for 30 seconds and then covered with mowiol and a coverslip. 
Three images per mouse were taken by an apotome microscope using AxioVisio (v4.8.2.0) with 
the MosaiX plugin and were analyzed using ImageJ. Either the area of the substantia nigra pars 
compacta (SN pc) or the Cornus Ammonis (CA) 3 region of the hippocampus was encircled 
and measured. Cells positive for either TH (applicable only in SN pc) or for NeuN in the 
selected area were counted only when their soma was completely visible. The co-staining with 
DAPI was used as additional reference. For the cell density the cell number was divided by the 
selected area and normalized to 3 months old wildtype mice. 
Additionally the width of the CA3 region and of the dentate gyrus (DG) in the hippocampus 
was measured. For this, the DAPI-/NeuN-co-staining was used as orientation. For the CA3 
region the width of the pyramidal cell layer (NeuN+ cells) located next to the most anterior part 
of the DG was chosen (indicated by the white left dotted line in Figure 15A). For the DG the 
granule cell layer (NeuN+ cells) was investigated anterior (DG1) and posterior (DG2). For DG1 
the widths of both anterior “arms” located next to the end of the CA3 region (indicated by the 
middle white dotted line in Figure 15A) were measured and the mean was calculated. For the 
second DG region (DG2) the width of the posterior curvature of the DG was measured as shown 
in Figure 15A (white right bar). The mean per animal was normalized to 3 months old wildtype 
mice. 
2.2.5.2 Astrocyte quantification 
For quantifying the astrocytes in the substantia nigra, sections of lateral levels around 1.40 mm 
of 9 months old mice were immunohistochemically stained. Sections were treated in the same 
staining protocol as for the quantification of the cell density (see paragraph 2.2.5.1) with one 
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exception: Instead of the primary antibody against TH, an antibody against the astrocyte 
specific marker Gfap (1:500) was used. 
Three z-stacks (3 x 2 µm) per mouse were taken in the substantia nigra pars reticulata by an 
inverted confocal laser scanning microscope. Maximum projection of the Gfap-/DAPI-double 
positive z-stack images were processed and used for analysis. Fluorescence intensity of Gfap 
per area was measured using ImageJ. Background intensity was subtracted. For the astrocyte 
number Gfap- and DAPI- double positive cells were counted in the selected area in each z-stack 
and the cell number per area was calculated. The resulting fluorescence intensity per area and 
the cell density of each animal were normalized to 9 months old wildtype mice. 
2.2.5.3 Microglia quantification 
For the quantification of the microglia, sections of lateral levels around 1.30 mm of 9 months 
old mice were immunohistochemically stained. Sections were washed once with 1x PBS and 
incubated in blocking solution (10 % BSA + 0.25 % Triton X-100 in PBS) in a wet chamber 
for two hours at room temperature, followed by incubation in primary antibodies directed 
against Iba1 (1:500) and Cd68 (1:500) in incubation solution (5 % BSA + 0.05 % Triton X-100 
in PBS) overnight at 4 °C. On the following day sections were washed five times with 
incubation solution for 5 min. After washing, sections were subsequently stained with the 
corresponding Alexa Fluor® 488- (1:400) or Cy3-conjugated antibodies (1:200) in incubation 
solution for two hours at room temperature. After three washing steps with 1x PBS, sections 
were stained for nuclei (DAPI, 1:10000) for 30 seconds and then covered with Aqua-Polymount 
and a coverslip. 
Three z-stacks (5x 2.5 µm – 3 µm) per mouse were taken in the substantia nigra pars reticulata 
(SN pr) by an inverted confocal laser scanning microscope. Maximum projection of the Iba1-
/Cd68-/DAPI-triple positive z-stack images were processed and used for analysis. Fluorescence 
intensity of Iba1 and Cd68 per area was measured using ImageJ. Background intensity was 
subtracted. Additionally, the soma area identified by Iba1 staining of each microglia was 
selected and measured. In addition, the fluorescence intensity of Iba1 and Cd68 of each selected 
soma was measured and calculated per soma area. For the microglia number Iba1- and DAPI- 
double positive cells were counted in the selected area in each z-stack. The resulting 
fluorescence intensities per area, the soma areas, and the cell numbers of each animal were 
normalized to 9 months old wildtype mice. 
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2.2.6 Statistical analysis 
Results were presented as mean ± SEM (= standard error of the mean) or mean + SEM of at 
least three independent experiments. Significant outliers were discovered by using the outlier 
calculator of GraphPad QuickCalcs and excluded from further analysis. Graphs were designed 
using Prism 7 (v7.01). For statistical analysis data with one variable (e.g. only genotype) were 
analyzed using the computer software IBM SPSS Statistics (v.22) and for more than one 
variable (e.g. age and genotype) the computer software STATA®/IC (v13.1) was used. In case 
of one variable, the Levene’s test was used to assess the equality of variances for each data set. 
Then, comparison between two groups was performed using the Student’s t-test (independent 
sample t-test) and multiple group comparisons were performed using one-way ANOVA 
followed by post hoc correction using the Bonferroni or the Dunnett’s T3 method. For more 
than one variable, a linear model (multiple linear regression) including an interaction term was 
applied, followed by a pairwise comparison with LSD-post hoc correction. The Breusch-Pagan 
/ Cook-Weisberg test for heteroscedasticity was performed to assess the equality of variances 
in the linear model. If variances were significantly different, a robust linear model including an 
interaction term was chosen for further analysis. Data were in general regarded as significant if 
p-values were below or equal 0.05 (*p ≤ 0.050; **p ≤ 0.010; ***p ≤ 0.001). 
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3 Results 
3.1 Characterization of the GNE+/- mice 
In in vitro murine and human neuron-microglia/macrophage co-cultures our group could 
previously show that glycocalyx alterations lead to phagocytic removal by 
microglia/macrophages in a complement-dependent manner (Linnartz et al., 2012b; Linnartz-
Gerlach et al., 2016). To investigate the role of an altered glycocalyx in vivo, I used a transgenic 
mouse heterozygous for GNE, the essential enzyme of sialic acid biosynthesis. According to 
Gagiannis and colleagues these mice show an overall reduction of membrane-bound sialic acids 
by 25 % but without having any obvious defects in organ architecture or function (Gagiannis et 
al., 2007). For further validation of this mouse line as a suitable model for an altered glycocalyx, 
extensive investigations for characterization were performed and in particular the influence of 
aging was analyzed. 
3.1.1 General observations 
3.1.1.1 Breeding and housing of mice 
For general breeding and housing evaluation 38 mice (21x females, 16x males) were monitored 
for a period of 33 weeks according to the guidelines of the German Federal Institute for Risk 
Assessment (“Severity assessment of genetically altered animals”). Within this monitoring time 
period GNE+/- mice and wildtype littermates showed a normal housing behavior. No obvious 
effects in posture, behavior, or motor behavior could be monitored. The fur and the body's 
orifices looked normal and the reactions of the mice to animal handling were not disturbed. 
Breeding of female GNE+/- mice with male GNE+/- mice proceeded in a normal manner. Four 
to six pups per female mouse were usual. The pups developed normally and could be separated 
from their mother at an age of 21 days. 
3.1.1.2 Weight analysis of mice 
Routinely, the weight of mice was measured directly before tissue collection for 
characterization. For the weight analysis in total 248 animals were analyzed (see Table 4). Sex 
and genotype were distinguished. 
As shown in Figure 10 the weight of the mice increased with age. Overall, female mice weighed 
less than male mice. The mean sex-specific differences of all time points were 7.0 ± 0.2 g in 
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GNE+/+ mice and 5.8 ± 0.6 g in GNE+/- mice. Male mice reached a steady weight at around 
9 months, while this was not yet visible for female mice until the age of 12 months. 
Table 4: Number of measured mice for weight analysis 
sex GNE+/+ GNE+/- total: 
female 55 74 129 
male 49 70 119 
total: 104 144 248 
    
A linear model including an interaction term was applied to study the weight development 
during aging. For the female dataset a robust linear model was necessary. Both models revealed 
age-differences, whereas in female mice sex-specific differences were additionally present (♀: 
R2 = 0.647, age effect: p < 0.001, genotype effect: p < 0.001; ♂: R2 = 0.873, age effect: 
p < 0.001, genotype effect: p = 0.274) but without any effect modulations (age*genotype: ♀ 
p = 0.369; ♂ p = 0.800). While the male mice gained equal weight (Figure 10B), female GNE+/- 
mice gained significantly higher weight at early time points compared to wildtype littermates 
(Figure 10A). 
 
Figure 10: Weight development of GNE mice during aging. (A) Female GNE+/- mice showed significant higher 
weight development during aging compared to wildtype littermates from three to 12 months (genotype effect: 
p < 0.001). Data shown as mean ± SEM; n = 9-23; pairwise comparison for GNE+/+ vs. GNE+/- mice at different 
age, *p < 0.050, **p < 0.010. (B) Weight analysis from 1 month to 12 months old male mice did not show 
genotype-specific differences (genotype effect: p = 0.274). Data shown as mean ± SEM; n = 8-17, without 
significant differences for GNE+/- vs. GNE+/+ at any time point. 
In detail, female GNE+/+ mice weighed 22.2 ± 0.3 g (3 months), 24.8 ± 0.4 g (6 months), 
26.6 ± 0.8 g (9 months), and 28.1 ± 1.0 g (12 months) and female GNE+/- mice weighed 
23.1 ± 0.3 g (3 months), 27.2 ± 0.8 g (6 months), 28.0 ± 0.6 g (9 months), and 30.0 ± 0.7 g 
(12 months). Pairwise comparisons between GNE+/+ and GNE+/- at each time point revealed 
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significant differences at 3 months (*p = 0.044) and at 6 months (**p = 0.004). Male GNE+/+ 
mice weighed 17.4 ± 0.9 g (1 month), 28.9 ± 0.6 g (3 months), 32.1 ± 0.7 g (6 months), 
34.0 ± 0.8 g (9 months), and 34.8 ± 0.8 g (12 months) and male GNE+/- mice weighed 
18.1 ± 0.7 g (1 month), 30.1 ± 0.5 g (3 months), 32.3 ± 0.5 g (6 months), 34.5 ± 0.7 g 
(9 months), and 34.5 ± 0.5 g (12 months). Pairwise comparisons between male GNE+/+ and 
GNE+/- at each time point revealed no significant differences. For all following investigations 
either only male or only female mice were analyzed to avoid sex-specific genotype differences. 
3.1.2 Sialic acid biosynthesis and sialylation status in the brain 
3.1.2.1 Gne gene transcription 
The altered gne gene in GNE+/-mice was not only tested by PCR during the standard genotyping 
procedure as described in the section “2.2.1.1 Materials and Methods” but was also specifically 
tested in the brain by sqRT-PCR. 
To confirm an altered gne transcription in the brain, male mice at the age of 1 month, 3 months, 
6 months, 9 months, and 12 months were screened by sqRT-PCR. Quantification of brain 
homogenates of transgenic mice showed an overall reduction of gne on mRNA levels by 54 % 
compared to wildtype littermates (see Figure 11). The robust linear model of gne transcript 
levels during aging revealed age- and genotype-specific differences (R2 = 0.694, age effect: 
***p < 0.001, genotype effect: ***p < 0.001) and showed also effect modulations 
(age*genotype: *p = 0.041), meaning that age and genotype had an effect on each other. 
Pairwise comparison between GNE+/- mice and wildtype littermates revealed strong significant 
differences between the genotypes (all time points: ***p < 0.001). 
In detail, in 1 month old mice gne transcript levels were reduced from 0.7 ± 0.1 fold change 
(FC) in GNE+/+ mice and to 0.3 ± 0.0 FC in GNE+/- mice, in 3 months old animals from 
1.0 ± 0.1 FC to 0.4 ± 0.0 FC, in 6 months old animals from 1.1 ± 0.1 FC to 0.5 ± 0.0 FC, in 
9 months old animals from 1.0 ± 0.1 FC to 0.4 ± 0.1 FC, and at the age of 12 months from 
1.0 ± 0.1 FC to 0.5 ± 0.0 FC (Figure 11).  
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Figure 11: Transcription analysis of gne mRNA levels. Levels of gne transcripts in half brain homogenates of 
GNE+/- mice at the age of 1 month, 3 months, 6 months, 9 months, and 12 months were significantly reduced 
compared to wildtype littermates. Data shown as mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-
14, pairwise comparison for GNE+/+ vs. GNE+/- mice at different age, **p ≤ 0.010, ***p ≤ 0.001. 
Data confirmed that the heterozygous mice transcribed different alleles and that the wildtype 
allele is much lower transcribed in the GNE+/- mice compared to wildtype littermates. 
3.1.2.2 Sialic acid levels in the brain 
Next, the overall sialic acid levels in brain homogenates at different age groups were 
investigated by flow cytometry. To assay different compositions of sialic acids, antibodies 
directed against polymers (NeuAc-alpha 2-8n, n > 10; PSA-NCAM; Figure 12B) and oligomers 
(trimer; A2B5; Figure 12C) of sialic acids were used as shown in Figure 12. To further 
distinguish the embryonic form of polysialylated N-CAM from the adult form, which has 
normally decreased polysialic acid expression (Miller et al., 1993), an antibody for the 12F8 
epitope was used (CD56; Figure 12D). In general, the relative mean fluorescence intensity was 
nearly always higher in wildtype animals compare to GNE+/- mice and decreased with age, 
regardless of sialic acid chain lengths or genotype. While values of long and short sialic acid 
chain lengths decreased continuously (Figure 12B+D), overall levels of oligomers seemed to 
be more fluctuating (Figure 12C). 
Linear modelling of PSA-NCAM data (R2 = 0.227) during aging did not reveal an age-
dependent effect (p = 0.056) but revealed a genotype-dependent effect (**p = 0.002). For A2B5 
during aging, multiple linear regression (R2 = 0.102) also showed no age-dependent effect 
(p = 0.473) but a genotype-dependent effect (*p = 0.047). In contrast, the linear model of CD56 
data (R2 = 0.253) during aging showed a strong age-dependent effect (***p < 0.001) but no 
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genotype-dependent effect (p = 0.369). Effect modulations were not present for any dataset 
(age*genotype: PSA-NCAM - p = 0.611; A2B5 - p = 0.665; CD56 - p = 0.396). Pairwise 
comparison between GNE+/- mice and wildtype littermates for each dataset resulted in the 
following p-values for the distinct time points: PSA-NCAM: p = 0.073 (3 months), **p = 0.008 
(6 months), p = 0.137 (9 months), p = 0.543 (12 months); A2B5: p = 0.235 (3 months), 
p = 0.857 (6 months), p = 0.054 (9 months), p = 0.443 (12 months); CD56: p = 0.828 
(3 months), p = 0.089 (6 months), p = 0.397 (9 months), p = 0.638 (12 months). 
 
Figure 12: Detection of different sialic acid lengths in the brain. (A) Representative scatter plots of GNE+/+ and 
GNE+/- mice for PSA-NCAM and the corresponding isotype control at 3 months are shown. PE - R-Phycoerythrin. 
(B-D) Flow cytometry revealed that the overall sialic acid levels in whole brain homogenates of GNE+/- mice 
decreased with age. Long polymers (PSA-NCAM; B), oligomers (A2B5; C), and short polymers (CD56; D) of 
sialic acids were investigated. Especially long polymers were significantly decreased in GNE+/- mice compared to 
wildtype littermates but also oligomers were significantly different between the genotypes. Data shown as 
mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-14, pairwise comparison for GNE+/+ vs. GNE+/- 
mice at different age: **p ≤ 0.010. 
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In detail, the detected relative mean fluorescence intensity of PSA-NCAM decreased in 
wildtype animals from 100 ± 16.0 % at 3 months, over 109.5 ± 11.2 % at 6 months, to 
91.0 ± 9.5 % at 9 months and ended at 64.7 ± 16.3 % at 12 months (Figure 12B). In 
comparison, intensity levels in GNE+/- mice varied from 67.0 ± 10.6 % at 3 months, to 
59.3 ± 19.4 % at 6 months, to 40.0 ± 14.5 % at 9 months and again to 51.9 ± 10.2 % at 
12 months. Quantification of A2B5 at the age of 3 months, 6 months, 9 months, and 12 months 
showed a mean fluorescence intensity of 100.0 ± 21.9 %, 48.4 ± 8.7 %, 119.3 ± 13.5 %, and 
84.4 ± 22.9 % in wildtype animals compared to the mean fluorescence intensities of 
74.3 ± 12.3 %, 62.2 ± 19.5 %, 42.6 ± 14.6, and 65.3 ± 10.8 % in transgenic mice, respectively 
(Figure 12C). The mean fluorescence intensity of CD56 (Figure 12D) in wildtype animals 
decreased from 100.0 ± 14.1 % and 102.2 ± 11.0 % at 3 months and 6 months, to 68.4 ± 10.8 % 
and 36.2 ± 14.6 % at the age of 9 months and 12 months, whereas in GNE+/- mice the mean 
fluorescence intensity decreased from 104.1 ± 14.2 %, over 69.4 ± 22.4 %, to 31.0 ± 10.9 %, 
and back to 46.4 ± 10.0 % at the respective time points. 
Data indicate that especially the polymers of sialic acids (NeuAc-alpha 2-8n) with a chain length 
of n > 10 might be impaired or cannot be synthesized in the GNE+/- mice to similar levels as in 
wildtype littermates. 
3.1.3 Neurodegeneration in the brain 
To prove the concept of phagocytosis of desialylated neurons by microglia/macrophages 
(Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016), GNE+/- mice were investigated for 
neurodegeneration in different brain regions. In vitro, the extent of neuronal loss was strongly 
dependent on the degree of sialic acid removal. Thus, I assumed that different brain regions 
might be differently regulated for sialic acid levels. 
3.1.3.1 Neurodegeneration analysis in the substantia nigra 
Since oxidative stress can lead to sialic acid removal, I first investigated neurodegeneration in 
the substantia nigra, a brain region known for high levels of oxidative stress (Di Giovanni et 
al., 2012). Furthermore, dopaminergic neurons of the substantia nigra are more susceptible to 
inflammatory damage compared to other neuronal subtypes (Block et al., 2007). 
Serial sagittal sections (lateral: 1.10 – 1.20 mm) of the substantia nigra pars compacta (SN pc) 
were analyzed by immunohistochemical antibody staining of the dopaminergic marker TH and 
the neuronal nuclei marker NeuN (see Figure 13A). Cells positive for TH or NeuN were counted 
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per area and the relative cell density in the SN pc was quantified at different time points to 
quantify the progression of the neuronal loss during aging (Figure 13B) including the latest time 
point investigated (12 months, Figure 13C). 
In general, the overall neuronal cell density, as well as the dopaminergic (TH-positive) cell 
density started at higher levels in 1 month old animals compared to 3 months old animals 
regardless of the genotype of the mice. From 3 months onwards the neuronal cell density as 
well as the dopaminergic cell density stayed very stable during aging in wildtype mice. In 
contrast, the density levels of NeuN- and of TH-positive cells strongly decreased over the 
different time points in GNE+/- mice. 
A robust multiple linear regression of the NeuN-positive cell density during aging revealed age- 
and genotype-specific differences (R2 = 0.595, age effect: ***p < 0.001, genotype effect: 
***p < 0.001) as well as differences in effect modulations (age*genotype: **p = 0.009). 
Pairwise comparison between GNE+/- mice and wildtype littermates revealed no significant 
differences at 1 month (p = 0.749), but increasingly significant differences between GNE+/- 
mice and wildtype littermates at all other time points (3 months: *p = 0.020; 6 months: 
**p = 0.008; 9 months: ***p = 0.001; 12 months: ***p < 0.001; Figure 14B upper graph). 
Multiple linear regression analysis of the TH-positive cell density during aging also resulted in 
age- and genotype-specific differences (R2 = 0.598, age effect: ***p < 0.001, genotype effect: 
***p < 0.001) as well as effect modulations (age*genotype: **p = 0.002). Pairwise comparison 
between GNE+/- mice and wildtype littermates showed no significant differences at 1 month 
(p = 0.184) and 3 months (p = 0.202), but strong significant differences between GNE+/- mice 
and wildtype littermates at later time points (6 months: ***p = 0.001; 9 months: *p = 0.013; 
12 months: ***p < 0.001; Figure 14B lower graph). 
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Figure 13: Increasing neurodegeneration in the substantia nigra of GNE+/- mice with age. (A) Representative 
images of the substantia nigra of 12 months old GNE+/+ and GNE+/- mice at lateral sections between 1.10 mm and 
1.20 mm are shown. Sagittal brain slices were stained with antibodies directed against tyrosine hydroxylase (TH, 
green) and neuronal nuclei (NeuN, red). SN pc – substantia nigra pars compacta, SN pr – substantia nigra pars 
reticulata. Scale bar: 200 µm. (B) Quantification of the cell density of NeuN- (upper graph) and TH-positive cells 
(lower graph) showed increasing neuronal loss in GNE+/- mice compared to wildtype littermates with increasing 
age. Data shown as mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-12, pairwise comparison for 
GNE+/+ vs. GNE+/- mice at different age: *p ≤ 0.050, ***p ≤ 0.001. (C) Quantification of the cell density of NeuN- 
(upper graph) and TH-positive cells (lower graph) at 12 months revealed a strong neuronal loss in GNE+/- mice 
compared to wildtype littermates. Data shown as mean + SEM; normalized to 3 months old GNE+/+ animals; n = 9-
12, Student’s t-test, ***p ≤ 0.001. 
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The measured neuronal cell density at 1 month was almost identical between GNE+/- mice and 
wildtype littermates (119.0 ± 2.6 % vs. 120.7 ± 4.8 %). While the relative neuronal cell density 
in wildtype mice stayed at a similar level between 3 months and 12 months (100.0 ± 5.6 % vs. 
98.9 ± 5.8 %; p = 0.889), it decreased by 29.9 % in GNE+/- mice from 3 months to 12 months 
(85.4 ± 2.7 % vs. 65.0 ± 5.6 %; **p = 0.002) and by even 45.4 % comparing 12 months to 
1 month (65.0 ± 5.6 % vs. 119.0 ± 2.6 %; ***p < 0.001). In detail, the exact relative density 
levels for NeuN-positive cells changed from 120.7 ± 4.8 %, to 100.0 ± 5.6 %, 97.8 ± 4.5 %, 
95.3 ± 4.7 %, and 98.9 ± 5.8 % in wildtype mice and from 119.0 ± 2.6 %, to 85.4 ± 2.7 %, 
68.6 ± 9.7 %, 72.0 ± 4.9 %, and 65.0 ± 5.6 % in GNE+/- mice starting from 1 month over 
3 months, 6 months, 9 months to 12 months, respectively. 
Similar trends were seen for the dopaminergic cell density, which started at 113.8 ± 4.8 % in 
GNE+/+ mice and at 125.6 ± 6.5 % in GNE+/- mice. From 3 months to 12 months the 
dopaminergic cell density levels in wildtype mice varied only between 100.0 ± 7.3 % 
(3 months) and 87.8 ± 3.8 % (9 months), while the levels steadily decreased in GNE+/- mice by 
overall 23.9 % from 3 months to 12 months (88.4 ± 2.4 % vs. 62.0 ± 6.0 %; ***p = 0.001) and 
by even 50.6 % comparing 12 months to 1 month (62.0 ± 6.0 % vs. 125.6 ± 6.5 %; 
***p < 0.001). In detail, the exact relative density levels for TH-positive cells changed from 
113.8 ± 4.8 %, to 100.0 ± 7.3 %, 98.9 ± 4.5 %, 87.8 ± 3.8 %, and 96.8 ± 4.1 % in wildtype mice 
and from 125.6 ± 6.5 %, to 88.4 ± 2.4 %, 68.9 ± 10.9 %, 65.8 ± 3.7 %, and 62.0 ± 6.0 % in 
GNE+/- mice starting from 1 month over 3 months, 6 months, 9 months to 12 months, 
respectively. 
Focusing only on the last time point of the characterization (12 months, Figure 13C), the direct 
comparison of GNE+/- mice with wildtype littermates showed a significant reduction in the 
neuronal cell density by 34.3 % (65.0 ± 5.6 % vs. 98.9 ± 5.8 %; ***p < 0.001, Student’s t-test) 
and a significant reduction in the dopaminergic cell density by 36.0 % (62.0 ± 6.0 % vs. 
96.8 ± 4.1 %; ***p < 0.001, Student’s t-test). 
Taken together, data show a clear loss in neuronal density with aging in the SN pc of GNE+/-
mice compared to wildtype littermates, which, although not yet present in young mice, shows 
a strong difference in neuronal density at 12 months old mice. 
3.1.3.2 Neurodegeneration analysis in the hippocampus 
Based on its importance in mental health, the hippocampus was selected as second brain region 
for the characterization of possible neurodegeneration. Here, the CA3 region was particularly 
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interesting, as it is known for its specific role in memory processes, susceptibility to seizures, 
stress and neurodegeneration (Cherubini and Miles, 2015). 
Serial sagittal sections (lateral: 1.10 mm to 1.20 mm) of the hippocampus were analyzed by 
immunohistochemical antibody staining of the neuronal nuclei marker NeuN and cellular nuclei 
marker DAPI (see Figure 14A). Cells positive for NeuN and DAPI were counted per area and 
the relative cell density in the CA3 region of the hippocampus was quantified at different time 
points to see the progression of the neuronal loss during aging (Figure 14B) and the status at 
the latest time point investigated (12 months, Figure 14C). 
In general, the neuronal cell density in the CA3 region of the hippocampus was stable at 
1 month and 3 months but then slowly decreased with increasing age. Interestingly, until 
6 months the neuronal density was almost identical between both genotypes but diverged at 
later time points (Figure 14B). The linear model of the NeuN-positive cell density during aging 
revealed age- and genotype-specific differences (R2 = 0.390, age effect: ***p < 0.001, genotype 
effect: **p = 0.003) but did not show any interactions between the effects (age*genotype: 
p = 0.400). Pairwise comparison between GNE+/- mice and wildtype littermates detected no 
significant differences at 1 month (p = 0.584), 3 months (p = 0.608), and 6 months (p = 0.360), 
but significant differences between GNE+/- mice and wildtype littermates at 9 months 
(*p = 0.023) and at 12 months (**p = 0.005; Figure 14B). 
Overall, the neuronal loss was stronger in the CA3 region of the GNE+/- mice (3 months vs. 
12 months: -24.1 %; ***p < 0.001) compared to wildtype littermates (3 months vs. 12 months: 
-12.3 %; *p = 0.030). In detail, the relative density levels for NeuN-positive cells changed from 
98.9 ± 4.6 %, to 100.0 ± 4.6 %, 93.4 ± 5.0 %, 90.9 ± 2.7 %, and 87.7 ± 6.2 % in wildtype mice 
and changed from 95.6 ± 2.7 %, to 97.1 ± 3.4 %, 88.4 ± 2.1 %, 78.6 ± 2.8 %, and 73.7 ± 2.0 % 
in GNE+/- mice starting from 1 month over 3 months, 6 months, 9 months to 12 months, 
respectively. 
Comparing only the 12 months old mice of both genotypes (Figure 14C), the differences in 
neuronal density already amounts to 14 %. This is a significant reduction by 16 % (Student’s t-
test: *p = 0.032) and a clear neurodegeneration in the old GNE+/- mice. 
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Figure 14: Increasing neurodegeneration in the CA3 region of the hippocampus of GNE+/- mice with age. 
(A) Representative images of the hippocampus of 12 months old GNE+/+ and GNE+/- mice at lateral sections 
between 1.10 mm and 1.20 mm are shown. Lower images show a higher magnification of the analyzed CA3 region 
of the hippocampus (white dotted line). Sagittal brain slices were stained with antibodies directed against neuronal 
nuclei (NeuN, red) and DAPI (blue). DG – dentate gyrus. Scale bar: 200 µm or 100 µm (higher magnification). 
(B) Quantification of the cell density of NeuN- positive cells showed stronger neuronal loss in GNE+/- mice 
compared to wildtype littermates with increasing age. Data shown as mean ± SEM; normalized to 3 months old 
GNE+/+ animals; n = 7-12, pairwise comparison for GNE+/+ vs. GNE+/- mice at different age: *p ≤ 0.050, 
**p ≤ 0.010. (C) Quantification of the cell density of NeuN-positive cells at 12 months for GNE+/- mice and 
wildtype littermates. Data shown as mean + SEM; normalized to 3 months old GNE+/+ animals; n = 10-12, 
Student’s t-test, *p ≤ 0.050. 
Since changes in neuronal numbers might influence tissue morphology, I further analyzed the 
width of the CA3 region as well as the width of the DG in the same sagittal sections (lateral: 
1.10 mm to 1.20 mm), which were used for the neuronal density analysis. The 
immunohistochemical antibody staining of NeuN and DAPI were used for anatomical 
orientation. The different positions used for measuring the widths in the hippocampus are 
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shown in Figure 15A. For the DG, the anterior (mean of two positions; DG1) and the posterior 
part (DG2) were distinguished and separately analyzed (Figure 15A). The analysis of the width 
at different age points did not show any differences between the genotypes at any of the 
measured positions (DG1, DG2, and CA3). Interestingly, the width was similarly increasing for 
all regions from 1 month to 9 months, after which a sudden decline to almost the levels of 
1 month was observed at 12 months. 
 
Figure 15: No genotype-dependent differences in the width of the dentate gyrus (DG) and the CA3 region 
during aging. (A) A representative image of the width analysis in the hippocampus of a 12 months old GNE+/+ 
mouse at a lateral section between 1.10 mm and 1.20 mm is shown. The sagittal brain slice was stained with 
antibodies directed against neuronal nuclei (NeuN, red) and DAPI (blue). White bars show the measured width 
positions. Dotted white lines indicate how the positions were chosen. DG – dentate gyrus. Scale bar: 200 µm. (B) 
Quantification of the relative width showed an age-dependent increase in DG1, DG2, and CA3 until 9 months (left 
to right). Data shown as mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-12, pairwise comparison 
for GNE+/+ vs. GNE+/- mice at different age showed no significant differences. (C) Quantification of the relative 
width for DG1, DG2, and CA3 at 12 months for GNE+/- mice and wildtype littermates (left to right). Data shown 
as mean + SEM; normalized to 3 months old GNE+/+ animals; n = 10-12, Student’s t-test, ns. = not significant. 
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The regression model for DG1 during aging revealed an age-dependent differences (R2 = 0.799, 
age effect: ***p < 0.001) but no genotype-dependent differences (genotype effect: p = 0.381). 
Pairwise comparison for DG1 between GNE+/- mice and wildtype littermates did not detect any 
significant differences at 1 month (p = 0.836), 3 months (p = 0.567), 6 months (p = 0.116), 
9 months (p = 0.492) or 12 months (p = 0.117; Figure 15B). A robust linear model was applied 
for DG2 resulting in an age-dependent effect (R2 = 0.750, age effect: ***p < 0.001) but again 
not in a genotype-dependent effect (genotype effect: p = 0.675). Also here, pairwise 
comparison did not show any genotype-specific differences at 1 month (p = 0.718), 3 months 
(p = 0.622), 6 months (p = 0.573), 9 months (p = 0.854), or 12 months (p = 0.744; Figure 15B). 
Even the robust linear model of the CA3 width could not detect a genotype-dependent effect 
(genotype effect: p = 0.599) but only an age-dependent effect (R2 = 0.721, age effect: 
***p < 0.001). Pairwise comparison for the CA3 width between the genotypes showed no 
significant differences either (1 month: p = 0.415, 3 months: p = 0.876, 6 months: p = 0.493, 
9 months: p = 0.286, 12 months: p = 0.145). Effect modulations were not present for DG1, 
DG2, or CA3 width analysis (age*genotype, DG1: p = 0.311, DG2: p = 0.941, CA3: p = 0.502). 
The age effect was strongest in the DG2 width. The width increased by 81 % in the GNE+/+ and 
by 69% in the GNE+/- from 3 months to 9 months and even doubled comparing 9 months to 
1 month. The increase in width of the CA3 region was similar strong (82.0 % in GNE+/+, 69.4 % 
in GNE+/-) comparing 3 months with 9 months. Even the DG1 width showed still an increase 
around 60 % for both genotypes. Although the measured widths at 12 months were much lower 
than the levels at 9 months, there were still different trends visible. Interestingly, the DG1 width 
(p = 0.057) and the CA3 width (p = 0.070) increased comparing 3 months to 12 months, 
whereas the DG2 width significantly decreased (*p = 0.019). 
In detail, the relative DG1 widths were 102.6 ± 2.2 % (1 month), 100.0 ± 4.6 % (3 months), 
102.6 ± 4.2 % (6 months), 161.1 ± 4.8 % (9 months), and 98.6 ± 3.8 % (12 months) for GNE+/+ 
mice and 103.9 ± 4.2 % (1 month), 96.5 ± 3.0 % (3 month), 112.0 ± 5.2 % (6 months), 
157.2 ± 3.1 % (9 months), and 106.8 ± 4.1 % (12 months) for GNE+/- mice. The measured 
relative DG2 widths were 88.9 ± 5.3 % (1 month), 100.0 ± 8.7 % (3 month), 122.8 ± 11.4 % 
(6 months), 180.7 ± 6.1 % (9 months), and 85.2 ± 5.4 % (12 months) for GNE+/+ mice and 
86.7 ± 3.0 % (1 month), 105.5 ± 7.2 % (3 month), 130.6 ± 6.0 % (6 months), 178 ± 12.6 % 
(9 months), and 87.2 ± 2.6 % (12 months) for GNE+/- mice. The mean values for the relative 
CA3 widths were 106.5 ± 4.0 % (1 month), 100.0 ± 6.0 % (3 month), 106.1 ± 7.0 % 
(6 months), 182.0 ± 9.1 % (9 months), and 99.0 ± 7.6 % (12 months) for GNE+/+ mice and 
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111.1 ± 3.9 % (1 month), 99.8 ± 4.9 % (3 month), 112.2 ± 5.6 % (6 months), 169.1 ± 7.9 % 
(9 months), and 111.9 ± 4.4 % (12 months) for GNE+/- mice. 
To investigate the old mice for neurodegeneration in particular, the relative mean widths at 
12 months were plotted and statistically analyzed in a separate graph (Figure 15C). Although 
there is a slight tendency for a larger DG1 width and a larger CA3 width for GNE+/- mice, these 
differences were not significant (Student’s t-test, DG1: p = 0.161, CA3: p = 0.145). 
Taken together, no genotype-dependent differences were detected in the width analysis of CA3 
but the data showed slowly increasing neurodegeneration in the CA3 region of the 
hippocampus, which was stronger in the transgenic mice. 
3.1.4 RNA sequencing of the brain 
To better understand the underlying mechanisms and to identify key players in the observed 
neurodegeneration in the brain a transcriptome analysis was performed comparing GNE+/- mice 
with wildtype littermates. For a detailed characterization, whole brain RNA of 9 months old 
mice was chosen because at that age the neuronal loss in the GNE+/- mice was already 
progressed in the SN pc and was getting significantly different in the hippocampus. 
RNA was isolated from four GNE+/- mice and four wildtype littermates. Quality controls and 
differences in gne transcription were validated by sqRT-PCR (***p ≤ 0.001; 1.0 ±0.0 FC 
GNE+/+ vs. 0.4 ± 0.0 FC GNE+/-; Figure 16A). The RNA sequencing, the processing and the 
analysis of the data were then performed by Dr. Sinkkonen and colleagues at the University of 
Luxembourg. Further in-depth analysis of the data was done in our lab in close collaboration. 
After normalization of the RNA sequencing data in total 52832 separate genes (summarizing 
hits for transcript variants and isoforms under one gene name) with a detection threshold over 
1 fragments per kilobase of transcripts per million mapped reads (> 1 FPKM) were detected. 
Then, statistical comparison using DeSeq2 was performed to detect differentially expressed 
genes (DEGs) between the groups. For this analysis it has to be taken into account that DeSeq2 
cannot distinguish between isoforms but was considered to be the better tool to use for pairwise 
comparison and the biological question asked here. In total, 45 genes with a FDR < 0.1 and 
with an adjusted p-value < 0.1 were found differentially expressed in the GNE+/- group 
compared to the wildtype group (Table 8, Appendix). Interestingly, most of the 45 DEGs were 
downregulated with Ppp1r3g, Ddit4, and Arl4d as the most downregulated transcripts and only 
three genes were upregulated (sox9, cxcl12, btg2). Many of the genes were transcription factors 
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with several genes being involved in apoptotic pathways or regulation of neurogenesis. The 
snake plot in Figure 16B shows the 25 out of the 45 DEGs, which have the highest log2 FC and 
an adjusted p-value < 0.05. 
Next, I wanted to know if the detected DEGs hint towards a neuroinflammation in the brain. 
From studies by Bodea and colleagues (Bodea et al., 2014) it was known that systemic 
inflammation after LPS challenge not only leads to neuroinflammation but also to strong 
neurodegeneration in the substantia nigra. I wondered if similar mechanisms were also involved 
in the neurodegeneration discovered in the GNE+/- mice or if at least similar key players could 
be detected. For this approach, the dataset was compared with the 45 DEGs (adjusted p < 0.1). 
Strikingly, only six genes were shared with the 1467 genes changing in mouse brains upon LPS 
exposure (see Figure 16C). The six common genes are listed in Table 5 and only one of them 
(dio2) shared the same directionality indicating that the transcriptome analysis of GNE+/- mice 
did not show a typical inflammatory signature. 
Table 5: List of the six shared genes of the GNE vs. LPS-induced neuroinflammation dataset 
Symbol Gene name Biological function1 
Acer2 alkaline ceramidase 2 enzyme; involved e.g. in lipid metabolism, cell 
proliferation and death, and protein 
glycosylation in Golgi 
Bhlhe40 basic helix-loop-helix family, 
member e40 
transcriptional regulator; involved e.g. in 
circadian rhythm and control of cell 
differentiation 
Dio2 deiodinase, iodothyronine, 
type II 
thyroid enzyme; involved in thyroid hormone 
generation and metabolism, and myelination 
Frmd6 FERM domain containing 6 regulator protein; involved in e.g. in actin-
filament-based processes and cellular protein 
localization 
Nostrin nitric oxide synthase 
trafficker 
transcriptional regulator; involved e.g. in 
endocytosis 
Per1 period circadian clock 1 transcriptional regulator; involved mainly in 
circadian rhythm but also in e.g. regulation of 
cytokine production or glucocorticoid receptor 
signaling pathway 
   
 1taken and modified from BioGPS (Wu et al., 2009) 
  
Nevertheless, I was interested to understand which other pathways might be involved. 
Therefore, an Ingenuity Pathway Analysis® (IPA, Qiagen®) was performed to explore general 
signs of biological functions related to the RNA sequencing data (FDR < 0.1). 
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Figure 16: RNA sequencing results of 9 months old GNE+/- mice compared to wildtype littermates. RNA 
from brain homogenates was sequenced in collaboration with Dr. Sinkkonen, University of Luxembourg. (A) 
Confirmation of different gne transcription levels in the analyzed sample sets. Data shown as mean + SEM; 
normalized to 9 months old GNE+/+ animals; n = 4, Student’s t-test, ***p ≤ 0.001. (B) Snake plot of the 25 most 
differentially expressed genes (DEGs) in GNE+/- mice compared to wildtype (WT) littermates with an adjusted p-
value (adj p) < 0.05. Genes are ranked by fold change (log2-scale) and color-coded for adj p. (C) Venn diagram 
comparing the total 45 DEGs (adj p < 0.1) with 1467 DEGs of brain samples upon systemic 4 x LPS-induced 
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neuroinflammation (dataset from Bodea et al., 2014). Only six genes were shared pointing out the big differences 
in the responses of these mice. (D) Presentation of the top five canonical pathways enriched in the Ingenuity 
Pathway Analysis on the significantly 45 DEGs (false discovery rate, FDR < 0.1). (E) Table of predicted upstream 
molecules targeting most of the 45 DEGs. Il1b - interleukin-1 beta; Crem - cAMP responsive element modulator; 
Nr3c1 – nuclear receptor subfamily 3 group C member 1; Mapk – mitogen-activated protein kinase; Clock - clock 
circadian regulator; Creb1 - cAMP responsive element binding protein 1. 
The top five canonical pathways that showed up in the IPA are listed in Figure 16D. The highest 
significant canonical pathway on the list was glucocorticoid receptor signaling. Almost 20 % 
of the DEGs are involved in this pathway. Glucocorticoid receptors are intracellular messengers 
and can directly or indirectly modulate the transcription of pro- and anti-inflammatory genes. 
Beside the canonical pathway analysis, IPA also predicted possible upstream regulators that 
could explain the 45 DEGs found in GNE+/- mice. A list of possible upstream regulators 
covering most of the 45 DEGs as target molecules can be found in Figure 16E. The regulator 
molecule having the most target molecules in the dataset was the cytokine Il1b. Nearly 30 % of 
the 45 DEGs interact with Il1b or are indirectly connected. Even 20 % of the DEGs can be 
regulated by the cAMP responsive element binding protein 1 (Creb1). Interestingly, the nuclear 
receptor subfamily 3 group C member 1 (Nr3c1), a member of the glucocorticoid receptor 
family, also showed up in the list of the predicted upstream regulator, connecting the upstream 
regulator with one of the canonical pathways. 
Taken together, no clear signs of neuroinflammation could be found in the brains of GNE+/- 
mice compared to wildtype littermates. Nevertheless, some pathways like the glucocorticoid 
signaling pathway could be altered in the transgenic mice on transcriptional level. 
3.1.5 Inflammation analysis on transcript level 
To confirm the RNA sequencing data of 9 months old mouse brains but also to review other 
age points, some genes were reanalyzed by sqRT-PCR. Therefore, RNA was isolated from 
brains of GNE+/- mice and wildtype mice at the age of 1 month, 3 months, 6 months, 9 months, 
and 12 months and screened for cytokines, factors of the complement system and typical 
microglia marker. 
3.1.5.1 Cytokines 
An indication for the activation of the innate immune system is the release of different 
cytokines. During inflammation mostly proinflammatory cytokines like Il1b and Tnfa are 
released. Therefore, I first investigated the relative transcript levels of the proinflammatory 
cytokines il1b and tnfa in more details (Figure 17). In Figure 17A the transcription levels at 
only 9 months are shown. While tnfa transcripts showed no difference (p = 0.624; 1.2 ± 0.3 FC 
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in GNE+/+ vs. 1.3 ± 0.1 FC in GNE+/-) at 9 months, il1b transcripts varied significantly in levels 
(*p = 0.041; 0.9 ± 0.2 FC in GNE+/+ vs. 1.7 ± 0.3 FC in GNE+/-). 
Comparing the findings at 9 months with the progression of the different transcript levels over 
age, they indeed reflected the time course quite well. The il1b transcription levels increased 
much stronger with age than the tnfa transcript levels (increase of 100 % for GNE+/- comparing 
3 months to 12 months). However, while at 6 months until 12 months the levels were much 
higher in the GNE+/- mice, they were still the same at 1 month and 3 months of age (Figure 17B, 
left graph). The tnfa transcription showed a slight increase with age (~20 %, 3 months vs. 
12 months) but independently of the genotype (Figure 17B, right graph). 
A robust multiple linear regression of il1b transcription during aging revealed age- and 
genotype-specific differences (R2 = 0.293, age effect: ***p < 0.001, genotype effect: 
*p = 0.013) but without any effect modulations (age*genotype: p = 0.122). Pairwise 
comparison between GNE+/- mice and wildtype littermates revealed no significant differences 
at 1 month (p = 0.364), 3 months (p = 0.491) and at 12 months (p = 0.281), but strong 
significant differences at 6 months (**p = 0.006) and at 9 months (*p = 0.031; Figure 17B, left 
graph). Multiple linear regression analysis of tnfa transcription during aging also resulted in 
age- but not in genotype-specific differences (R2 = 0.168, age effect: ***p < 0.001, genotype 
effect: p = 0.415) as well as not in effect modulations (age*genotype: p = 0.978). Pairwise 
comparison between GNE+/- mice and wildtype littermates showed no significant differences at 
any time point measured (1 month: p = 0.281; 3 months: p = 0.753; 6 months: p = 0.364; 
9 months: p = 0.672; 12 months: p = 0.874; Figure 17B, right graph). 
In detail, the il1b transcription levels increased from 0.6 ± 0.1 FC (1 month) to 1.1 ± 0.2 FC 
(3 months), back to 0.4 ± 0.1 FC (6 months), and further to 0.9 ± 0.2 FC (9 months) and 
1.5 ± 0.3 FC (12 months) in wildtype animals. The il1b transcription levels of GNE+/- mice 
started at 0.7 ± 0.1 FC in 1 month and increased to 1.0 ± 0.2 FC (3 months), 0.8 ± 0.1 FC 
(6 months), 1.7 ± 0.3 FC (9 months), and to 2.0 ± 0.4 FC (12 months). The tnfa transcript levels 
changed from 0.6 ± 0.0 FC (1 month), to 1.1 ± 0.2 FC (3 months), 0.9 ± 0.1 FC (6 months), 
1.2 ± 0.3 FC (9 months), and 1.4 ± 0.2 FC (12 months) in wildtype mice and from 0.7 ± 0.1 FC 
(1 month), to 1.2 ± 0.2 FC (3 months), 1.1 ± 0.2 FC (6 months), 1.3 ± 0.1 FC (9 months), and 
1.3 ± 0.2 FC (12 months) in GNE+/- mice. 
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Figure 17: Transcriptional profiles of the proinflammatory cytokines Il1b and Tnfa. (A) Levels of interleukin 
1 beta (il1b) and tumor necrosis factor alpha (tnfa) transcription in the brains of 9 months old GNE+/- mice and 
wildtype littermates are compared. Level of il1b is significantly higher in GNE+/- mice. Data shown as 
mean + SEM; normalized to 3 months old GNE+/+ animals; n = 7-14, Student’s t-test, *p ≤ 0.050. (B) Progression 
of il1b (left graph) and tnfa (right graph) transcription levels in the brains from 1 month until 12 months. Levels 
are increasing with age and much stronger in GNE+/- mice for il1b. Data shown as mean ± SEM; normalized to 
3 months old GNE+/+ animals; n = 7-15, pairwise comparison for GNE+/+ vs. GNE+/- mice at different age: 
*p ≤ 0.050, **p ≤ 0.010. 
Taken together, the levels of the proinflammatory cytokines il1b and tnfa at 9 months reflect 
the overall trend in transcript levels. Genotype-specific differences were found in il1b 
transcription levels but not in tnfa transcription levels during aging and while the levels for tnfa 
were only slightly increasing with age the levels for il1b showed a much stronger increase. 
3.1.5.2 Complement system 
In addition, I checked the transcription levels of different components of the complement 
system. The complement system is involved in not only neurodegenerative diseases, but also in 
development and homeostasis of the brain, to facilitate synaptic and neuronal clearance via 
microglial phagocytosis. To evaluate whether the complement cascade is altered in our 
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transgenic mouse model, I determined the transcript levels of the complement component 1 q 
subcomponent with alpha or beta polypeptide, or c chain (c1qa, c1qb, c1qc), the complement 
component 4b (c4b), the complement component 3 (c3), and the integrin alpha M (itgam, a 
subunit of complement receptor 3) in the brains of 1 month, 3 months, 6 months, 9 months, and 
12 months old GNE+/- mice and wildtype littermates. A schematic drawing in Figure 18B 
describes complement interactions. The complement receptor 3 (Itgam + Itgb2) can be found 
on macrophages like microglia (not displayed in Figure 18B). 
I first evaluated the 9 months old brains in more details (Figure 18). Here, a significant 
difference between the genotypes was found for c1qb (**p = 0.007; 1.0 ± 0.1 FC in GNE+/+ vs. 
0.8 ± 0.0 FC in GNE+/-). The level of c1qc was also strongly reduced in GNE+/- mice (p = 0.062; 
2.2 ± 0.6 FC in GNE+/+ vs. 0.9 ± 0.2 FC in GNE+/-). Similar transcript levels between GNE+/+ 
and GNE+/- were detected for c1qa, c4b, and c3. For c3 and itgam the levels were slightly 
elevated in GNE+/- mice compared to wildtype littermates. 
Similar to the transcription levels of the cytokines, the 9 months data of the complement 
components reflected quite well the overall course of the transcription levels from 1 month to 
12 months. For c1qa the levels were always minimally higher in the transgenic mice but were 
always reduced for c1qb and c4b levels. The levels of c1qc were also always between ~30 % 
to ~60 % reduced in the transgenic mice. The levels of c3 and itgam showed slightly higher 
level in GNE+/- for 6 months and 9 months. Overall, a clear age-dependent increase was found 
for c4b and for c3 transcripts but was also present for all other investigated components. 
A robust multiple linear regression confirmed age-specific differences for all components 
(c1qa: R2 = 0.150, age effect: ***p < 0.001; c1qb: R2 = 0.223, age effect: *p = 0.008; c1qc: 
R2 = 0.206, age effect: *p = 0.013; c4b: R2 = 0.330, age effect: ***p < 0.001; c3: R2 = 0.281, 
age effect: ***p < 0.001; and itgam: R2 = 0.094, age effect: ***p < 0.001). A genotype-specific 
effect showed only the linear model for c1qb (genotype effect: **p = 0.009) and c1qc (genotype 
effect: ***p < 0.001) and significant effect modulations (age*genotype) were not present in any 
model. Pairwise comparison between GNE+/- and wildtype littermates detected significant 
differences for c1qb levels at 9 months (**p = 0.004), c1qc levels at 1 month (*p = 0.038) and 
9 months (*p = 0.032), and for c4b levels at 6 months (*p = 0.012). 
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Figure 18: Transcriptional profiles of components of the complement system. (A) Transcription levels of 
complement component 1 with q subcomponent and alpha or beta polypeptide, or c chain (c1qa, c1qb, c1qc), 
complement component 4b (c4b), complement component 3 (c3), and integrin alpha M (itgam, a subunit of 
complement receptor 3) in the brains of 9 months old GNE+/- mice and wildtype littermates are compared. Data 
shown as mean + SEM; normalized to 3 months old GNE+/+ animals; n = 8-14, Student’s t-test, **p ≤ 0.010. (B) 
Schematic overview of all three pathways of the complement system showing some of the analyzed complement 
components in bold letters. (C) Progression of the transcription levels of the C1q subunits c1qa, c1qb, c1qc (upper 
graphs) and the complement components c4b, c3, and itgam (lower graphs) in the brains from 1 month until 
12 months. Age-dependent upregulation was seen for c4b and c3. Higher levels in GNE+/- mice were detected for 
c1qa, c3, and itgam. Data shown as mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-15, pairwise 
comparison for GNE+/+ vs. GNE+/- mice at different age: *p ≤ 0.050, **p ≤ 0.010. 
In detail, the transcript levels of c1qa changed from 0.6 ± 0.1 FC (1 month), to 1.1 ± 0.2 FC 
(3 months), 0.6 ± 0.1 FC (6 months), 1.2 ± 0.3 FC (9 months), and 1.2 ± 0.2 FC (12 months) in 
wildtype mice and from 0.8 ± 0.1 FC (1 month), to 1.2 ± 0.2 FC (3 months), 0.9 ± 0.2 FC 
(6 months), 1.4 ± 0.2 FC (9 months), and 1.4 ± 0.2 FC (12 months) in GNE+/- mice. Levels of 
c1qb varied from 0.8 ± 0.0 FC (1 month), to 1.0 ± 0.1 FC (3 months), 0.9 ± 0.1 FC (6 months), 
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1.0 ± 0.1 FC (9 months), and 1.2 ± 0.2 FC (12 months) in wildtype mice and from 0.8 ± 0.1 FC 
(1 month), to 0.8 ± 0.1 FC (3 months), 0.8 ± 0.0 FC (6 months), 0.8 ± 0.0 FC (9 months), and 
1.0 ± 0.1 FC (12 months) in GNE+/- mice. Transcription of c1qc fluctuated between 
1.7 ± 0.4 FC (1 month), to 1.4 ± 0.3 FC (3 months), 2.5 ± 0.4 FC (6 months), 2.2 ± 0.6 FC 
(9 months), and 2.7 ± 0.9 FC (12 months) in wildtype mice and between 1.1 ± 0.2 FC 
(1 month), 0.8 ± 0.1 FC (3 months), 1.7 ± 0.3 FC (6 months), 0.9 ± 0.2 FC (9 months), and 
1.4 ± 0.4 FC (12 months) in GNE+/- mice. In contrast, the transcription levels of c4b steadily 
increased from 0.5 ± 0.1 FC (1 month) to 1.0 ± 0.1 FC (3 months), over 1.3 ± 0.1 FC 
(6 months), 1.8 ± 0.2 FC (9 months), to 2.3 ± 0.3 FC (12 months) in wildtype mice and 
increased similar from 0.4 ± 0.0 FC (1 month), over 0.9 ± 0.1 FC (3 months), 1.0 ± 0.1 FC 
(6 months), 1.6 ± 0.4 FC (9 months), to 1.8 ± 0.3 FC (12 months) in GNE+/- mice. The course 
of c3 transcripts also increased from 0.8 ± 0.2 FC (1 month) to 1.0 ± 0.1 FC (3 months) over 
1.5 ± 0.2 FC (6 months), 1.5 ± 0.1 FC (9 months), to 2.1 ± 0.3 FC (12 months) in wildtype 
mice and increased similar from 0.6 ± 0.0 FC (1 month), over 1.0 ± 0.1 FC (3 months), 
1.6 ± 0.3 FC (6 months), 1.8 ± 0.3 FC (9 months), to 2.1 ± 0.3 FC (12 months) in GNE+/- mice. 
In addition, the levels of itgam stayed relatively constant with 0.8 ± 0.0 FC (1 month), 
1.0 ± 0.1 FC (3 months), 1.1 ± 0.1 FC (6 months), 1.1 ± 0.1 FC (9 months), and 1.3 ± 0.1 FC 
(12 months) in wildtype mice and with 0.9 ± 0.1 FC (1 month), 0.9 ± 0.1 FC (3 months), 
1.4 ± 0.3 FC (6 months), 1.3 ± 0.3 FC (9 months), and 1.3 ± 0.2 FC (12 months) in GNE+/- 
mice. 
Taken together, transcription levels of different components of the complement system 
increased with age but to very diverse extents. Significant differences between GNE+/- mice and 
wildtype littermates were detected for c1qb, c1qc, and c4b transcription and with reduced levels 
in the transgenic mice. The overall findings were well reflected by the 9 months old results. 
3.1.5.3 Microglia markers 
To better understand if microglia sense an altered glycocalyx and sialic acid changes in the 
transgenic mouse model, the mRNA levels of the macrophage- and microglia-specific marker 
allograft inflammatory factor 1 (aif1; the Iba1 encoding gene), the phagocytosis and activation 
marker CD68 antigen (cd68), and the newly identified microglia-specific marker 
transmembrane protein 119 (tmem119; described in Bennett et al., 2016) was determined in 
brain homogenates of GNE+/- mice and wildtype mice at the age of 1 month, 3 months, 
6 months, 9 months, and 12 months (Figure 19). 
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First, in addition to the RNA sequencing results the transcription levels at 9 months were 
investigated in more details (Figure 19A). Overall, the transcript levels of aif1, cd68, and 
tmem119 were always higher in GNE+/ mice with differences in aif1 transcripts at significant 
level (*p = 0.029; 0.9 ± 0.1 FC in GNE+/+ vs. 1.7 ± 0.3 FC in GNE+/-). 
Careful investigations of the time courses of all microglia markers showed similar tendencies 
(Figure 19B). While at 1 month and 3 months of age transcription levels were almost equal 
(except cd68, 3 months), detected levels for 6 months, 9 months, and 12 months were always 
higher in the transgenic mice. Furthermore, levels of aif1 (left graph) and tmem119 (right graph) 
were increasing with age with a discontinuum between 3 months and 6 months, while levels of 
cd68 (middle graph) were rather decreasing after 3 months. 
 
Figure 19: Transcriptional profiles of microglial markers. (A) Levels of allograft inflammatory factor 1 (aif1; 
gene of Iba1), the CD68 antigen (cd68), and the transmembrane protein 119 (tmem119) transcripts in the brains of 
9 months old GNE+/- mice and wildtype littermates are compared. Transcription of il1b is higher in GNE+/- mice. 
Data shown as mean + SEM; normalized to 3 months old GNE+/+ animals; n = 8-14, Student’s t-test, *p ≤ 0.050. 
(B) Progression of aif1 (left graph), cd68 (middle graph), and tmem119 (right graph) transcription levels in the 
brains from 1 month until 12 months. Levels of il1b increase with age. Transcription levels are mostly higher in 
GNE+/ mice. Data shown as mean ± SEM; normalized to 3 months old GNE+/+ animals; n = 7-15, pairwise 
comparison for GNE+/+ vs. GNE+/- mice at different age: *p ≤ 0.050. 
Results  71 
 
 
A robust multiple linear regression during aging revealed age-specific differences for all three 
markers (aif1: R2 = 0.278, age effect: ***p < 0.001; cd68: R2 = 0.100, age effect: ***p < 0.001; 
tmem119: R2 = 0.122, age effect: **p = 0.003). A genotype-specific effect was seen in the 
model of aif1 (genotype effect: **p = 0.003) and of tmem119 (genotype effect: *p = 0.040) but 
not in the linear model of cd68 (genotype effect: p = 0.109). However, significant effect 
modulations (age*genotype) were not present in any model (aif1: p = 0.130; cd68: p = 0.416; 
tmem119: p = 0.735). Interestingly, pairwise comparison between GNE+/- and wildtype 
littermates detected only significant differences for aif1 levels at 9 months (*p = 0.018). 
In detail, the transcript levels of aif1 changed from 0.6 ± 0.1 FC (1 month) to 1.0 ± 0.1 FC 
(3 months), and from 0.6 ± 0.0 FC (6 months), over 0.9 ± 0.1 FC (9 months), to 1.0 ± 0.1 FC 
(12 months) in wildtype mice and similar from 0.6 ± 0.1 FC (1 month) to 1.0 ± 0.1 FC 
(3 months), and from 0.8 ± 0.1 FC (6 months), to 1.7 ± 0.3 FC (9 months), to 1.4 ± 0.2 FC 
(12 months) in GNE+/- mice. Transcription of cd68 increased strongly from 0.5 ± 0.1 FC 
(1 month) to 1.3 ± 0.3 FC (3 months) and then decreased to 1.0 ± 0.3 FC (6 months), 
1.0 ± 0.3 FC (9 months), and 1.2 ± 0.3 FC (12 months) in wildtype mice. In GNE+/- mice 
transcription of cd68 increased also from 0.4 ± 0.0 FC (1 month) to 1.7 ± 0.4 FC (3 months) 
and steadily decreased from 1.6 ± 0.4 FC (6 months), to 1.5 ± 0.5 FC (9 months), and to 
1.4 ± 0.4 FC (12 months). Mean levels of tmem119 changed from 0.7 ± 0.0 FC (1 month), to 
1.1 ± 0.1 FC (3 months), 0.7 ± 0.0 FC (6 months), 0.9 ± 0.2 FC (9 months), and 1.0 ± 0.2 FC 
(12 months) in wildtype mice and from 0.8 ± 0.1 FC (1 month), to 1.1 ± 0.1 FC (3 months), 
1.0 ± 0.2 FC (6 months), 1.3 ± 0.2 FC (9 months), and 1.2 ± 0.2 FC (12 months) in GNE+/- 
mice. 
Altogether, differences in the transcription levels of microglial markers were minor but present. 
Especially at 6 months and 9 months levels were increased in the brain of GNE+/- mice 
compared to wildtype littermates. 
3.1.6 Inflammation analysis on protein level 
Although no typical inflammatory signature was found in the brain transcriptome analysis, 
neuroinflammation occurring on protein level could not automatically be excluded. Typical 
sensors of neuronal stress are glial cells, like microglia and astrocytes. Changes in the brain 
parenchyma might be sensed and lead to activation and morphological changes in these cells. 
Over-activation and dysregulation of these cells can have detrimental effects on the neurons, 
like neuroinflammation. 
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3.1.6.1 Microglia analysis 
As described by Linnartz-Gerlach and colleagues (Linnartz et al., 2012b; Linnartz-Gerlach et 
al., 2016) sialylation serves as an inhibitory flag for the innate immune system. Thus, an altered 
sialylation in the brain can lead to the activation of microglia. Inflammatory microglia 
activation is often described along with morphological changes. Activation markers like Cd68 
are upregulated and microglia retract their processes, which normally results in a larger soma 
area. To quantify some of these parameters, sagittal sections of the SN pr of 9 months old mice 
were stained with antibodies against the microglial membrane receptor Iba1 and the 
activation/lysosomal marker Cd68. Z-stack images were acquired to consider the three-
dimensional stretch of a microglia. 
As displayed in Figure 20A, the microglia morphology was not obviously altered in the GNE+/- 
mice compared to wildtype littermates. The lysosomal protein Cd68 was often co-stained with 
Iba1-positive structures and could be observed in the soma as well as in microglial processes. 
Microglia were equally distributed in the sagittal sections investigated and the density of Iba1-
/DAPI-positive cells was not significantly different between the genotypes (p = 0.075; Figure 
20B). The overall fluorescence intensity of Iba1 was slightly higher in the GNE+/- mice 
(p = 0.244). In contrast, the overall Cd68 fluorescence intensity per area was minor but 
significantly decreased in GNE+/- mice (*p = 0.013; Figure 20C).  
In detail, the relative density of Iba1-/DAPI-positive cells was 100.0 ± 13.4 % in GNE+/+ mice 
and 68.1 ± 3.4 % in GNE+/- mice. As quantified in Figure 20C, the measured Iba1 fluorescence 
intensity per area was 100.0 ± 10.1 % in GNE+/+ mice and 125.0 ± 49.7 % in GNE+/- mice and 
the measured Cd68 fluorescence intensity per area was 100.0 ± 1.3 % in GNE+/+ mice compared 
to 86.7 ± 4.1 % in GNE+/- mice. 
Additionally, the microglial soma area was selected and quantified separately. As shown in 
Figure 20D no genotype-specific differences in the soma area were detected (p = 0.571). The 
Iba1 fluorescence intensity of the soma did also not show any genotype-specific differences 
(p = 0.776; Figure 20E, left graph). In contrast, the Cd68 fluorescence intensity was again 
reduced, but not significantly in GNE+/- mice compared to wildtype littermates (p = 0.134; 
Figure 20E, right graph). 
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Figure 20: No genotype-dependent differences in the microglia morphology of 9 months old mice. (A) 
Representative z-stack images of the microglia in the SN pr of 9 months old GNE+/- mice and wildtype littermates 
at lateral sections of ~1.30 mm are shown. The sagittal brain slices were stained with antibodies directed against 
the microglial marker ionized calcium binding adaptor molecule 1 (Iba1; green), the microglial activation marker 
Cd68 (red) and the nucleus marker DAPI (blue). White arrows indicate some representative Iba1-/Cd68 co-
staining. Scale bar: 50 µm. (B) Quantification of the relative microglial (Iba+/DAPI+) cell density showed a slight 
decrease for GNE+/- mice. Data shown as mean + SEM; n = 5-8, Student’s t-test, ns. = not significant. (C) 
Quantification of the relative fluorescence intensity per area of Iba1 (left graph) and of Cd68 (right graph) revealed 
no differences in Iba1 and a slight decrease in Cd68 in GNE+/- mice. Data shown as mean + SEM; n = 4-8, 
Student’s t-test, ns. = not significant, *p ≤ 0.050. (D) Quantification of the relative soma area of Iba-/DAPI-
positive cells showed no difference. Data shown as mean + SEM; n = 5-8, Student’s t-test, ns. = not significant. 
(E) Quantification of the relative fluorescence intensity per soma area of Iba1 (left graph) and of Cd68 (right graph) 
revealed no difference for Iba1 and a decrease in Cd68 for GNE+/- mice. Data shown as mean + SEM; n = 4-8, 
Student’s t-test, ns. = not significant. 
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In detail, the relative soma area was 100.0 ± 6.3 % in GNE+/+ mice and 94.8 ± 5.9 % in GNE+/- 
mice. The measured Iba1 fluorescence intensity per soma was 100.0 ± 5.2 % in GNE+/+ mice 
compared to 97.4 ± 6.3 % in GNE+/- mice and the measured Cd68 fluorescence intensity per 
soma was 100.0 ± 16.3 % in GNE+/+ mice compared to 69.4 ± 4.1 % in GNE+/- mice. 
3.1.6.2 Astrocytes analysis 
Astrocytes are star-shaped glial cells in the brain that originate from precursor cells of the 
neuronal lineage and do not belong to the innate immune system such as microglia. 
Nevertheless, astrocytes closely interact with the neuronal tissue like microglia. Beside a range 
of different functions, they can support neurons by provisions of nutrients, regulating 
transmitter and ion concentrations in the extracellular space and are closely associated with 
synaptic activity modulation. In inflammatory brains, astrogliosis can be detected by increased 
fluorescence intensity of the glial fibrillary acidic protein (Gfap) and increased numbers of 
astrocytes. To investigate astrogliosis as possible inflammatory sign in the brain of GNE+/- 
mice, sagittal sections of the SN pr of 9 months old mice were stained with antibodies directed 
against the astroglial marker Gfap and the nucleus marker DAPI. Z-stack images were acquired 
to consider the three-dimensional stretch of an astrocyte. 
Representative z-stacks of the Gfap-positive cells are shown in Figure 21A. More and thicker 
processes branch from the soma of astrocytes compared to microglia, which gives them a star-
like shape. All z-stacks investigated show a rather equal cell distribution and no differences in 
cell density between the genotypes could be observed in the SN pr of 9 months old mice 
(p = 393; Figure 21B). The Gfap fluorescence intensity per area was slightly but not 
significantly reduced in GNE+/- mice (p = 250; Figure 21C). 
In detail, the measured relative density of Gfap-/DAPI-positive cells was 100.0 ± 4.9 % in 
GNE+/+ mice compared to 93.2 ± 6.0 % in GNE+/- mice. The overall Gfap fluorescence intensity 
per area was 100.0 ± 16.1 % in GNE+/+ mice and 77.3 ± 9.2 % in GNE+/- mice. 
Taken together, the analyzed data on protein level showed no typical inflammatory changes in 
the morphology of microglia and astrocytes. Only minor genotype-dependent differences could 
be observed. 
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Figure 21: No genotype-dependent differences in astrocytes in the SN pr. (A) Representative z-stack images 
of the astrocytes in the SN pr of 9 months old GNE+/- mice and wildtype littermates at lateral sections of ~1.40 mm 
are shown. The sagittal brain slices were stained with antibodies directed against the astrocytic marker glial 
fibrillary acidic protein (Gfap; green) and the nucleus marker DAPI (blue). Scale bar: 25 µm. (B) Quantification 
of the relative astrocyte (Gfap+/DAPI+) cell density in the SN pr of 9 months old animals revealed no difference. 
Data shown as mean + SEM; n = 9-10, Student’s t-test, ns. = not significant. (C) Quantification of the relative 
Gfap fluorescence intensity per area in the SN pr of 9 months old animals showed a slight but not significant 
decrease for GNE+/ mice. Data shown as mean + SEM; n = 9-10, Student’s t-test, ns. = not significant.  
3.2 Rescue of the GNE+/--specific phenotype 
The characterization of the transgenic mouse model indicated major changes in the homeostasis 
of the brains of these mice probably due to the altered sialylation. Neuronal loss correlates with 
microglial activation and supported the hypothesis of Linnartz-Gerlach and colleagues 
(Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016) that in the absence of sialic acids, 
complement-mediated phagocytosis is initiated. To confirm that the above described neuronal 
loss is indeed dependent on the activation of the complement cascade, I crossbred GNE mice 
with mice deficient for C3. The complement component C3 is the central player in the 
complement cascade and a C3 knockout prevents complement activation. The GNE/C3 
offspring were investigated with similar parameters as used for the characterization of the 
GNE+/- mice. 
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3.2.1 RNA sequencing 
First, a transcriptome analysis on 9 months old brains was performed in direct comparison to 
the GNE+/- mice (now written as GNE+/-C3+/+). The direct comparison should enable to detect 
the rescue of even small changes. In addition to the samples described in section 3.1.4, RNA 
was isolated from four GNE+/-C3-/- mice and four GNE+/+C3-/- mice. The RNA sequencing, the 
processing and the analysis of the data were again performed by Dr. Sinkkonen and colleagues 
at the University of Luxembourg. Further in-depth analysis of the data was carried out in our 
lab in close collaboration. 
To compare the overall gene expression profiles between the four different genotypes, a 
principle component analysis (PCA) was performed. The PCA displayed in Figure 22A 
demonstrated that in general the RNA sequencing analysis was successful because all four 
groups were distinguishable by their genotype. The PCA plot shows that samples with C3 
wildtype background clustered strongly together as well as samples with C3-deficient 
background. Furthermore, all GNE+/+ samples were located together regarding the principle 
component (Pc) 2 (Pc2 < 0), while the GNE+/- samples were rather located above Pc2 = 0. 
Interestingly, the samples with GNE+/+ background clustered closer together than samples with 
a GNE+/- background and those samples seemed to be more diverse. Still, the C3 background 
was dividing the samples strongest (C3-/-: Pc1 < -2; C3+/+: Pc1 > 2). Noteworthy, the sample 
G5 was most different to all other samples according to the PCA but without being a significant 
outlier. Thus, it was not excluded from further investigations. In Figure 22B volcano plots were 
used to visualize the comparison of GNE+/+C3-/- samples (upper graph) and of GNE+/-C3-/- 
samples (lower graph) with the wildtype samples (GNE+/+C3+/+). Each dot of the volcano plot 
represents a gene and the overall distribution gives an idea of the extent of changes in the C3-
deficient samples. Plenty of genes were affected in both directions but with modest fold change 
(≤ 2 –fold) except for C3, which was located in the far upper left corner of the volcano plots. 
This furthermore confirmed that the analysis was working and that the modest changes in 
GNE+/- are biological and not some technical artifacts. Overall, 64 % of the DEGs in GNE+/+C3-
/- mice and 62 % in GNE+/-C3-/- mice were downregulated. Additional quality controls and 
differences in gne and c3 transcription were validated by sqRT-PCR (**p ≤ 0.001; Figure 22C).  
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Figure 22: RNA sequencing results of 9 months old GNE+/-C3-/- mice compared to wildtype controls. RNA 
from brain homogenates was sequenced in collaboration with Dr. Sinkkonen, University of Luxembourg. (A) A 
principle component (Pc) analysis of all 4 genotype groups represented by a color code is shown. Dashed lines 
indicate zero for both x- and y-axis. n = 4. (B) Volcano plots displaying the extent of the changes in the C3-
deficient mice compared to wildtype mice with C3 highly downregulated. Each dot represents a gene. The order 
of the plots indicates that the baseline value is that from wildtype samples and the indicated fold change happens 
in the compared condition. Red dotted line represents adjusted p-value < 0.05. n = 4. (C) Confirmation of different 
gne and c3 transcription levels in the analyzed sample sets by sqRT-PCR. Data shown as mean + SEM; normalized 
to 3 months old GNE+/+C3+/+ animals (indicated as grey dashed line). n = 4; Student’s t-test, **p ≤ 0.010 (D) Venn 
diagram comparing the differentially expressed genes (DEGs; adj p < 0.1) of each genotype group in regard to the 
wildtype group (WT = GNE+/+C3+/+) with each other. Overlapping areas show number of shared genes. n = 4. 
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While the transcript levels of gne of the GNE+/-C3-/- mice were reduced by 50% (0.5 ± 0.0 FC), 
GNE+/+C3-/- mice showed similar gne levels as the wildtype mice (0.9 ± 0.1 FC). Transcription 
of c3 was almost undetectable (0.1 ±0.0 FC in GNE+/+C3-/- and 0.1 ±0.0 FC in GNE+/-C3-/-) in 
the C3-deficient mice. 
The analysis of the RNA sequencing data revealed that while in the GNE+/-C3+/+ group 45 genes 
were differentially expressed compared to the wildtype group as mentioned before, the C3-
deficient mice showed much more DEGs. In detail, the sample group GNE+/+C3-/- had 1334 
DEGs compared to the wildtype group (Table 9, Appendix) and the group of GNE+/-C3-/- 
samples had 987 DEGs (Table 10, Appendix) compared to the wildtype group. Comparing the 
different data sets in form of a Venn diagram (see Figure 22D) it becomes obvious that 21 
DEGs of the “GNE+/-C3+/+ vs. WT” group were also present independently in the “GNE+/+C3-
/- vs. WT” group and 18 genes out of them remained dysregulated in the “GNE+/-C3-/- vs. WT” 
group. Furthermore, 14 genes out of the 45 DEGs in GNE+/-C3+/+ remained also dysregulated 
in GNE+/-C3-/- mice. Consequently, there were ten DEGs that were specific to GNE+/-C3+/+ and 
those got partially or fully corrected in GNE+/-C3-/- (listed in Table 6). In addition, there are 
three genes that were dysregulated in both the GNE+/-C3+/+ and in the GNE+/+C3-/- group that 
returned closer to the wildtype group in GNE+/-C3-/- (listed in Table 7). 
Table 6: List of the ten DEGs unique for GNE+/-C3+/+ 
Symbol Gene name Biological function1 
log2 fold 
change 
adjusted 
p-value 
Arrdc2 arrestin domain 
containing 2 
not exactly known yet -0,235 0,018 
Pdk4 pyruvate 
dehydrogenase kinase, 
isoenzyme 4 
mitochondrial protein; helps to 
decrease metabolism and 
conserve glucose; involved e.g. 
in ROS metabolism; regulated by 
glucocorticoids 
-0,239 0,099 
Mknk2 MAPK-interacting 
serine/ threonine 
kinase 2 
transcriptional regulator; 
involved in e.g. apoptotic 
processes, intracellular signal 
transduction, and hemopoiesis 
-0,172 0,062 
Trp53inp1 transformation related 
protein 53 inducible 
nuclear protein 1 
SIP or "stress inducible protein"; 
involved e.g. in autophagosome 
assembly, apoptotic processes, 
and transcriptional regulation 
-0,231 0,096 
Acer2 alkaline ceramidase 2 enzyme; involved e.g. in lipid 
metabolism, cell proliferation 
and death, and protein 
glycosylation in Golgi 
-0,322 0,002 
Klf13 Kruppel-like factor 13 transcriptional regulator; 
associated with obesity and 
-0,190 0,073 
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orexigenic processes; negative 
regulator of cell proliferation 
Kdm3a lysine (K)-specific 
demethylase 3A 
demethylase; involved in 
hormone-dependent 
transcriptional activation 
-0,138 0,094 
1810011 
O10Rik 
RIKEN cDNA 
1810011O10 gene 
positive regulator of the Wnt / 
beta-catenin signaling pathway; 
involved e.g. in apoptotic 
processes and immune response 
-0,195 0,094 
Myh1 myosin, heavy 
polypeptide 1, skeletal 
muscle, adult 
unique protein for striated 
muscle; important in muscle 
contraction 
-0,126 0,052 
Numbl numb-like protein; involved e.g. in 
neurogenesis, cytokine-mediated 
signaling pathway, and protein 
metabolic processes 
-0,131 0,094 
     
1taken and modified from BioGPS (Wu et al., 2009) 
 
Overall, the Venn diagram showed that the C3-deficiency caused much greater changes on 
transcription level than the Gne-heterozygosity. The 13 DEGs described in Table 6 and Table 
7 were the most likely genes to explain any transcriptional correction of GNE+/--induced 
dysregulation by deletion of the C3 gene. The low number was consistent with the absence of 
major overall transcriptome changes described before. Indeed, the differences between the 
individual biological replicates were sometimes bigger than the differences between the 
different genotypes. 
Table 7: List of the 3 DEGs common in GNE+/-C3+/+ and GNE+/-C3-/- 
Symbol Gene name Biological function³ 
log2 fold 
change 
adjusted 
p-value 
Per1 
period circadian 
clock 1 
important for the maintenance of 
circadian rhythms in cells 
-0,2451 0,0191 
-0,1382 0,1732 
Mxi1 
MAX interactor 1, 
dimerization protein 
transcriptional repressor thought to 
negatively regulate c-myc function, 
and therefore a potential tumor 
suppressor 
-0,1511 0,0621 
-0,0782 0,3212 
Arl4d 
ADP-ribosylation 
factor-like 4D 
GTP-binding proteins; may play a 
role in membrane-associated 
intracellular trafficking; mutations 
in this gene have been associated 
with Bardet–Biedl syndrome 
-0,3701 0,0001 
-0,1562 0,1162 
     
1Wildtype vs. GNE+/-C3+/+    2Wildtype vs. GNE+/+C3-/- 
³taken and modified from BioGPS (Wu et al., 2009) 
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Furthermore, some of the top five canonical pathways mentioned in Figure 16D, like the 
glucocorticoid receptor signaling pathway did not show up anymore in the IPA of GNE+/-C3-/- 
mice. The same was true for some of the predicted upstream regulators, like Il1b. 
3.2.2 Inflammation analysis on transcript level 
Specific transcription analysis of the brain of the GNE+/-C3+/+ mice showed that some genes 
were still affected more strongly than the RNA sequencing approach revealed and thus, are of 
particular interest. Therefore, the transcript levels of the cytokines, the complement components 
and the microglia markers as described earlier were re-evaluated in the C3-deficient mice by 
sqRT-PCR. 
The cytokine analysis (Figure 23A) showed no differences in tnfa transcript levels but it showed 
GNE-dependent differences in il1b levels. Transcription of il1b was decreased after C3-
knockout indicating a possible rescue effect. In detail, the il1b levels were 1.1 + 0.2 FC 
(GNE+/+C3+/+), 2.2 + 0.4 FC (GNE+/-C3+/+), 1.3 + 0.2 FC (GNE+/+C3-/-), and 1.6 + 0.2 FC 
(GNE+/-C3-/-) and the transcription levels of tnfa were 0.9 + 0.2 FC (GNE+/+C3+/+), 1.0 + 0.1 FC 
(GNE+/-C3+/+), 0.9 + 0.2 FC (GNE+/+C3-/-), and 1.0 + 0.1 FC (GNE+/-C3-/-). 
As representative complement components the transcripts of the c1q subunits c1qa, c1qb, and 
c1qc were investigated, as well as the transcription of the soluble factor c4b, the central player 
c3, and one of the genes of the complement receptor 3 (itgam; Figure 23B). First, the c3 
transcription was clearly downregulated and almost undetectable in the C3-deficient samples, 
whereas the transcription of c1qa and of c4b seemed not to be affected by the C3-deficiency. 
Levels of c1qc reduced to levels of GNE+/-C3+/+ mice independently of the GNE-genotype. 
Interestingly, the significant reduction of c1qb transcript levels in GNE+/-C3+/+ samples 
(**p = 0.009) were not present anymore after C3-knockout (ns. p = 1). A similar tendency was 
observed for itgam levels. The slightly elevated levels in GNE+/-C3+/+ mice compared to 
wildtype littermates were not observed any more in C3-deficient mice. In detail, the c1qa levels 
differed between 1.3 + 0.3 FC (GNE+/+C3+/+), 1.5 + 0.2 FC (GNE+/-C3+/+), 1.4 + 0.3 FC 
(GNE+/+C3-/-), and 1.6 + 0.2 FC (GNE+/-C3-/-). The transcription levels of c1qb differed 
between 1.0 + 0.1 FC (GNE+/+C3+/+), 0.8 + 0.0 FC (GNE+/-C3+/+), 1.0 + 0.0 FC (GNE+/+C3-/-), 
and 0.9 + 0.0 FC (GNE+/-C3-/-) and the transcription levels of c1qc differed between 
1.4 + 0.4 FC (GNE+/+C3+/+), 0.6 + 0.1 FC (GNE+/-C3+/+), 0.5 + 0.1 FC (GNE+/+C3-/-), and 
0.4 + 0.1 FC (GNE+/-C3-/-). The detected levels of c4b were at 1.0 + 0.1 FC (GNE+/+C3+/+), 
0.9 + 0. FC (GNE+/-C3+/+), 0.9 + 0.2 FC (GNE+/+C3-/-), and 0.8 + 0.1 FC (GNE+/-C3-/-) and for 
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c3 at 1.0 + 0.1 FC (GNE+/+C3+/+), 1.2 + 0.2 FC (GNE+/-C3+/+), 0.1 + 0.0 FC (GNE+/+C3-/-), and 
0.1 + 0.0 FC (GNE+/-C3-/-). Levels of itgam varied from 1.0 + 0.1 FC (GNE+/+C3+/+) and 
1.3 + 0.3 FC (GNE+/-C3+/+) and stayed similar at 0.8 + 0.1 FC (GNE+/+C3-/-), and 0.8 + 0.0 FC 
(GNE+/-C3-/-). 
Microglia markers were re-evaluated on transcription levels (Figure 23C). The increase in aif 
levels in GNE+/-C3+/+ mice (p = 0.147) was not visible any more in GNE+/-C3-/- samples and the 
level was almost reduced back to wildtype level. The slight increase of cd68 transcription was 
also gone in C3-deficient mice. Interestingly, the overall levels were very much reduced after 
C3-knockout. Transcript levels of tmem119 were equal in GNE+/+C3-/- and GNE+/-C3-/- mice 
and similar to GNE+/-C3+/+ mice. In detail, the aif1 levels were 1.0 + 0.1 FC (GNE+/+C3+/+), 
1.9 + 0.3 FC (GNE+/-C3+/+), 0.8 + 0.1 FC (GNE+/+C3-/-), and 1.1 + 0.1 FC (GNE+/-C3-/-) and the 
transcription levels of cd68 were at 1.2 + 0.3 FC (GNE+/+C3+/+), 1.7 + 0.6 FC (GNE+/-C3+/+), 
0.4 + 0.1 FC (GNE+/+C3-/-), and at 0.5 + 0.0 FC (GNE+/-C3-/-). Levels of tmem119 varied 
between 1.1 + 0.2 FC (GNE+/+C3+/+), 1.5 + 0.2 FC (GNE+/-C3+/+), 1.5 + 0.4 FC (GNE+/+C3-/-), 
and 1.5 + 0.1 FC (GNE+/-C3-/-). 
Taken together, some transcript levels that were altered in GNE+/-C3+/+ mice compared to 
wildtype mice do not show these differences anymore in GNE+/-C3-/- mice compared to 
GNE+/+C3+/+ mice and thus, might be rescued by the C3-knockout. 
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Figure 23: Transcriptional profiles of 9 months old GNE mice in comparison with C3-deficient background. 
Transcript levels of cytokines (A), complement components (B), and microglia markers (C) were measured in 
brain homogenates from GNE+/+C3-/- and GNE+/-C3-/- mice and were compared to GNE mice with C3-wildtype 
background. Red rectangles label graphs with a possible phenotype-rescue. Data shown as mean + SEM; 
normalized to 9 months old GNE+/+C3+/+ animals. n = 4-14; one-way ANOVA with Bonferroni or Dunnett’s T3 
post hoc correction, ns. = not significant, *p ≤ 0.050, **p ≤ 0.010, ***p ≤ 0.001. (A) Levels of interleukin 1 beta 
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(il1b) and tumor necrosis factor alpha (tnfa) transcription were almost equal after knockout of C3. (B) 
Transcription levels of complement component 1 with q subcomponent and alpha or beta polypeptide, or c chain 
(c1qa, c1qb, c1qc), complement component 4b (c4b), complement component 3 (c3), and integrin alpha M (itgam, 
one of the genes of complement receptor 3) are shown. Levels of c1qa and c4b were similar in all groups. 
Differences in c1qb, c1qc and itgam levels were rescued by knockout of C3, whereas c3 levels were undetectable. 
(C) Levels of allograft inflammatory factor 1 (aif1; gene of Iba1), the CD68 antigen (cd68), and the transmembrane 
protein 119 (tmem119) transcripts in the brains of 9 months old GNE+/- mice and wildtype littermates showed no 
GNE-dependent difference anymore after knockout of C3. 
3.2.3 Neuronal loss in the brain 
The characterization of the GNE+/- mice revealed not only an altered sialylation in the brain but 
was also accompanied by increasing neuronal loss in different brain regions compared to 
wildtype littermates. Based on the introduced concept of Linnartz-Gerlach and colleagues 
(Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016) it should be possible to prevent the 
neuronal loss in mice with reduced sialic acid levels by inhibiting the complement system. 
Therefore, the neuronal density was also investigated in the substantia nigra and in the 
hippocampus of GNE+/-C3-/- mice and as control also in GNE+/+C3-/- mice. 
3.2.3.1 Neuronal loss analysis in the substantia nigra 
Serial sagittal sections (lateral: 1.10 – 1.20 mm) of the SN pc were again analyzed by 
immunohistochemical antibody staining of the dopaminergic marker TH and the neuronal 
nuclei marker NeuN in 12 months old mice (see Figure 24A). Cells positive for TH or NeuN 
were counted per area and the relative cell density in the SN pc was quantified in all four 
genotypes (Figure 24B). 
Strikingly, the strong overall neuronal loss seen in the SN pc of 12 months old GNE+/-C3+/+ 
mice (34 % reduction; ***p ≤ 0.001 vs. GNE+/+C3+/+) was not present anymore in 12 months 
old GNE+/-C3-/- mice (p = 1.000 vs. GNE+/+C3-/-). The neuronal cell density of GNE+/-C3-/- mice 
(93.8 + 5.2 %) reached almost the same levels as those of GNE+/+C3+/+ mice (100.0 + 5.9 %) 
and of GNE+/+C3-/- mice (103.6 + 4.6 %) compared to 65.8 + 5.7 % in GNE+/-C3+/+ mice (left 
graph; Figure 24B). The same strong rescue-effect was seen for the dopaminergic cell density 
in the SN pc (right graph; Figure 24B). While in GNE+/-C3+/+ mice the relative cell density of 
TH-positive cells was at 64.1 + 6.2 % compared to 100.0 + 4.2 % in GNE+/+C3+/+ mice (34 % 
reduction; ***p ≤ 0.001), the density was back at wildtype levels after C3-knockout 
(95.5 + 4.1 % in GNE+/-C3-/- and 104.2 + 5.7 % in GNE+/+C3-/-). 
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Figure 24: Neuronal loss in the substantia nigra of GNE+/-C3+/+ mice was rescued in GNE+/-C3-/- mice. (A) 
Representative images of the substantia nigra of 12 months old GNE+/-C3+/+ and GNE+/-C3-/- mice at lateral sections 
between 1.10 mm and 1.20 mm are shown. Sagittal brain slices were stained with antibodies directed against 
tyrosine hydroxylase (TH, green) and neuronal nuclei (NeuN, red). SN pc – substantia nigra pars compacta, SN pr 
– substantia nigra pars reticulata. Scale bar: 200 µm. (B) Quantification of the cell density of NeuN- (left graph) 
and TH-positive cells (right graph) in 12 months old brain section revealed almost a complete rescue of the GNE+/-
-dependent neuronal loss. Data shown as mean + SEM; normalized to 12 months old GNE+/+C3+/+ animals; n = 9-
13, one-way ANOVA with Bonferroni post hoc correction, ns. = not significant, **p ≤ 0.010, ***p ≤ 0.001. 
Data of the neuronal density in the SN pc strongly showed that the GNE-dependent 
neurodegeneration was prevented under C3-deficient background. 
3.2.3.2 Neuronal loss analysis in the hippocampus 
Serial sagittal sections (lateral: 1.10 mm to 1.20 mm) of the hippocampus were analyzed by 
immunohistochemical antibody staining of the neuronal nuclei marker NeuN and the cellular 
nuclei marker DAPI (see Figure 25A). The cell density was determined by counting the cells 
positive for NeuN per area in the CA3 region of 12 months old brain of all four genotypes as 
shown in Figure 25B. 
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Although the neuronal loss in the CA3 region was not as strong as in the SN pc, there was still 
a significant difference in the GNE+/-C3+/+ mice compared to the wildtype mice (~16 % 
reduction; *p = 0.045) that was absent in the GNE+/-C3-/- mice compared to GNE+/+C3-/- mice 
(p = 1.000). Comparing the GNE+/--genotypes with each other, the C3-knockout showed a 
significant rescue-effect on the neurodegeneration (**p = 0.003 GNE+/-C3+/+ vs. GNE+/-C3-/-). 
In detail, the neuronal density in the CA3 region was quantified with 100.0 + 9.3 % 
(GNE+/+C3+/+), 84.1 + 2.3 % (GNE+/-C3+/+), 96.9 + 2.6 % (GNE+/+C3-/-), and 104.3 + 3.0 % 
(GNE+/-C3-/-). 
 
Figure 25: Neuronal loss in the CA3 region of the hippocampus of GNE+/-C3+/+ mice was rescued in GNE+/-
C3-/- mice. (A) Representative images of the hippocampus of 12 months old GNE+/-C3+/+ and GNE+/-C3-/- mice at 
lateral sections between 1.10 mm and 1.20 mm are shown. Lower images show a higher magnification of the CA3 
region in the hippocampus (white dotted line). Sagittal brain slices were stained with antibodies directed against 
neuronal nuclei (NeuN, red) and DAPI (blue). DG – dentate gyrus. Scale bar: 200 µm or 100 µm (higher 
magnification). (B) Quantification of the cell density of NeuN-positive cells at 12 months old brain sections 
revealed the complete rescue of neuronal cell density by knockout of C3. Data shown as mean + SEM; normalized 
to 12 months old GNE+/+C3+/+ animals; n = 10-13, one-way ANOVA with Bonferroni post hoc correction, ns. = 
not significant, *p ≤ 0.050, **p ≤ 0.010. 
The same immunohistochemical staining was also used to measure the width of the CA3 region 
and the DG at different positions as described before. The mice deficient for C3 showed similar 
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mean widths for all three positions as the C3-wildtype mice (Figure 26). The only difference 
was found in the width of the CA3 region in GNE+/+C3-/- mice, which was slightly increased 
compared to GNE+/+C3+/+ mice. In detail, the relative measured widths of the DG1 position 
were 100.0 + 3.9 % (GNE+/+C3+/+), 108.4 + 4.2 % (GNE+/-C3+/+), 110.5 + 4.1 % (GNE+/+C3-/-), 
and 108.3 + 3.3 % (GNE+/-C3-/-) and the measured widths for the DG2 position was 
100.0 + 6.3 % (GNE+/+C3+/+), 102.3 + 3.1 % (GNE+/-C3+/+), 100.4 + 4.4 % (GNE+/+C3-/-), and 
111.3 + 3.7 % (GNE+/-C3-/-). The relative width of the CA3 region was 100.0 + 7.7 % 
(GNE+/+C3+/+), 113.1 + 4.4 % (GNE+/-C3+/+), 130.0 + 9.2 % (GNE+/+C3-/-), and 110.8 + 6.4 % 
(GNE+/-C3-/-). 
 
Figure 26: Minor changes in the width of the dentate gyrus (DG) and of the CA3 region in C3-deficient 
mice. Quantification of the relative width for DG1, DG2, and CA3 at 12 months old sagittal brain sections (left to 
right) revealed significant differences in CA3 for GNE+/+C3-/- vs. GNE+/+C3+/+. Data shown as mean + SEM; 
normalized to 12 months old GNE+/+C3+/+ animals; n = 9-13, one-way ANOVA with post hoc correction, ns. = not 
significant, *p ≤ 0.050. 
Taken together, knocking out C3 prevented the increased neuronal loss in the hippocampus of 
GNE+/C3-/- mice but did not alter the width in these mice compared to wildtype animals. 
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4 Discussion 
Strong improvements in medical care and hygiene have allowed an increasingly aging 
population worldwide. At the same time neurodegenerative diseases, like AD, PD or dementia 
are emerging tremendously (Bishop et al., 2010). One of the key events of these diseases and 
during aging is a general or cell-type specific neuronal loss. Although enormous research 
investigations have been carried out to unravel the underlying mechanisms leading to neuronal 
loss and to develop suitable drugs for therapy, still, rather the symptoms but not the causes can 
be treated by now. Meanwhile glial research is postulating microglia as a key mediator in most 
of the neurodegenerative diseases in the aging population (Lull and Block, 2010; Šišková and 
Tremblay, 2013; von Bernhardi et al., 2015). Being the only immune cells in the immune-
privileged brain, microglia not only work as policemen but also as nannies. Maintaining the 
homeostasis involves close interaction with neurons and other cell types, like astrocytes. This 
important crosstalk is mediated by the cellular glycocalyx, a dense network of receptors, 
signaling proteins and lipids on the cell surface that is covered by a fine regulated glycosylation 
structure. The tight regulation of this interface enables precise communication between neurons 
or neuron-glial cells in the brain. 
Studying the neuronal glycocalyx in vitro has demonstrated that even small alterations like the 
removal of sialic acids, which form the terminal caps, can lead to a dysregulated crosstalk 
between microglia and neurons. This resulted in phagocytic removal by microglia of otherwise 
viable neurons. Furthermore, it was proven that phagocytosis was mediated by the complement 
system in a CR3-dependent manner. Desialylated but not sialylated neuronal structures were 
opsonized by C1q. Moreover, inhibition of CR3 prevented the microglia-mediated 
phagocytosis. This mechanism was not only proven in mouse microglia-neuron co-cultures 
(Linnartz et al., 2012b) but was demonstrated in human microglia/macrophage-neuron co-
cultures as well (Linnartz-Gerlach et al., 2016). 
However, many in vitro studies lack validation in vivo or even worse, in vitro results cannot be 
confirmed in the complex in vivo situation as discussed by Ransohoff and Perry (2009). To 
confirm the complement-mediated phagocytosis of desialylated neuronal structures by 
microglia in vivo, the brains of mice heterozygous for GNE were thoroughly characterized in 
this study and were evaluated as possible model for an altered glycocalyx in vivo. Furthermore, 
the need of transgenic mouse models and the clinical relevance of mutations in GNE will be 
discussed. 
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4.1 Characterization of the GNE+/- mice 
Gagiannis and colleagues reported that GNE+/- mice have an overall reduction of membrane-
bound sialic acids by 25 % but do not have any obvious defects in organ architecture or function 
compared to wildtype mice (Gagiannis et al., 2007). In the present study, I investigated the 
brain of these mice in more detail and discovered some additional genotype-specific 
differences. 
First of all, routinely mouse monitoring indeed did not identify differences in the appearance 
or in the behavior of the mice but female GNE+/- mice were significantly heavier than their 
wildtype littermates. Male mice did not show these genotype-specific differences in weight. 
Because GNE has other roles beside the sialic acid biosynthesis (Wang et al., 2006; Grover and 
Arya, 2014), I assume that the GNE-heterozygosity might influence the female metabolism 
more than the male metabolism. However, deeper investigations on metabolism were beyond 
this study. 
In general, sex-specific differences are not yet routinely tested in scientific experiments. Recent 
publications that compared sex-specific transcriptomes of female and male brains discovered 
notable differences between microglia and neuroimmune signaling (Lenz and McCarthy, 2015; 
Hanamsagar et al., 2017; Mangold et al., 2017). Furthermore, not only the signaling but also 
microglia numbers vary significantly between sexes and female mice show a more 
inflammatory neuroimmune milieu than males, which is increasing with age (Nissen, 2017). 
Hormones like estradiol have a potential influence on the brain anatomy and are capable of 
promoting neurite outgrowth and thus, shaping the local environment (Amateau and McCarthy, 
2002; McCarthy, 2008). Considering these findings, it was not surprising that the X 
chromosome was found to have the highest concentration of immune-related genes compared 
to the whole genome (Bianchi et al., 2012). This once more explains the stronger immune-
imprint in the female brain and is possibly also the reason why autoimmune disorders (e.g. MS) 
mostly occur in females. Nevertheless, studies with PD mouse models revealed that female 
mice are less sensitive for the loss of dopaminergic neurons and exhibit a higher variability 
(Przedborski et al., 2001). In addition, estrogen levels in female mice seem to be 
neuroprotective in PD mouse models (Miller et al., 1998) and thus, male mice are preferentially 
chosen for neurodegeneration analysis. These findings highlight how important it is to clearly 
distinguish between sexes in brain research. 
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Taken this into account, I strictly distinguished between male and female data in the 
experiments of this study. Female mice were mainly used for the sialylation status and male 
mice were investigated for neuronal loss and transcription levels. The only exception was the 
RNA sequencing data that was performed in female mice but were confirmed in male mice after 
discovering sex-specific differences. 
4.1.1 Evaluation of the sialylation status 
Sialylation of proteins or lipids on the cell surface belongs to the most common posttranslational 
modification in the mammalian brain and is highly dynamic. The biosynthesis as well as the 
incorporation of sialic acids as terminal caps is essential for the cell-cell interaction and is 
tightly regulated by a number of enzymes, like GNE being a rate-limiting enzyme. 
In the GNE+/- mice the mRNA levels of GNE were reduced by about 50% compared to wildtype 
as it was also shown for the heterozygous embryonic stem cell line generated by Schwarzkopf 
and colleagues (Schwarzkopf et al., 2002). This clearly demonstrated that one copy of the 
wildtype allele of GNE is not sufficient to produce the wildtype transcription levels 
(haploinsufficiency). Schwarzkopf and colleagues even measured reduced protein levels of 
GNE and reduced enzyme activity. However, the transcription analysis did only account for the 
two most known isotypes of GNE. At the time of the study, 14 transcripts of the mouse GNE 
gene (ENSMUSG00000028479) were listed at ensembl annotations (v.89) with eight 
transcripts listed for protein coding (Yates et al., 2016). From these eight protein coding 
transcripts only two transcripts were validated in more details and listed in NCBI GenBank 
(5384 bp: NM_015828 and 2920 bp: NM_001190414) and NCBI GenPept (753aa: NP_056643 
and 722aa: NP_001177343). Therefore, differences in transcription level of other GNE variants 
cannot be ruled out and it remains unclear, which effects they may have. 
On protein level, the sialylation of the whole brain was significantly altered in the GNE+/- mice. 
Greatest differences were detected in long polymers of sialic acids (n > 10). At 3 months, I 
found an overall reduction of 33% in PSA-NCAM levels, which confirms the study of 
Gagiannis and colleagues (Gagiannis et al., 2007) that showed 32% reduction in membrane-
bound sialic acids in the brain. The data is also in line with the study of the heterozygous GNE 
embryonic stem cell line from Schwarzkopf and colleagues (Schwarzkopf et al., 2002). 
Heterozygous cells expressed much lower amounts of polysialic acids on NCAM than the 
wildtype cells. PSA-NCAM levels of GNE wildtype mice were increasing until about 6 months 
90  Discussion 
and then were steadily decreasing. Similar results were shown for muscle sialylation in mice 
(Hanisch et al., 2013). 
In comparison, levels of oligomers were reduced by 26% at 3 months, whereas levels of the 
embryonic form of NCAM were the same between genotypes and only lower in older GNE+/- 
mice. The epitope of CD56 distinguishes the embryonic form of NCAM from the adult, less 
sialylated form. The measured decline in CD56 levels with aging, corresponds to the decline I 
saw for PSA-NCAM and is also described for polysialic acids in literature (Miller et al., 1993; 
Sato and Endo, 2010). While overall polysialylation decreases in the adult brain, some plastic 
regions like the olfactory bulb, the hypothalamus or the hippocampus remain highly positive 
for polysialic acids (Seki and Arai, 1993; Kuhn et al., 1996). Altogether, data indicate that 
mostly long sialic acid chains are affected by the reduced or altered sialic acid supply in the 
mice. This is in agreement with data shown by Kreuzmann and colleagues suggesting that the 
intracellular sialic acid concentration regulates polysialylation on NCAM in vivo (Kreuzmann 
et al., 2016). These findings support my idea that polysialyltransferases need higher 
concentrations of CMP-sialic acids than normal alpha-2,3- und alpha-2,6-sialyltransferases, 
which are necessary for surface sialylation. 
Nevertheless, it remains unclear whether the levels of membrane-bound sialic acids are equally 
affected all over the brain. Sialylation might be differently regulated in different organs and 
even in different brain regions. Murray and colleagues have shown for example that the 
distribution of PSA-NCAM in post-mortem human brain tissue is very abundant in cortical 
regions (especially in layers II and III) but is sparsely distributed in the cerebellum (Murray et 
al., 2016). Furthermore, variable intensity of PSA-NCAM staining was found in the visual 
cortex and throughout the substantia nigra. In the hippocampus, the CA1 region showed the 
strongest staining for PSA-NCAM. Due to these regional differences, I assume that some brain 
regions might also be more affected by the GNE-heterozygosity than others. A specific analysis 
of membrane-bound sialic acids in different brain regions GNE+/- mice and wildtype littermates 
could clarify if such an effect is occurring. 
Polysialylation of NCAM is directly connected with learning and memory formation. NCAM-
deficient mice as well as mice deficient for polysialyltransferases, which are responsible for the 
polysialylation, show deficits in learning and memory formation but otherwise no phenotype 
differences compared to wildtype mice (Cremer et al., 1994; Eckhardt et al., 2000). Thus, to 
clarify if the reduced levels of polysialylation in the GNE+/- mice have already an impact on 
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memory and cognitive functions, behavior tests for spatial and temporal learning, like the 
Morris-Water-Maze or the novel object recognition test could be used. 
Desialylation can also be seen as first step of protein turnover and consequently as “protein 
aging”. The life span of secreted proteins is regulated by glycosylation. Endogenous 
glycosidases like neuraminidase 1, beta-galactosidase and hexosaminidase have been shown to 
progressively remodel glycosylated proteins with aging. Removal of sialic acids leads to 
exposure of different saccharides that are then recognized by phagocytes resulting in protein 
degradation (Yang et al., 2015). Similar control mechanisms were shown in the turnover of 
blood cells and platelets (Grozovsky et al., 2014; Li et al., 2015; Qiu et al., 2016), concluding 
that unwanted desialylation is a form of accelerated aging and might activate or enhance aging 
processes in the organism as observed in the GNE+/- mice. 
4.1.2 Evaluation of the transcriptional and morphological changes in 
the brain 
4.1.2.1 Loss of neurons in different brain regions 
One of the major questions of the study was whether an altered glycocalyx with reduced 
sialylation is sufficient to cause neuronal loss in vivo. In the in vitro studies it was clearly 
demonstrated that microglia remove desialylated neurites (Linnartz et al., 2012b; Linnartz-
Gerlach et al., 2016). However, it was not described at which level of desialylation microglia 
are able to significantly change the neuronal density. 
In the GNE+/- mice a clear reduction in neuronal density was observed during aging in the SN pc 
as well as in the CA3 region of the hippocampus compared to wildtype littermates. This loss of 
neurons further progressed with decreasing sialic acid levels. Worth to mention, the neuronal 
density was not different in 1 month old mice, suggesting that the neuronal loss in the substantia 
nigra and the hippocampus of older GNE+/- mice is likely not a result of abnormal neuronal 
development or a developmental artefact. Interestingly, the findings in the substantia nigra and 
the hippocampus show distinct neurodegeneration progression. While the neuronal density in 
GNE+/- mice decreased much earlier in the substantia nigra than in the hippocampus, in contrast, 
the neuronal density of wildtype animals was more stable in the substantia nigra than in the 
hippocampus. In the hippocampus even for wildtype mice (3 months vs. 12 months) a 
significant neuronal decline was measured, although to a lower extent than in GNE+/- mice. 
Nevertheless, this neuronal decline is in line with findings in other wildtype mice reported by 
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Shi and colleagues (Shi et al., 2015). They saw a significant reduction in neuronal numbers at 
16 months but not at 4 months. 
From the obtained data I cannot judge whether the neuronal loss seen in the hippocampus is 
delayed compared to the substantia nigra due to more protective sialic acids. As mentioned 
before, sialic acid levels of different brain regions have not yet been investigated in GNE+/- 
mice but might help to understand the regional differences in neuronal loss. Alternatively, the 
neuronal loss seen in the hippocampus is simply slower progressing than in the substantia nigra. 
One aspect supporting this hypothesis is the microglial density. The substantia nigra is the brain 
region with the highest microglia density (Lawson et al., 1990). This could explain why the 
neuronal loss in the GNE+/- mice is progressing faster and earlier in the substantia nigra 
compared to the hippocampus. However, it was also described that the otherwise stable 
microglia number is increasing exceptionally in the hippocampus, the visual and auditory 
cortices, and in the retina with age (Mouton et al., 2002; Damani et al., 2011; Tremblay et al., 
2012). Thus, with increasing number of microglia in the aged hippocampus the neuronal loss 
might accelerate to a degree seen in the substantia nigra. In addition, the sensitivity to 
inflammatory stimuli varies across different brain regions. It even differs within a brain region 
as it was shown for the hippocampus by Shi and colleagues (Shi et al., 2015), where only the 
CA3 region but not the CA1 region or the DG was affected by the age-dependent neuronal loss. 
At the same time, no neuronal loss was detected in the V1 region of the cortex or the cerebellum 
in these mice (Shi et al., 2015). 
Taken together, age-dependent neuronal loss is normal but varies strongly between brain 
regions and even sub-regions and apparently, can be accelerated by reduced sialic acid levels. 
Therefore, it would be interesting to understand at which level of sialic acids or at which age a 
cognitive decline can be measured. One study from Vidal and colleagues showed that the 
neuronal density in the CA1 region of AD patients decreases with progressing Braak stages and 
resulted in 38% reduction at Braak stages V/VI compared to age-matched controls with Braak 
stage 0 (Vidal et al., 2016). These findings are in line with a study from Padurariu and 
colleagues who analyzed different CA regions in the hippocampus of postmortem human 
brains. CA1 showed the strongest decline in neuronal density (-34%), while in the CA3 the 
neuronal loss was about 25% (Padurariu et al., 2012), suggesting that the neuronal decline in 
the CA3 region of the 12 months old GNE+/- mice might be similar severe as for AD patients 
with advanced cognitive decline. Additional learning and memory tests in 12 months or older 
mice might further clarify the cognitive status of the GNE+/- mice. It might also help to 
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understand at which time point reduced sialic acid levels can result in cognitive deficits and 
thus, can have a major impact on aging. 
I also measured the width of hippocampal regions because neuronal loss might lead to atrophy 
and shrinkage of the tissue or at the opposite, inflammatory processes could lead to swellings 
and increased volume of the affected areas. Width measurements were previously introduced 
as a valid and affordable method for detecting the levels of neurodegeneration and 
neuroprotection in the hippocampus (Öz and Saybaşılı, 2017). In an earlier study in diabetic 
mice, selective deficits in spatial memory were correlating with increased width of the DG and 
CA1 region in the hippocampus and reduced spine densities in CA1 neurons (Taylor et al., 
2015). Indeed, I saw an increase in width in the CA3 region and the DG, which peaked at 
9 months but it occurred independently of the genotype. Strikingly, the increase was greatly 
diminished in 12 months old mice. These findings could hint towards a tissue remodeling. 
Increasing swelling might precede final atrophy of the tissue. Still, these width changes stay 
elusive. 
Oxidative stress might also play a major role in the neuronal loss seen in this study. In particular 
the neurons in the substantia nigra are very susceptible to oxidative stress compared to other 
neurons. First of all, the dopamine biosynthesis in the dopaminergic neurons is associated with 
elevated ROS production (Di Giovanni et al., 2012), which is in fact a highly regulated process. 
It is assumed that regulatory mechanisms fail during aging. Furthermore, dopaminergic neurons 
express less glutathione. Glutathione normally works as a buffer against ROS (Loeffler et al., 
1994) by neutralizing the radicals. Reduced levels of glutathione decrease the potential of 
regulating ROS in the substantia nigra. Besides, oxidative stress supports the release of 
membrane-bound sialic acids (Goswami et al., 2003) because sialic acids are good scavengers 
and possible antioxidants. This might amplify the phenotype in GNE+/- mice, which have a 
reduced capacity of building up sialic acids in the glycocalyx, and might reduce the levels of 
membrane-bound sialic acid even further. For a follow-up study it would be interesting to 
analyze the correlation of oxidative stress and sialic acid levels in the brain. Two possible 
options for an indirect measurement of oxidative stress in tissue is the quantification of 
malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE), which are both natural bi-products of 
lipid peroxidation. Lipid peroxidation is the result of free radicals and therefore, quantification 
of MDA and 4-HNE can be used as marker for oxidative stress (Ho et al., 2009; Wu et al., 2013; 
Zhang et al., 2016a; Kleniewska and Pawliczak, 2017). 
94  Discussion 
Neurodegeneration in the substantia nigra is a major hallmark of PD. PD is characterized by 
progressive loss of dopaminergic neurons in the SN pc and the nerve terminals in the striatum 
(Dauer and Przedborski, 2003). The clinical symptoms are mainly motor impairment like 
bradykinesia, rigidity, tremors, and postural instability but also non-motor symptoms including 
disorganized speech and altered moods were described (Fakhoury, 2016). Precise analysis of 
postmortem brains of PD patients showed around 80% loss of dopaminergic cells compared to 
age-matched controls (Damier et al., 1999), which is double as much as I have seen in the SN pc 
of 12 months old GNE+/- mice (-36% loss in TH-positive neurons) and hence, explains why I 
did not observe any obvious motor impairment. It is possible that progressing neuronal loss 
with further age might be strong enough to develop clear clinical symptoms in GNE+/- mice and 
might be worth to test. 
Beside the appearance of neuronal loss, abnormal intracytoplasmic filamentous aggregates, so 
called Lewy bodies, are found in somas and axons of PD patients. These aggregates consist of 
phosphorylated neurofilament, parkin, alpha-synuclein and components of the protheosomic-
ubiquitin pathway (Orr et al., 2002). It is conceivable that sialylation is involved in the normal 
folding of proteins, suggesting that impaired sialylation results in aggregation. Recently, the 
study of Oikawa and colleagues showed that an imbalance of ganglioside 
(sialoglycoconjugates) composition triggered amyloid beta deposition (Oikawa et al., 2015) and 
altered sialylation of proteins in AD was already discussed before (Schedin-Weiss et al., 2014). 
However, the underlying cause is not completely understood. PD has also been suggested as 
accelerated form of aging but neuronal loss in normal aging is not sufficient to cause PD. 
Similar conclusions were drawn for neuronal loss in aging versus AD (Morrison and Hof, 
2002). Additional confirmed etiological factors for the neurodegeneration in PD are 
environmental toxins like herbicides (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin, MPTP), 
insecticides (Rotenone), or metals and genetic factors. Mutations in alpha-synuclein and parkin 
but also mitochondrial dysfunction and oxidative stress can lead to the accumulation of 
misfolded proteins and aggregates (reviewed in Ramirez et al., 2017). 
4.1.2.2 The absence of neuroinflammation 
The composition and function of the brain is much more complex than a cell culture dish with 
defined cell types. Transcriptomic studies are a helpful tool to understand complex pathways 
and provide an overview of the expression levels of all genes and functional elements in the 
CNS. Nowadays, high-throughput RNA sequencing technology enables to map and quantify a 
large number of transcripts simultaneously and cost-effectively. In direct comparison to the 
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former predominantly used method of microarrays, RNA sequencing has the advantage to 
discover novel transcripts, alternative splicing events, and even genetic variations. Thus, 
nowadays RNA sequencing is more quantitative, accurate and comprehensive than a microarray 
approach (Dong et al., 2015). 
In this study we used the RNA sequencing approach to study the effects of altered sialic acid 
levels on gene transcription. Interestingly, the transcriptome analysis of whole brain RNA 
revealed no major changes between the genotypes. This was not entirely unexpected, as we 
have a modest perturbation of GNE (heterozygote) and used total brain tissue RNA. Even if 
there would be robust changes in some cell types, they can easily be masked by other cell types 
in the tissue. Also opposite directions in different cell types might neutralize each other in whole 
brain homogenate analysis. However, robust effects are normally seen by this approach 
suggesting that indeed, the GNE heterozygosity had no deeper effect on gene expression. 
Inconsistent with this statement is the finding that gne did not appear within the 45 DEGs in 
GNE+/- mice, although I was able to confirm reduced transcription levels by sqRT-PCR. This 
discrepancy is probably due to the primer design and the statistical analysis we applied. The 
primers used for gne detection are exon 2 – exon 3 spanning and were designed to distinguish 
between the wildtype and the knockout allele. This primer pair was further confirmed to 
recognize the two main known protein coding isoforms published by NCBI (mGne1: 
NM_001190414 and mGne2: NM_015828) but probably does not recognize all possible splice 
variants (e.g. see Ensembl: Gne, ENSMUSG00000028479; Yates et al., 2016) as mentioned 
earlier. Since only the two major isoforms of these 14 listed transcripts are confirmed to be 
protein coding (Reinke et al., 2009; Yardeni et al., 2013) it remains unclear if and how many 
of the other splice variants are functional and should be taken into account. However, as 
mentioned before DeSeq2 is not distinguishing between transcript variants and is counting all 
identified isoforms of Gne. In contrast, CuffLinks and CuffDiff, two alternative statistical 
approaches that has been tested for the RNA sequencing data (data not shown), distinguish 
between variants. The analysis using CuffLinks and CuffDiff revealed that not all gne variants 
were downregulated in GNE+/- mice explaining why the summarized levels of all gne variants 
are not listed as differentially expressed in the DeSeq2 analysis. Nevertheless, based on quality 
checks these statistical approaches were not as appropriate for the dataset as DeSeq2. 
Furthermore, no typical inflammatory signature could be found in the brain, which typically 
accompanies a neuronal loss seen in neurodegeneration. We compared our dataset with a study 
of inflammatory neurodegeneration sharing the neuronal loss in the substantia nigra. In this 
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study the neuronal loss was mediated by the activation of the microglial complement-
phagosome pathway (Bodea et al., 2014) and the neuronal loss was already observed 14 days 
after a systemic repeated LPS challenge (on four consecutive days). Furthermore, already 
within five days of treatment, inflammatory response pathways were enriched in the brain of 
these mice and increased production of proinflammatory cytokines like Tnfa or Il1b was 
measured. However, a similar upregulation of inflammatory markers was not seen in GNE+/- 
mice. Furthermore, the number of DEGs in the brains of GNE+/- mice was only 3 % of the 
number of altered genes in the LPS-challenged brains. Almost all shared genes differed in 
directionality, except the deiodinase, iodothyronine, type II (Dio2). Dio2 being downregulated 
in both datasets is normally mentioned as activator of thyroid hormone synthesis but also 
indirectly promotes myelination via thyroxine upregulation. Interestingly, Dio2 was found to 
be a risk factor for late-onset AD and was confirmed to be downregulated in late-onset AD 
patients similar as in the GNE+/- mice (Humphries et al., 2015). 
Taken together, the direct comparison with the whole genome transcriptome analysis of the 
brain with inflammatory neurodegeneration demonstrated clearly that an inflammatory profile 
was not present in GNE+/- mice, suggesting that inflammation is not the underlying mechanism 
for the neuronal loss observed in this study. Furthermore, the transcriptional profile of 9 months 
could be validated for several genes and transcriptional time series of these genes confirmed 
similar trends at earlier time points. 
Yet, minor changes in transcription were at least discovered for 45 DEGs. Most of these genes 
were surprisingly downregulated in GNE+/- mice, whereas only three genes were significantly 
upregulated (Cxcl12, Btg2, and Sox9). C-X-C Motif Chemokine Ligand 12 (Cxcl12), also 
known as stromal cell-derived factor-1 (SDF1), is a chemoattractant for immune cells such as 
microglia and has anti-inflammatory properties (Azizi et al., 2014). Its receptor is the C-X-C 
Motif Chemokine Receptor 4 (Cxcr4). Cxcl12/Cxcr4 signaling plays an important role in adult 
neurogenesis and was shown to be upregulated after stroke (Cui et al., 2013). In the rat cochlea, 
Cxcl12 was found to be highly expressed in degenerating spiral ganglion neurons and promoted 
the migration of Cxcr4-expressing neural stem cells to the degenerated site (Zhang et al., 2013). 
In line with Cxcl12, the B cell translocation gene 2 (Btg2) was described as regulator of neuron 
differentiation during embryonic development (Canzoniere et al., 2004) and plays a role in adult 
neurogenesis in the subventricular zone and in the DG of the hippocampus (Farioli-Vecchioli 
et al., 2008). These findings suggest that the upregulation of Cxcl12 and Btg2 levels in GNE+/- 
is an attempt to counteract the neuronal loss by promoting neurogenesis. Puzzling is the 
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upregulation of Sox9 (also known as SRA1 or sex determining region Y-box 9). Sox9 plays a 
pivotal role in male sexual development and inhibits the formation of the female reproductive 
system (De Santa Barbara et al., 1998; Moniot et al., 2009). Why a transcript supporting male 
sexual development is upregulated in female GNE+/- mice cannot be explained. 
Among the 45 DEGs the protein phosphatase 1 regulatory subunit 3G (Ppp1r3g) was the 
strongest downregulated gene. It is a glucose metabolism-related enzyme that regulates 
postprandial glucose homeostasis and lipid metabolism (Zhang et al., 2017). Liver-specific 
overexpression of Ppp1r3g in mice enhanced postprandial blood glucose clearance and mice 
showed a reduced fat mass (Zhang et al., 2014b). Therefore, reduced ppp1r3g transcription 
might be a sign of a changed metabolism and might account for the increased weight in female 
GNE+/- mice. Another strongly downregulated gene was DNA-damage-inducible transcript 4 
(Ddit4), also known as protein regulated in development and DNA damage response 1 
(REDD1) or under the name “RTP801”. It regulates a variety of cellular functions such as 
growth, proliferation and autophagy by inhibiting the mammalian target of rapamycin complex-
1 (mTORC1; Corradetti et al., 2005; Sofer et al., 2005; Ota et al., 2014). Interestingly, in the 
substantia nigra of postmortem PD brains highly elevated levels of Ddit4 were measured but 
not in cerebellar neurons. It was concluded that elevated Ddit4 may mediate degeneration and 
death of substantia nigral neurons (Malagelada et al., 2006) meaning that the downregulation 
of Ddit4 in the brains of GNE+/- mice is another unsuccessful attempt to counteract the neuronal 
loss and to maintain homeostasis. Why the ADP-ribosylation factor-like protein 4D (Arl4d), 
the third most downregulated DEG, was also downregulated is unclear. Arl4d was identified as 
neuroprotective molecule by Dai and colleagues (Dai et al., 2010) and is normally upregulated 
during BDNF dependent long-term potentiation and promotes adaptive neuronal plasticity in 
the brain (Alme et al., 2007). The downregulation of Arl4d might be a first sign that the ability 
of neuronal plasticity such as synapse formation is impaired. 
Interestingly, the proinflammatory cytokine Il1b was predicted as most possible upstream 
regulator in GNE+/- mice and was confirmed to be upregulated in GNE+/- mice at several ages. 
Although Il1b is an important mediator between the brain and the immune system, it has also 
been shown to play a role in a number of homeostatic functions, including fever (Morimoto et 
al., 1986; Blatteis and Sehic, 1998; Netea et al., 2000), sleep (Ingiosi et al., 2015), feeding and 
drinking behavior (De Castro E Silva et al., 2006; Luz et al., 2006, 2009), and cardiovascular 
control, such as body temperature, blood pressure, and fluid homeostasis (Takahashi et al., 
1992; Yamamoto et al., 1994; Cerqueira et al., 2016). Furthermore, Il1b was shown to be 
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negatively affected by gangliosides, the sialic acid-containing glycosphingolipids. Gangliosides 
are considered to play an important role in tissue homeostasis and repair in the CNS. Via protein 
kinase A (PKA)-mediated phosphorylation gangliosides can activate the cAMP response 
element binding protein (CREB), which was also among the predicted upstream regulators 
(Chandra et al., 1995; Min et al., 2004). In addition, the promoter region of the gene encoding 
Il1b contains a CREB binding site (Stylianou and Saklatvala, 1998). Thus, gangliosides are able 
to regulate il1b levels via several second messengers, such as the transcription factor CREB. 
Considering that most sialic acids are found on gangliosides in the brain, it is most likely that 
the ganglioside composition is altered in GNE+/- mice and affects il1b transcription. Similar 
upregulation of il1b was shown for other transgenic mouse models affecting the ganglioside 
composition in the cerebellum and in the spinal cord (Ohmi et al., 2011, 2014). The 
transcription of il1b was upregulated with increasing severity of ganglioside ablation. 
Furthermore, increasing il1b levels were observed during aging, similar to our study. In another 
study from Ba and colleagues it was shown that the treatment with the ganglioside GM1 was 
able to reduce elevated il1b levels in a rat model of PD (Ba, 2016). Taken together, these 
publications draw a link between altered sialic acids, ganglioside and il1b levels. 
In the canonical pathway analysis the glucocorticoid signaling pathway appeared as first hit. 
Glucocorticoids are hormones that are secreted from the adrenal glands in response to acute 
stress signals deriving from the hypothalamus and from the pituitary gland and help to maintain 
homeostasis or to adapt to a stress situation (reviewed in Hall et al., 2015). Lately, 
glucocorticoids were also found to be involved in synaptic plasticity. Endogenous 
glucocorticoid oscillations promoted spine formations and were required for spine stabilization, 
whereas chronic excessive glucocorticoid signaling eliminated new spines (Liston et al., 2013). 
Chronic elevation and prolonged exposure to glucocorticoids were also measured in several 
psychiatric disorders like depression (Carroll et al., 1976; Starkman et al., 1992). Thus, 
quantification of the synaptic density in different brain regions would be interesting. 
Glucocorticoid signaling is mediated by glucocorticoid receptors and mineralocorticoid 
receptors. While mineralocorticoid receptors are mainly expressed in neurons as well as in glial 
cells (Sierra 2008, see Herrero 2015), glucocorticoid receptors are almost ubiquitously 
expressed in the brain (Herrero et al., 2015). If glucocorticoid signaling is significantly altered 
in GNE+/- mice it is not unexpected that the glucocorticoid receptor Nr3c1 is among the 
predicted upstream regulators. These data are also in line with the decreased glucocorticoid 
receptor levels reported in the substantia nigra of a PD patient and in a PD mouse model (Ros-
Bernal et al., 2011). Unfortunately, the activity of Nr3c1 as well as of Creb1 is not really 
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regulated on transcription levels but usually by ligand binding (glucocorticoid levels for Nr3c1) 
or phosphorylation (in response to cAMP signaling), respectively. Thus, levels cannot be 
verified by sqRT-PCR. To validate their predicted activity it would be necessary to measure 
glucocorticoid protein levels or CREB1 phosphorylation by Western blot. 
Taken these findings and the fact that glucocorticoids can also act on microglia rhythms by 
inducing the expression of period circadian clock 1 (Per1; Fonken et al., 2016), which is also 
among the 45 DEGs, glucocorticoid signaling plays clearly a role in the brain of the GNE+/- 
mice. Nonetheless, further investigations are needed to better understand its specific function 
here. It is even possible that the differences in glucocorticoids are a hint of a starting muscle 
weakness in the GNE+/- mice because glucocorticoids were reported to regulate muscle atrophy 
(Schakman et al., 2013; Bodine and Furlow, 2015). Furthermore, muscle atrophy correlates 
with muscle weakness as it was observed in a transgenic mouse model expressing the human 
p.D207V mutant GNE but not their own Gne anymore (Malicdan et al., 2008). 
For a more in-depths understanding of the underlying pathway a single cell analysis of 
microglia or neurons or RNA sequencing of different brain regions might be suitable to unravel 
any hidden differences. In fact, a regional transcriptome analysis by Mangold and colleagues 
detected very different transcriptional profiles comparing hippocampus with cortex (Mangold 
et al., 2017). Single-cell RNA sequencing helps to elucidates biological complexity (Zhang et 
al., 2014a; Dong et al., 2015; Grabert et al., 2016; Wes et al., 2016) but nevertheless, it must be 
taken into account that sample isolation can alter gene expression and data sets might not be 
comparable. 
4.1.2.3 Involvement of microglia and the complement system 
The second challenge of this study was to validate the involvement of the complement system 
and of microglia in the neuronal loss and to confirm the underlying mechanism known from the 
in vitro studies (Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016). In vitro, it was 
demonstrated that C1q binds to desialylated neurites and that blocking of CR3 on microglia 
prevents the uptake of desialylated neuronal structures by microglia. The transcriptome analysis 
at 9 months did not clearly hint towards a microglia-mediated mechanism that could explain 
the neuronal loss in the brain. A typical inflammatory process mediated by microglia was also 
excluded, which was in line with the non-inflammatory in vitro situation. 
However, transcription levels of specific microglial markers (aif1, cd68, and tmem119) were 
consistently upregulated in brains of GNE+/- mice throughout aging (6 months to 12 months) 
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compared to wildtype mice. Especially the general increase of wildtype aif1 (gene encoding 
Iba1) levels with aging were in line with the findings of Mangold and colleagues (Mangold et 
al., 2017) and was also reported by other researchers (Mouton et al., 2002; Tremblay et al., 
2012). Tmem119 is a rather new microglia-specific marker for a protein with so far unknown 
function (Satoh et al., 2015; Bennett et al., 2016). Its specificity has the advantage that microglia 
differences are not masked by tmem119 transcription on other cell types in the brain. Thus, the 
observed increased tmem119 transcription levels in GNE+/- mice during aging could either 
indicate higher microglia numbers or morphological changes. Remodeling of the membrane 
surface might require increased receptor expression. 
Iba1 is expressed by all mononuclear phagocytes and is a widely used marker for microglia and 
macrophages in the brain. Immunohistochemistry with an antibody against Iba1 allows 
detection of all morphological and functional forms of microglia in both rodent and human 
preparations. It further allows direct comparison of microglia in translational studies, and 
between species (Ito et al., 1998; Hirasawa et al., 2005). Therefore, tissue from 9 months old 
mice (highest aif1 transcript levels) was chosen and microglia in the SN pr, the region with the 
higher neuronal loss was investigated. Here, I could confirm the significant increase in aif1 
transcription levels at 9 months also on protein level. Surprisingly, the number of Iba1-positive 
cells was slightly reduced in 9 months old GNE+/- mice. Although not fully investigated, 
changes in microglial number with age are still controversially discussed. In some studies no 
changes in microglial numbers were described for mice (Long et al., 1998; Askew et al., 2017) 
and rats (VanGuilder et al., 2011), but in other publications lower numbers in mice were found 
with age (Hayakawa et al., 2007), or an increase in female mice but not in male mice was 
reported (Mouton et al., 2002). The discrepancy in microglial number might also be a result of 
different markers used for microglia staining (e.g. isolectin B4, Mac-1, Iba1) and different 
counting techniques, and thus, needs to be carefully revised. As mentioned before, Iba1 staining 
can also be used for morphology analysis. Microglia activation is often described as amoeboid 
cell morphology with enlarged soma and shorter processes. In this study such differences in 
soma area were not found between the genotypes and also the Iba1 intensity in the soma was 
not stronger expressed in the GNE+/- mice. 
The lysosomal membrane protein Cd68 is associated with microglia activation and 
phagocytosis (Ramprasad et al., 1996) and was shown to be increased in GNE+/- mice on 
transcription level. However, immunohistochemical staining of Cd68 was rather reduced in 
GNE+/- mice and in particular in the soma, even though only slightly. Thus, from this basic 
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morphological analysis a clear conclusion was not possible. Variations were often higher than 
differences. Therefore, I conclude that either a morphological change occurred earlier and at 
9 months microglia do not differ anymore in shape or alternatively, the expected changes in 
microglia morphology and function change in a homeostatic range and consequently, are too 
small to be captured by the methods applied here. In addition, microglia morphology was only 
investigated in the substantia nigra. If the underlying mechanism for the neuronal loss seen in 
the substantia nigra is occurring before 9 months and as proposed, if the neuronal loss in the 
hippocampus appears much later than in the substantia nigra, it is likely that at 9 months 
changes in microglia morphology can be seen in the hippocampus but not in the substantia nigra 
anymore. Interestingly, Bodea and colleagues were only able to see differences in Iba1 
fluorescence one day after the final LPS injection but not two weeks later when the neuronal 
loss was present (Bodea et al., 2014). This was an unexpected finding considering that systemic 
LPS challenge has a major impact on the brain transcriptome and inflammatory processes as it 
was mentioned before. Similar data were also shown for Cd68 immunohistochemical staining. 
This indicates again that changes in microglia morphology not necessarily occur in parallel with 
neuronal loss and might need strong inflammatory input. Thus, for a detailed morphology 
analysis a 3D reconstruction of microglia in different brain regions is recommended. This 
analysis is more precise and might clarify the circumstances. 
It has to be kept in mind that the in vitro studies were a reduced model system meaning that it 
is likely, that in the in vivo situation other cells types are involved as well. Astrocytes are also 
involved in the complex regulation of the CNS inflammation and tightly interact with microglia. 
Under pathological conditions astrocytes and microglia can orchestrate together and induce an 
inflammatory response. For instance, after brain injury, astrocytes produce cytokines and 
chemokines that activate microglia and recruit peripheral immune cells to the CNS (Ramirez et 
al., 2017). Furthermore, Il1b secreted by microglia was shown to be a potent activator of 
astrogliosis (Lee et al., 1993; Giulian et al., 1994). Reactive astrogliosis is a physiological 
response to destruction of nearby neurons in all forms of CNS injury and diseases and 
considered as a protective reaction at first place (De Strooper and Karran, 2016). Typically, an 
abnormal increase in the number of astrocytes and increased GFAP fluorescence can be seen 
(Sofroniew and Vinters, 2010; Sofroniew, 2014) but was not detected in the tissue of GNE+/- 
mice. This is in line with the absence of neuroinflammation on transcriptional level and argues 
against an inflammatory crosstalk between microglia and astrocytes via Il1b. However, under 
pathological conditions atypical activation of gliosis was already observed. In PD, for instance, 
microglia are highly activated by the disease, whereas astrogliosis is often largely absent 
102  Discussion 
(Ramirez et al., 2017). Nevertheless, similar to the microglia data only astrocytes in the 
substantia nigra were analyzed in this study and thus, astrogliosis cannot be excluded for other 
brain regions. 
The complement system is a part of the innate immune system. Beside its immune function it 
is essential for refining the neuronal network in the developing brain via microglia-mediated 
synaptic pruning. Removal of pathogens and cellular debris as well as removal of inappropriate 
synapses are the basic functions. Later in life, complement proteins still play a role in the adult 
and aging brain. The increase in the expression of complement components I found is supported 
by human data of aged hippocampus (Cribbs et al., 2012) and studies in male mice (Stephan et 
al., 2013). Increasing levels were especially seen for old mice (18-24 months). A significant 
increase of the initiation factor C1q was also seen in both, human and mouse brains (Stephan 
et al., 2013) and increasing c4b transcript levels with age were, for example, demonstrated by 
Bonasera and colleagues in the mouse cerebellum (Bonasera et al., 2016). Remarkably, the 
measured transcription levels of the C1q genes were fluctuating over time, in particular c1qc 
levels showed an oscillating pattern. In comparison, the study of Kraft and colleagues measured 
the transcription levels of c1qa, c1qb, and c1qc in response to induced death of dentate granule 
neurons in the hippocampus (Kraft et al., 2016). The transcription levels of all three 
complement factors were increasing with the severity of neuronal loss. Similar to our findings, 
their data also showed the highest response levels for c1qc and the lowest for c1qb transcripts, 
whereas in the study of Mangold and colleagues, differences between c1qa and c1qc were 
minor in male hippocampi but higher for c1qa in female hippocampi (Mangold et al., 2017). 
Surprisingly, itgam, one of the genes encoding the CR3, is expressed on the surface of many 
leukocytes, including macrophages and microglia and was barely altered with age. Yet, levels 
were slightly increased in GNE+/- mice and corresponded to the transcript levels of the 
microglial marker tmem119. 
Considering the fact that the complement system is involved in normal synapse formation and 
regulation, an altered expression of complement components most likely plays a significant role 
in synapse loss with aging and neurodegenerative diseases as it was discussed before (Stevens 
et al., 2007; Stephan et al., 2012). With exception of c1qc, most genotype-specific transcription 
differences occurred after 3 months but it remains unclear why transcript levels of c1qb, c1qc 
and c4b were higher in wildtype mice, whereas transcript levels of c1qa, c3 and itgam were 
higher in GNE+/ mice. Again, regional differences might be masked when analyzing overall 
brain tissue and might only be visible when analyzing distinct brain regions as described for 
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instance for the neocortex and the cerebellum (Lee et al., 2000). Moreover, the lack of major 
differences speaks in favor for a homeostatic regulation on protein level. 
4.1.2.4 Rescue of the GNE+/--dependent phenotype 
Crossbreeding with C3-deficient mice enabled us to confirm the involvement of the 
complement system in microglia-mediated neuronal loss as observed in vitro. The knockout of 
C3 prevented neuronal loss in different brain regions of aged GNE+/- mice. Furthermore, even 
for some important markers, like il1b and aif1 transcription levels were reduced similar to 
wildtype levels. Also the predicted pathways, which were altered in GNE+/- mice were rescued 
and did not show up in IPA anymore after knockout of C3, suggesting that these pathways did 
not play a major role anymore. The increased width I found in GNE+/+C3-/- mice might be 
explained by the C3 deficiency. C3-deficient mice were reported to have in general more 
synapses and thus, maybe have an higher brain volume (Kalm et al., 2016). As mentioned 
before, the quantification of the synaptic density in different brains regions could unveil 
whether synapses are being excessively removed in GNE+/- mice and whether this removal can 
be prevented in GNE+/-C3-/- mice. 
In double knockout mice of ganglioside GM2/GD2 synthase (B4ganlt1) and GD3 synthase 
(St8sia1), another mouse model of glycocalyx alterations, a similar rescue was possible (Ohmi 
et al., 2011, 2014). In these mice progressive deterioration with aging was observed in in the 
spinal cord and in the cerebellum accompanied by increased complement-related genes. The 
double-knockout mouse developed an even more severe phenotype but mating with C3-
deficient mice was able to restore the neuronal numbers and the complement transcription levels 
as it was shown in GNE+/-C3-/- mice. These studies not only confirm our findings but also 
support the important role of the complement system in neuronal loss. 
4.1.3 Reactivation of developmental synaptic pruning 
Bodea and colleagues discovered that systemic LPS leads to inflammatory neurodegeneration 
and a complement-mediated response that activates microglia via CR3 and ITAM-associated 
signaling. This signaling results in the formation of the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and presumably in the production of neurotoxic ROS (Bodea et 
al., 2014). In contrast to the inflammatory proposed mechanism by Bodea and colleagues, I 
propose a non-inflammatory and homeostatic removal of neurons as underlying mechanism of 
this study. Silent phagocytosis of desialylated neurons is one of the main beneficial functions 
of microglia (Neumann et al., 2009; Linnartz et al., 2012a) and might be aberrantly regulated 
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in GNE+/- mice. Under normal conditions sialic acids mask important “eat me” signals on 
neurons that are essential for synaptic pruning and consequently, are highly controlled. 
Especially the long polysialic acid chains are necessary for a proper inhibitory Siglec signaling. 
In GNE+/- mice this inhibition is simply gone or at least reduced. Further hints come from the 
ganglioside-based literature showing that the ganglioside composition is crucial for synapse 
regulation (Palmano et al., 2015; Zhang et al., 2016b). Synaptic degeneration was described to 
be an early hallmark of aging as well as of neurodegenerative diseases and followed by neuronal 
loss (reviewed in Morrison and Baxter, 2012). It is already under current debate if the 
developmental synaptic pruning is recapitulated in the aging brain (Zabel and Kirsch, 2013). 
Under normal conditions, microglia can clearly distinguish between wanted and unwanted 
synapses. They selectively remove axosomatic inhibitory synapses while leaving excitatory 
synapses intact (Wolf et al., 2017) but during aging microglia-mediated synaptic development 
might transform into pathological alterations. An aberrantly reactivated synapse pruning in the 
aged brain was confirmed to contribute to the synapse loss seen in AD (Hong et al., 2016a). 
However, if microglia actively initiate synapse remodeling or clear synapses passively, this 
remains unsolved. 
Here, I show that reduced masking of the neuronal surface in GNE+/- mice accelerated the 
normal aging process and possibly provokes increased and unwanted synaptic pruning by 
microglia. As suggested previously (Shi et al., 2015), in aging early synapse loss in neurons 
precedes late neuronal loss. That implies that the age-dependent loss of neurons in either the 
substantia nigra or the hippocampus might be a result of post-developmental complement-
mediated synapse elimination in the adult brain and in fact, occurs much earlier in the GNE+/- 
mice than in wildtype littermates. 
In summary, I hypothesize that the early neuronal loss I observed in the GNE+/- mice might be 
due to unwanted accelerated synapse elimination. To further clarify the synaptic loss, brain 
region-specific investigations on synaptic density and synaptic turnover are essential.  
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4.2 Transgenic mice for modeling an altered glycocalyx 
As previously mentioned most in vitro data lack confirmation in vivo and this has a huge impact 
on data validation or clinical trials. Therefore, it is important to find suitable animal models to 
reproduce pathways in a complex organism that were obtained in a limited cell culture dish. 
Nevertheless, the reduction of complexity is necessary to understand a basic concept before 
transferring it to a more complex organism and it is important to understand the limitation of 
each applied model. 
4.2.1 GNE+/- mice as model for an altered glycocalyx 
To model an altered glycocalyx in vivo, a mouse heterozygous for the enzyme GNE was used 
that was described with an overall reduction of membrane-bound sialic acid by 32% in the brain 
(Gagiannis et al., 2007). As mentioned before the complete knockout of the GNE enzyme 
results in embryonic lethality (Schwarzkopf et al., 2002) and could not be used. Surprisingly, 
the introduced loss-of function mutation into only one allele was enough to reduce the total 
sialic acid production. Although GNE is described to be ubiquitously expressed in all cells, 
regional differences in GNE function (summarized in Willems et al., 2016) and different sialic 
acid regulation might result in regional or global differences. 
In direct comparison, GNE+/- mice are a good model for an altered glycocalyx and a good 
translation of both in vitro models. Only some minor differences occur. First of all, in vitro the 
sialic acid residues were removed enzymatically by a combination of an exo- and an endo-α-
sialidase and only at the neuronal cell surface (Linnartz et al., 2012b; Linnartz-Gerlach et al., 
2016), whereas in vivo, reduced sialic acid levels were achieved by systemic reduction of the 
de novo biosynthesis of sialic acids. Secondly, in vitro the effect of the altered glycocalyx was 
investigated at a particular time point because enzymatic removal is a temporary situation. In 
contrast, the systemic reduction of the sialic acid synthesis in vivo provides the option to study 
long-term effects and in addition, sialic acid levels further decreased with age in the mouse 
brain and enhanced the phenotype. The increasing neuronal loss in the brain of the GNE+/- mice 
was in line with the documented neuronal loss of desialylated neurites in both in vitro studies 
(Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016). Furthermore, I could show small 
alterations in transcription and on protein levels of microglial markers that hinted towards a 
microglial involvement. However, to confirm the microglial phagocytosis of desialylated 
neuronal debris as it was shown in the cell culture experiments, in vivo imaging would be the 
necessary follow-up experiment. The thinned-skull imaging method by two-photon laser 
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microscopy might be an appropriate method (Guo et al., 2017) that could be realized in form of 
a collaboration but it has to be kept in mind that this method needs the crossbreeding with a 
microglia reporter line. Nevertheless, even with in vivo imaging it will be difficult to prove the 
new concept of silent phagocytosis. 
Importantly, I could prove the involvement of the complement system in vivo. By genetic 
inhibition of the complement system, the neuronal loss was prevented in the GNE+/- mice. In 
contrast to the in vitro studies that used blocking antibodies against CR3 to inhibit microglial 
phagocytosis, in the in vivo situation, the complete downstream signaling pathway of the 
complement system was inhibited by C3 knockout. This approach is much stronger but might 
also cause some additional effects in the mice. 
Although the mouse model was reflecting nicely most of the in vitro data some limitations have 
to be taken into account. First of all, sexual dimorphism is not yet a question in vitro but it is a 
not negligible environmental factor in vivo, especially when addressing microglia-specific 
questions. Also the sexual dimorphism of the brain anatomy has to be considered and possible 
differences in immune functions. In particular, when it comes to aging, male and female mice 
develop different phenotypes (Hanamsagar et al., 2017; Mangold et al., 2017). Furthermore, it 
was observed that the GNE heterozygosity leads to dynamic variabilities between generations 
and also litters (data not shown). Different protein expression might have a large impact on the 
phenotype. As a consequence, only global effects will be visible in GNE+/- mice but smaller 
effects might be masked by these variations. When studying neuronal loss in these mice, it also 
has to be taken into account that dependent on the brain region of interest a certain age is 
mandatory to detect and investigate significant neuronal loss. However, the slowly developing 
phenotype in the GNE+/- mice might in fact reflect much better an age-dependent neuronal loss. 
Another limitation of studying an altered glycocalyx in mice is the difference in sialic acid 
monomers. While in the mouse both monomers, Neu5Ac and Neu5Gc, are synthesized, in 
humans only Neu5Ac is synthesized. As a consequence, the SIGLEC composition and binding 
preferences in humans had to adapt to these changes (Sonnenburg et al., 2004; Varki and 
Angata, 2006). Therefore, the mouse as model organism might not be suitable for some human 
diseases related to SIGLEC signaling. 
In general, the reduced sialic acid levels and thus, an altered glycocalyx were confirmed in the 
mouse model and the neuronal loss could not only be successfully recapitulated in the brain of 
the GNE+/- mice but was also rescued via inhibition of the complement system. Therefore, the 
GNE+/- mouse was validated as suitable model for an altered glycocalyx.  
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4.2.2 Other transgenic mouse models with glycocalyx alterations 
GNE+/- mice are not the only transgenic mice for studying an altered glycocalyx. Other mouse 
models have been engineered to modify specific sialoglycoconjugates, like gangliosides and to 
study the role of sialic acids in different pathologies. All these models develop comparable 
pathologies as the GNE+/- mice but with different degrees of severity (Sheikh et al., 1999; 
Sugiura et al., 2005; Furukawa et al., 2014). 
Mutations in enzymes of the early ganglioside biosynthesis can result in the disruption of 
complex gangliosides and the impairment of nervous tissue integrity. Thus, modifying the 
ganglioside composition in the brain can shed light on their specific functions in brain 
development and maintenance. For instance, the B4galnt1 mutant mice (“complex ganglioside 
KO”) are deficient for the GM2/GD2 synthase and cannot synthesize the major brain 
gangliosides GM1, GD1b, GD1a, and GT1b. They only express GM3 and GD3 (Sheikh et al., 
1999; Pan et al., 2005). The absence of complex brain gangliosides in these mice leads to strong 
CNS disorders, including motor impairment, depletion of striatal dopamine, selective loss of 
TH-expressing neurons, and aggregation of alpha-synuclein (Chiavegatto et al., 2000; Wu et 
al., 2012). Similar to the GNE+/- mice these mutants are viable and show a normal development 
at young age. However, with increasing age these mice develop heavy neurodegeneration 
accompanied by motor defects and dysmyelination in the CNS, which was partially observed 
in GNE+/- mice but less severe. In contrast, mice expressing only GM3 as major brain 
ganglioside establish strong epileptic seizures and die already early after birth (Kawai et al., 
2001). Strikingly, the only structural difference between GM3 and GD3 is a mono-sialic acid 
residue (for GM3) instead of a di-sialic acid residue (for GD3) on galactose but the absence of 
one sialic acid residue on the ganglioside seems to have a major effect on the glycocalyx 
structure and its function. This is further confirmed by mice that lack even mono-sialic acid 
gangliosides (GM3) and die at E7.5 (Yamashita et al., 1999).  
Sialyltransferases are necessary for transferring sialic acids to their final carrier and to build 
more complex gangliosides (see introduction, Figure 4). Moreover, they also sialylate 
glycoproteins. The sialyltransferases ST3Gal-II and ST3Gal-III are mainly responsible for the 
biosynthesis of GD1a, GT1b, and GQ1b that form half of all ganglioside types in the 
mammalian brain. Mice deficient for St3gal2 have a 50% reduction in GD1a/GT1b/GQ1b but 
higher levels of the gangliosides GM1 and GD1b, while mice deficient for St3gal3 show 50% 
reduction in sialoglycoproteins. Double-knockout of St3gal and St3gal3 in mice blocked two 
of the four major brain gangliosides (GD1a and GT1b) almost completely and resulted in strong 
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dysmyelination, reduction in hippocampal neurons and impaired motor functions (Yoo et al., 
2015). In the brains of mice deficient for polysialyltransferases (St8SiaII-/-, St9SiaIV-/-) 
polysialylated glycoconjugates are completely absent. The mice show major defects in long-
term depression and long-term potentiation in the hippocampus (Eckhardt et al., 2000). These 
findings are in line with the neurological abnormalities in NCAM-deficient mice (Bork et al., 
2007; Sato and Endo, 2010). Those mice have reduced long-term potentiation in the CA3 region 
of the hippocampus and show a decreased ability for spatial memory and cell migration. In 
combination, the different mouse models confirm that mice need at least simple sialylated 
gangliosides in early development of the brain but complex sialylation and as a consequence 
complex gangliosides for the correct maturation and maintenance of the brain. 
Not only the sialic acid synthesis is crucial for maintenance in the brain but also the functional 
regulation and degradation of sialoglycoconjugates is essential. Important findings were 
obtained in mice lacking the neuraminidases 3 and 4. Impaired degradation of gangliosides can 
result in GM3 storage in microglia, neurons, and vascular pericytes causing memory loss, 
neuroinflammation and the accumulation of lipofuscin bodies (Pan et al., 2017). Aggregation 
of alpha-synuclein was also detected in GM1-deficient mice (Wu et al., 2012). These findings 
draw a link to the reduced polysialylation that has been described for patients with PD or AD 
(Murray et al., 2016) and in schizophrenia (Sato et al., 2016). 
Although other mutations can result in similar pathologies as shown in the GNE+/- mouse, the 
GNE+/- mouse is a distinct model for aging. While the other mouse models are useful to 
understand the functions of specific sialoglycoconjugates in the glycocalyx, the GNE+/- mice 
mimic the natural overall decline in sialic acid levels with aging and thus, are a good model of 
studying the effects of aging based on glycocalyx alterations. 
4.2.3 Further implications for GNE+/- mice 
The GNE+/- mouse model was proven to be a good model to study alterations in the neuronal 
glycocalyx in the brain, especially in aging. However, alterations in gangliosides have been 
demonstrated to play a major role in several other brain diseases, including ALS (Rapport, 
1990) and PD (Wu et al., 2012). It is very likely that glycocalyx alterations are also involved in 
a wide range of other age-related diseases, including retinal diseases, such as age-related 
macular degeneration (AMD) and glaucoma. AMD is an inflammatory, degenerative disease 
of the eye resulting in a gradual loss of vision. More than 30 million people worldwide are 
affected with increasing numbers. Therapy of AMD is limited and the available treatments help 
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only temporary (Rofagha et al., 2013). Although the mechanism for developing AMD is not 
fully understood, activation of the complement system and release of ROS play a central role 
in the disease (Ambati and Fowler, 2012; Harvey and Durant, 2014). Highly reactive 
phagocytes can be found in the retina of AMD patients (Gupta et al., 2003) and in mouse model 
of light-damaged retinas (Scholz et al., 2015). Based on the important role of complement 
factors in the retina it is very likely that the reduced sialic acid levels in GNE+/- mice can also 
facilitate neurodegeneration of photoreceptors in the retina during aging. From another 
approach, it was already shown that sialic acid treatment inhibits complement activation and 
reduces the reactivity of phagocytes in the retina of an AMD mouse model (Karlstetter et al., 
2017). At this point, I would also like to highlight the common mechanisms of AMD with AD. 
Both, the complement system as immunological player as well as the microglia as neuronal 
supporting cells are involved in these diseases. During aging something fundamental must turn 
wrong in these two players leading to the neurological pathology. Using insights of one 
neurodegenerative disease might help to understand the other (Harvey and Durant, 2014; 
Ramirez et al., 2017) and could also be applied on the GNE+/- mice. 
Another neuronal pathology worth to investigate in GNE+/- mice is acquired hearing loss. About 
half of the 700 million cases of hearing loss worldwide are not heritable but develop during 
aging, or are caused by increased noise exposure or by ototoxic substances like aminoglycosides 
(antibiotics). The degeneration of hair cells, the sensory receptors in the cochlea and the 
vestibular organ lead to a gradual loss of hearing. Hair cell loss precedes neuronal loss in the 
spiral ganglion but not much is known about the initial cause of the degeneration. Similar as in 
the retina the release of radicals is one of the suggested mechanisms and inhibition of the tissue 
macrophages in the cochlea was able to prevent ototoxicity-induced hair cell degeneration (Sun 
et al., 2014). Recent findings propose changes in cochlear synaptopathy after acoustic 
overexposure as initial event to induce hair cell loss (Liberman et al., 2015) and currently new 
attempts are made to explore the clinical potential of these findings (summarized in Hickox et 
al., 2017). Furthermore, two aminoglycoside treatments with different ototoxic potentials were 
shown to reduce the expression of sialoglycoconjugates on the glycocalyx of hair cells (Groot 
et al., 2005). Sialic acids are known to play an important function as “Don’t eat me signal” but 
also as scavenger molecules. Age-dependent reduction of sialic acid levels in the cochlea or 
release of membrane-bound sialic acids to neutralize free radicals after noise exposure or 
ototoxicity might be the first occurring step in this disease, followed by synaptic changes that 
finally turn into neurodegeneration. Consequently, the GNE+/- mice present a suitable model to 
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unravel the underlying mechanism of neuronal loss in the inner ear and to clarify the potential 
role of sialic acids in neuronal maintenance. 
Last but not least, the GNE+/- mice are also useful to understand the role of sialic acids in 
embryonic development. GNE-/- embryos die between E8.5 and E9.5 (Schwarzkopf et al., 
2002). The developmental time frame until around E9.5 can be used to study the essential role 
of sialic acid in embryogenesis and brain development. So far, it is not clear why the embryos 
die around E9.5 and not earlier or later. One suggestion is the immigration of microglia into the 
brain during that crucial time period (Ginhoux et al., 2010), once again highlighting the 
importance of microglia in recognizing the neuronal glycocalyx. Similar findings were made in 
mice deficient for CMAS. These mice lack the ability to activate sialic acid to CMP-sialic acid 
for successful glycosylation. Cmas-/- embryos were shown to be embryonic lethal similar to 
GNE-/- mice and die at a similar time point (Abeln et al., unpublished data). In earlier studies it 
was shown that desialylation of embryos by neuraminidase treatment led to a fast complement-
mediated lysis (Klemke and Weitlauf, 1993; Kircheis et al., 1996) suggesting the complement 
system as important mediator. Furthermore, it seems that sialylation is crucial to prevent early 
rejection of the blastocyst by the immune system, which is in line with a study from Whyte and 
Loke (1978) that showed that trophoblasts are much stronger sialylated than the inner cell mass. 
Still, it remains unclear if the complement system induces the death of the embryo or if its main 
function is to remove the dead embryo. GNE-/- mice could be an alternative model to study the 
role of sialic acids in early embryogenesis. 
4.3 Clinical relevance of GNE mutations and mouse models 
Mutations in GNE have important clinical relevance. By now, two completely different diseases 
caused by GNE mutations are known: GNE myopathy (OMIM #605820) and sialuria (OMIM 
#269921). Their pathomechanisms are not fully understood yet and different mice models are 
currently under investigations to find suitable drug therapies. 
4.3.1 GNE myopathy 
GNE myopathy is an autosomal, bi-allelic recessive genetic disorder of GNE. A number of 
different mutations in GNE have been detected that lead to reduced enzyme activity and result 
in reduced sialic acid biosynthesis. GNE myopathy manifests predominantly in progressive 
muscle atrophy and weakness, mainly at the distal muscles (Mirabella et al., 2000; Broccolini 
et al., 2002) and was first described as Nonaka myopathy in Japan (Nonaka et al., 1981). In 
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some populations, e.g. the Iranian-Jewish population, the frequency of GNE myopathy is 
greater than one in every 1500 individuals (Jay et al., 2009) and recently 154 reported and novel 
GNE variants associated with GNE myopathy were published (Celeste et al., 2014). The 
different mutations in GNE display a variety of different pathological features and thus, it is not 
surprising that alternative names for the same genetic disorder emerged, like distal myopathy 
with rimmed vacuoles (DMRV; Nonaka et al., 1981), hereditary inclusion body myopathy 
(HIBM; Askanas and Engel, 1995), or rimmed vacuole myopathy (Argov and Yarom, 1984) 
that are now summarized as ‘GNE myopathy’ (Huizing et al., 2014). Unfortunately, there are 
other hereditary inclusion body myopathies having different genetic defects but sharing also 
common features of pathology and thus, make a clear diagnosis difficult (Murnyák et al., 2015). 
In general, the pathology starts in early adulthood with weakness in the anterior tibialis muscles. 
Within ten to twenty years it progresses from the distal to the proximal skeletal muscles in the 
lower, then in the upper extremities and leads to wheelchair-bound patients. Interestingly, most 
reports of patients describe sparing of the quadriceps even in advanced stage of GNE myopathy. 
However, the severity of the disease varies highly and even among siblings (Boyden et al., 
2011; Mori-Yoshimura et al., 2012; Cho et al., 2014; Huizing et al., 2014). In a subset of 
patients, weakness of respiratory muscles appears at advanced stage or dilated 
cardiomyopathies have been observed as well (Celeste et al., 2014). The histopathological 
features are decreased sialylation of specific muscle proteins and 'rimmed' vacuole inclusions 
in the affected muscle tissue. Some of the degenerating muscle fibers contain even abnormal 
accumulations of amyloid beta protein (Argov and Yarom, 1984) but no protein aggregates 
have so far been described in the CNS. In addition, no indication for neuronal loss as I have 
observed in the GNE+/- mice has been described so far either. At least, there was one case report 
with mild ptosis on one eye and diminished neuronal sensation in the feet, which might be an 
early sign of neuropathy (Weihl et al., 2011). However, most patients probably die too early to 
develop clear cognitive symptoms, neuronal loss or any abnormal accumulations of amyloid 
beta protein in the CNS. In some patients hyposialylated NCAM1 was detected in degenerating 
muscles but not in normal muscles (Ricci et al., 2006). This was also confirmed in other 
patients, where many vacuolated muscle fibers showed immunoreactivity to NCAM1 and were 
at the same time immunoreactive for amyloid beta protein, ubiquitin, and tau protein (Murakami 
et al., 1995). In fact, the question remains, whether AD might share some common pathogenic 
mechanisms with GNE myopathy. However, similarities such as for the formation of rimmed 
vacuoles can be found in different neurodegenerative diseases not only in AD (Mizuno et al., 
2003) and might be based on a common mechanism. 
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In GNE myopathy, the huge phenotype variations make it difficult to draw a direct link to the 
genotype and thus, to fully understand the underlying mechanisms. As mentioned before, the 
general pathomechanism is hyposialylation, which could be due to reduced CMP-sialic acid 
levels in serum. However, serum transferrin glycosylation, a standard diagnostic assay for GNE 
patients is normal in patients (Sparks et al., 2007). Hyposialylation is tissue- and protein-
specific and depends on the loci of the GNE mutation (Saito et al., 2004). Comparison with 
patients having different GNE mutations suggested that mutations in the epimerase domain 
impair sialylation, while most mutations in the kinase domain lower enzyme activity but not 
cellular sialylation. It is likely that the kinase function can be substituted by other kinases and 
most variations might occur due to the sialic acid salvage pathway that can bypass GNE. The 
bypassing efficiency, indeed, varies in some patients more than in others (Willems et al., 2016). 
To better understand the pathology of GNE myopathy, mice models for the different subtypes 
are meanwhile under investigations, like the mouse model of DMRV that expresses the human 
GNE D176V mutation (Malicdan et al., 2007; Anada et al., 2014; Cho et al., 2017) or the knock-
in mouse carrying the human GNE M712T mutation (Galeano et al., 2007). Nevertheless, the 
limitation for a mouse model of human GNE myopathy is that in humans meanwhile eight 
functional isoforms have been detected compared to the two functional murine isoforms 
(Yardeni et al., 2011, 2013). The additional isoforms might have additional cellular functions 
that cannot be modelled in mice. 
However, studying the Gne-deficient mice expressing the human D176V-GNE mutation 
revealed hyposialylation in serum, muscle tissue, and organs (Malicdan et al., 2007). The motor 
performance of these mice markedly decreased after 20 weeks (~5 months) of age (Malicdan et 
al., 2008) and 10 weeks later amyloid beta deposition was discovered, followed by rimmed 
vacuoles formation at 40 weeks of age (Malicdan et al., 2009). With these results the Gne-
deficient mice expressing the human D176V-GNE mutation resemble quite well the 
histological and pathological findings of many GNE myopathy patients and present a promising 
human disease model. In a follow-up study, Malicdan and colleagues used these GNE 
myopathy mice to test the supplementation of sialic acid precursor molecules and successfully 
provided evidence that the prophylactic oral administration of ManNAc, Neu5Ac, and 
sialyllactose can increase sialic acid levels in blood and tissue (Malicdan et al., 2009). 
Importantly, the therapy improved the motor performance of these mice. Even after disease 
onset (50 weeks old) treatment of GNE myopathy mice with sialyllactose was able to 
ameliorated the myopathic phenotype (Yonekawa et al., 2014). The promising results of the 
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preclinical studies in mice have meanwhile realized a number of clinical trials for human 
patients: phase 1 (NCT01359319, sialic acid, completed 2012; NCT01634750, ManNAc, 
completed 2017), phase 2 (NCT01517880, sialic acid, completed 2016; NCT02346461, 
ManNAc, still ongoing), and a phase 3 (NCT02377921, sialic acid, completed 2017). This once 
more highlights the importance of using mouse models. Even if they cannot completely 
recapitulate the human disease they might still be very useful to investigate the underlying 
mechanisms and to develop suitable treatment strategies. 
4.3.2 Sialuria 
Sialuria is a completely different congenital disorder based on GNE mutations. In contrast to 
GNE myopathies, the human mutations (R266W, R266Q, and R263L) in sialuria affect the 
allosteric feedback site of GNE and prevent the regulating feedback by CMP-sialic acids 
(Kamerling et al., 1979; Seppala et al., 1999; Leroy et al., 2001). This gene defect causes 
excessive sialic acid synthesis. Sialuria is a rare autosomal dominant disorder starting at early 
age and the main symptoms are hepatomegaly, coarse facies, and varying skeletal and cognitive 
developmental delays (Enns et al., 2001; Leroy et al., 2001). So far, only eight individuals are 
diagnosed for sialuria (Champaigne et al., 2016) but the real number is probably underestimated 
because heterozygous mutations cause much milder cognitive delays and thus, might be 
misdiagnosed. The physiopathology is not well understood. Recently, the group from Kaya 
Bork developed a transgenic mouse model of sialuria using the human sialuria GNE mutation 
R263L (Kreuzmann et al., 2016). Their transgenic mice excreted up to 400 times more Neu5Ac 
than wildtype mice due to the missing feedback regulation in GNE and showed increased 
polysialylation in the brain. However, further investigations showed that the sialic acid levels 
increased mainly in the blood and not in peripheral organs and after 6 months the differences 
in polysialylation were not significantly different anymore. So far, the attempt to model sialuria 
in mice has not been successful and this explains why no clinical trial was realized until now. 
Taken together, these two different GNE disorders exhibit completely different pathologies but 
exhibit both a rather underestimated clinical prevalence. Although GNE might have additional 
functions in humans, the attempt to find suitable treatments for clinical therapy by modelling 
the human pathology in mice should not be underestimated. At least for GNE myopathy it was 
proven that mouse models can be very helpful for a successful therapy of human patients. This 
once more highlights the importance of using mouse models to understand the underlying 
mechanisms of human diseases. 
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4.4 Summary and further prospects 
The present study describes a new model for glycocalyx alteration. Mice heterozygous for GNE 
have only been described for reduced sialylation in several organs so far. No further 
investigations were performed in aging mice. In this study, thorough characterization of the 
brains of GNE+/- mice could now demonstrate that gne transcription is reduced by 50% during 
lifetime and reduced sialylation levels further decrease with age in the brain. In addition, it was 
shown that polysialylation is more affected by the genotype than shorter sialic acid oligomers.  
Furthermore, the model was used to successfully transfer the previously published in vitro 
findings from Linnartz and colleagues into a complex living organism. Linnartz and colleagues 
showed the removal of desialylated neurons by complement-mediated microglial phagocytosis 
(Linnartz et al., 2012b; Linnartz-Gerlach et al., 2016). Similar to that, GNE+/- mice started to 
loose neurons from the age of 3 months to 6 months. Aging and simultaneous loss of sialic 
acids accelerated the neuronal loss in different brain regions. Furthermore, crossbreeding with 
C3-deficient mice could prevent the neuronal loss with aging and confirmed that also in vivo 
removal of desialylated neurons is mediated by the complement system. Surprising was the 
absence of any neuroinflammation aside of the proceeding neuronal loss. Neither on 
transcription level, nor on protein levels could a typical activation profile be confirmed. Slightly 
elevated microglia marker indicated the involvement of microglia but a typical activatory 
phenotype was not found. These findings went along with the minor transcriptome differences 
found at 9 months of age and encouraged me to extend the in vitro model to a model of 
homeostatic removal of desialylated neurons by complement-mediated microglial 
phagocytosis. 
In line with a recent publication demonstrating a role of the complement system in synaptic 
pruning in an AD mouse model (Hong et al., 2016b), I now postulate that the neuronal loss 
observed in the GNE+/- mice is a false reactivation of developmental synaptic pruning. Aberrant 
loss of sialic acids on the glycocalyx during aging can cause this reactivation. High-resolution 
microscopy will help to proof the direct involvement of microglia in this synaptic plasticity and 
will help to correlate sialic acid levels with synapse density. 
One question that turned up during this study was not addressed yet and might be applied to 
future projects: Are mice with reduced sialic acids more susceptible to oxidative stress? Several 
hints from literature were given that connect sialic acids with oxidative stress in 
neurodegenerative diseases. Sialic acid as a known antioxidant on the glycocalyx is likely to be 
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affected by enhanced oxidative stress in tissue assuming that in a chronic stress situation 
elevated ROS levels might possibly effect the glycocalyx composition. Consequently, increased 
removal of sialic acids from the glycocalyx will result in neuronal loss similar as it has been 
seen in the GNE+/- mice. Furthermore, it is easily conceivable that GNE+/- mice having an 
altered glycocalyx might be more susceptible to systemic inflammation. While in general the 
substantia nigra seems to be very sensitive to LPS-induced neuronal death, the hippocampus, 
for instance, appeared to be more resistant to LPS (Espinosa-Oliva et al., 2011). Thus, LPS 
treatment of GNE+/ mice could provide new insights how vulnerable the glycocalyx might be 
during systemic inflammation, especially in certain types of neurons. By this idea, I would like 
to point out that the glycocalyx composition in general should be more the focus of investigation 
in any model of oxidative stress and in neurodegenerative diseases. 
For future therapy purpose it is helpful that sialic acids belong to the group of metabolites. As 
it was already shown in several studies, sialic acid precursor molecules can be used to treat 
mice and increase sialylation in different organs. However, the uptake and incorporation of 
sialic acids lacks optimization. The GNE+/- mice offer a suitable model to understand the uptake 
of sialic acid precursor molecules, like ManNAc or sialyllactose, to optimize its therapeutic 
function and to test the treatment effects in the suggested disease models (e.g. AMD, hearing 
loss, or AD). Successful reconstitution of a normal glycocalyx and thus, preventing 
neurodegeneration in different organs can then be transferred to a successful treatment for a 
number of neurodegenerative diseases. 
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6 Appendix 
6.1 Lists of differentially expressed genes (DEGs) 
Table 8: List of all 45 DEGs in GNE+/- vs. wildtype 
Symbol Gene name 
1810011
O10Rik 
RIKEN cDNA 1810011O10 
gene 
Acer2 alkaline ceramidase 2 
Ankrd13b ankyrin repeat domain 13b 
Arid5b 
AT rich interactive domain 5B 
(MRF1-like) 
Arl4d ADP-ribosylation factor-like 4D 
Arrdc2 arrestin domain containing 2 
Arrdc3 arrestin domain containing 3 
Bcl2l1 BCL2-like 1 
Bhlhe40 
basic helix-loop-helix family, 
member e40 
Btg2 
B cell translocation gene 2, anti-
proliferative 
Cdkn1a 
cyclin-dependent kinase 
inhibitor 1A (P21) 
Chka choline kinase alpha 
Cxcl12 
chemokine (C-X-C motif) 
ligand 12 
Dbp 
D site albumin promoter 
binding protein 
Ddit4 
DNA-damage-inducible 
transcript 4 
Dio2 
deiodinase, iodothyronine, type 
II 
Errfi1 
ERBB receptor feedback 
inhibitor 1 
F3 coagulation factor III 
Frmd6 FERM domain containing 6 
Fst follistatin 
Hspa1a heat shock protein 1A 
Hspa1b heat shock protein 1B 
Irs2 insulin receptor substrate 2 
Kdm3a 
lysine (K)-specific demethylase 
3A 
  
Symbol Gene name 
Klf13 Kruppel-like factor 13 
Klf15 Kruppel-like factor 15 
Lzts2 
leucine zipper, putative tumor 
suppressor 2 
Mat2a 
methionine adenosyltransferase 
II, alpha 
Mknk2 
MAPK-interacting 
serine/threonine kinase 2 
Mxi1 
MAX interactor 1, dimerization 
protein 
Nfkbia 
nuclear factor of kappa light 
polypeptide gene enhancer in B 
cells inhibitor, alpha 
Nostrin nitric oxide synthase trafficker 
Numbl numb-like 
Pdk4 
pyruvate dehydrogenase kinase, 
isoenzyme 4 
Per1 period circadian clock 1 
Plekhf1 
pleckstrin homology domain 
containing, family F (with 
FYVE domain) member 1 
Ppp1r3g 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
3G 
Rtn4rl1 reticulon 4 receptor-like 1 
Sgk1 
serum/glucocorticoid regulated 
kinase 1 
Sox9 
SRY (sex determining region 
Y)-box 9 
Spns2 spinster homolog 2 
Trp53inp
1 
transformation related protein 
53 inducible nuclear protein 1 
Tsc22d3 
TSC22 domain family, member 
3 
Txnip thioredoxin interacting protein 
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Table 9: List of the 50 most differently expressed genes of all 1334 DEGs in GNE+/+C3-/- vs. wildtype 
Top 25 downregulated genes: 
Symbol Gene 
C3 complement component 3 
Hddc3 HD domain containing 3 
Iqgap1 IQ motif containing GTPase 
activating protein 1 
Rps3a3 ribosomal protein S3A3 
Folh1 folate hydrolase 1 
Hspa1b heat shock protein 1B 
Dio2 deiodinase, iodothyronine, 
type II 
Btaf1 B-TFIID TATA-box binding 
protein associated factor 1 
Homer1 homer scaffolding protein 1 
Manf mesencephalic astrocyte-
derived neurotrophic factor 
Gm15506 predicted gene 15506 
Nptx2 neuronal pentraxin 2 
Xbp1 X-box binding protein 1 
Gm6969 cytochrome c oxidase subunit 
VIIa polypeptide 2-like 
pseudogene 
Coa4 cytochrome c oxidase 
assembly factor 4 
Heatr5a HEAT repeat containing 5A 
Olfml1 olfactomedin-like 1 
4632427E
13Rik 
RIKEN cDNA 4632427E13 
gene 
Banp BTG3 associated nuclear 
protein 
Sdf2l1 stromal cell-derived factor 2-
like 1 
Crem cAMP responsive element 
modulator 
Slc5a3 solute carrier family 5 
(inositol transporters), 
member 3 
Pdia4 protein disulfide isomerase 
associated 4 
Sik2 salt inducible kinase 2 
Egr3 early growth response 3 
 
 
 
 
 
 
 
 
Top 25 upregulated genes: 
Symbol Gene 
Pkd2l1 polycystic kidney disease 2-
like 1 
Chaf1a chromatin assembly factor 1, 
subunit A (p150) 
Pla2g4e phospholipase A2, group IVE 
Rec8 REC8 meiotic recombination 
protein 
Rnf169 ring finger protein 169 
Wnt9a wingless-type MMTV 
integration site family, 
member 9A 
Gstm6 glutathione S-transferase, mu 
6 
Ighm immunoglobulin heavy 
constant mu 
Ighm immunoglobulin heavy 
constant mu 
Zc3h6 zinc finger CCCH type 
containing 6 
Heyl hairy/enhancer-of-split 
related with YRPW motif-
like 
Zkscan2 zinc finger with KRAB and 
SCAN domains 2 
Gm9866 predicted gene 9866 
Tnni1 troponin I, skeletal, slow 1 
E230029
C05Rik 
RIKEN cDNA E230029C05 
gene 
Hrasls HRAS-like suppressor 
Gdpgp1 GDP-D-glucose 
phosphorylase 1 
Gm765 predicted gene 765 
Sytl2 synaptotagmin-like 2 
Mrpl48 mitochondrial ribosomal 
protein L48 
Tmc7 transmembrane channel-like 
gene family 7 
Cirbp cold inducible RNA binding 
protein 
Catsperd cation channel sperm 
associated auxiliary subunit 
delta 
A430105I
19Rik 
RIKEN cDNA A430105I19 
gene 
Ucp3 uncoupling protein 3 
(mitochondrial, proton 
carrier) 
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Table 10: List of the 50 most differently expressed genes of all 987 DEGs in GNE+/-C3-/- vs. wildtype 
Top 25 downregulated genes: 
Symbol Gene 
C3 complement component 3 
Rps3a3 ribosomal protein S3A3 
Dio2 deiodinase, iodothyronine, 
type II 
Folh1 folate hydrolase 1 
Nptx2 neuronal pentraxin 2 
Hddc3 HD domain containing 3 
Sdf2l1 stromal cell-derived factor 2-
like 1 
Xbp1 X-box binding protein 1 
Homer1 homer scaffolding protein 1 
Ppp1r3g protein phosphatase 1, 
regulatory (inhibitor) subunit 
3G 
Iqgap1 IQ motif containing GTPase 
activating protein 1 
Gm6969 cytochrome c oxidase subunit 
VIIa polypeptide 2-like 
pseudogene 
Pdia4 protein disulfide isomerase 
associated 4 
Dusp4 dual specificity phosphatase 4 
Gm15506 predicted gene 15506 
Pcsk1 proprotein convertase 
subtilisin/kexin type 1 
Hspa5 heat shock protein 5 
Slc25a41 solute carrier family 25, 
member 41 
Manf mesencephalic astrocyte-
derived neurotrophic factor 
Sik2 salt inducible kinase 2 
Tinagl1 tubulointerstitial nephritis 
antigen-like 1 
Irs2 insulin receptor substrate 2 
Fbln2 fibulin 2 
Creld2 cysteine-rich with EGF-like 
domains 2 
Banp BTG3 associated nuclear 
protein 
 
 
 
 
 
 
 
 
Top 25 upregulated genes: 
Symbol Gene 
Pla2g4e phospholipase A2, group IVE 
Rec8 REC8 meiotic recombination 
protein 
Btg2 B cell translocation gene 2, 
anti-proliferative 
Pot1b protection of telomeres 1B 
Pkd2l1 polycystic kidney disease 2-
like 1 
Gm9866 predicted gene 9866 
Zc3h6 zinc finger CCCH type 
containing 6 
Dusp1 dual specificity phosphatase 1 
Ier2 immediate early response 2 
Gstm6 glutathione S-transferase, mu 
6 
Wnt9a wingless-type MMTV 
integration site family, 
member 9A 
Sytl2 synaptotagmin-like 2 
Chaf1a chromatin assembly factor 1, 
subunit A (p150) 
4732491K
20Rik 
RIKEN cDNA 4732491K20 
gene 
Ighm immunoglobulin heavy 
constant mu 
2700046G
09Rik 
RIKEN cDNA 2700046G09 
gene 
Mybpc3 myosin binding protein C, 
cardiac 
Bche butyrylcholinesterase 
Heyl hairy/enhancer-of-split 
related with YRPW motif-
like 
Gucy1a3 guanylate cyclase 1, soluble, 
alpha 3 
Khsrp KH-type splicing regulatory 
protein 
Zkscan2 zinc finger with KRAB and 
SCAN domains 2 
Lmo2 LIM domain only 2 
Rnf169 ring finger protein 169 
Nxpe4 neurexophilin and PC-
esterase domain family, 
member 4 
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